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Abstract 
The aim of this thesis is to explore pregnancy and perinatal outcomes in diagnosed 
HIV-infected women receiving antiretroviral therapy (ART) in the UK (United 
Kingdom) and Ireland. Population-based surveillance data on HIV-infected pregnant 
women and their children is collected through the National Study of HIV in 
Pregnancy and Childhood (NSHPC), which includes information on over 8000 
pregnancies delivered between 1990 and 2007. The majority of diagnosed infected 
women now take highly active antiretroviral therapy (HAART) in pregnancy, which 
reduces the risk of mother-to-child HIV transmission. However, there have been 
concerns over the potential for maternal and fetal adverse effects, with conflicting 
findings from European and American studies regarding the association between 
HAART and premature delivery.  
In this thesis, trends over time in the demographic characteristics of HIV-infected 
pregnant women in the UK and Ireland are described, along with changes in the 
uptake of interventions for preventing mother-to-child transmission. Transmission 
rates are explored over a period when HAART was routinely available, and 
subgroups of women managed in the context of regularly updated national guidelines 
are compared with respect to their risk of transmission. Multivariable logistic 
regression models are used to assess the association between type of ART exposure 
in pregnancy and adverse outcomes including pre-eclampsia, prematurity, stillbirth, 
neonatal death and congenital abnormality. In addition, using data from the European 
Collaborative Study and the Pediatric Spectrum of HIV Disease project alongside the 
UK and Ireland data, the effects of differences in populations and methodologies 
(study design and analytical approach) on the observed association between HAART 
and premature delivery are investigated, and a pooled analysis of individual mother-
child pairs is carried out. Finally, the risks and benefits of ART in terms of adverse 
pregnancy outcomes and mother-to-child transmission were jointly modelled using 
Monte Carlo simulation methods, to produce a risk-benefit ratio. 
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Chapter 1 Introduction 
1.1 Global epidemiology of HIV  
In the 25 years since the human immunodeficiency virus type-1 (HIV) was first 
identified, around 60 million people have been infected with the virus and at least 25 
million have died (UNAIDS/WHO, 2007; Volberding et al., 2008). In 2007 alone, an 
estimated 33 million people were living with HIV worldwide, including 15 million 
women and 2.5 million children. Western and Central Europe accounted for 760,000 
of those individuals (UNAIDS/WHO, 2007), about a tenth (77,400) of whom were 
living in the United Kingdom (UK) (Health Protection Agency, 2008). Sub-Saharan 
Africa is by far the region most severely affected by the HIV pandemic, accounting 
for two thirds of all infections but only 10% of the world’s population (Volberding et 
al., 2008).  
HIV is transmitted through contact with infected blood, for example through blood 
transfusions or sharing of contaminated needles, through sexual contact, and 
vertically from mother-to-child, during pregnancy, delivery or breastfeeding (Thorne 
& Newell, 2003). In the early years of the HIV epidemic most infections occurred in 
high risk groups such as injecting drug users and homosexual men. Although these 
groups continue to experience higher rates of transmission than the general 
population, the HIV pandemic today is driven mainly by heterosexual transmission 
(UNAIDS, 2008). There is, however, widespread regional variation in the relative 
importance of these transmission routes. In Africa, where the epidemic is more 
generalised, the vast majority of infections are acquired heterosexually, while in 
Asia, ongoing transmission is driven by injecting drug use as well as commercial sex 
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(UNAIDS, 2008). An increase in heterosexually-acquired infections in Western 
Europe, particularly in people originating from sub-Saharan Africa, has led to a 
corresponding increase in the proportion of new infections in women from 25% in 
1995 to around 35% in 2006 (Hamers & Downs, 2004; Herida et al., 2007). In the 
UK, about 55% of newly diagnosed infections in 2007 were in heterosexual men and 
women, over two thirds of whom were born in Africa (Health Protection Agency, 
2008; The UK Collaborative Group for HIV and STI Surveillance, 2007). Paediatric 
HIV infection, acquired mainly through mother-to-child transmission (MTCT), 
accounts for only a small proportion of infections in Western Europe and other 
developed countries, thanks to effective prevention measures including antiretroviral 
therapy (ART), elective caesarean section delivery and avoidance of breastfeeding 
(Newell, 1998). In Africa, however, the absence of such measures means that over 
400,000 children are infected with HIV each year (UNAIDS/WHO, 2007). 
1.2 Biology of HIV infection and treatment 
HIV is a blood-borne ribonucleic acid (RNA) retrovirus that targets the immune 
system. There are two main variants, HIV-1 (discussed here) and HIV-2; HIV-2 is 
believed to have arisen from a different primate reservoir, is less pathogenic, and is 
rarely found outside of Western Africa (Lemey et al., 2003; Schim van der Loeff & 
Aaby, 1999). The HIV-1 epidemic is dominated by a number of subtypes, or clades, 
characterised by their geographic distribution: for example, subtype B accounts for 
most infections in Europe and the Americas, while subtype C dominates in southern 
Africa and South Asia (Osmanov et al., 2002).  
The HIV virus infects CD4+ T lymphocyte cells (CD4 cells) using CD4 receptors on 
the outside of the cell; after entry into the cell, the HIV RNA is transcribed into 
  23 
deoxyribonucleic acid (DNA), which becomes integrated into the host genome 
(Figure 1.1) (Male et al., 2006). The cell’s internal processes are then used to 
transcribe new viral RNA strands and produce viral proteins, including reverse 
transcriptase, protease and integrase enzymes, which are important in the life cycle 
of the virus and are the targets of different antiretroviral drugs. These viral products 
are assembled into new virions, which are released from the cell and proceed to 
infect new cells. The number of viral particles in the blood (viral load) reflects the 
severity of infection and can be measured using standard tests, which detect the 
number of HIV RNA copies per milliliter of blood. Viral load is said to be 
undetectable if it falls below the detection limit of the laboratory assay, which has 
been reduced from 1000 copies/ml to 50 copies/ml with improvements in assays 
(Mulder et al., 1994; Mulder et al., 1997). 
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Figure 1.1 HIV life cycle and structure 
 
 
 
Source: http://en.wikipedia.org/wiki/HIV (Accessed 25 January 2009)  
 
HIV impairs normal T lymphocyte function, eventually causing cell death, and 
infection is associated with a decline in CD4 cell levels in infected individuals 
(Figure 1.2). Primary infection is usually followed by a long and largely 
asymptomatic latent period (Figure 1.2). Median time from seroconversion to onset 
of symptoms is around 9 to 11 years and varies by age at infection and route of 
acquisition (Collaborative Group on AIDS Incubation and HIV Survival including 
the CASCADE EU Concerted Action, 2000). In the absence of treatment, a gradual 
decline in CD4 cells occurs throughout this period (Figure 1.2), leaving the 
individual increasingly vulnerable to mild opportunistic infections. Progression to 
acquired immune deficiency syndrome (AIDS) usually occurs once CD4 counts fall 
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below 200 cells/µl, and is associated with a more serious risk of opportunistic 
infections and ultimately death (Male et al., 2006).  
 
Figure 1.2 Relationship between HIV copies (viral load) and CD4 counts over 
the average course of untreated HIV infection 
 
 
 
 
Source: (Luzzi et al., 2003), obtained from http://en.wikipedia.org/wiki/HIV (Accessed 25 January 
2009). 
Antiretroviral therapy 
There are currently five main classes of antiretroviral drugs available, which target 
different stages of the HIV life cycle (Table 1.1). These drugs reduce viral replication 
and slow the onset of disease progression, but cannot completely clear the virus. The 
first three classes of antiretroviral drugs to be licensed were nucleoside or nucleotide 
reverse transcriptase inhibitors (NRTIs) in 1987, protease inhibitors (PIs) in 1995, 
and non-nucleoside reverse transcriptase inhibitors (NNRTIs) in 1996; entry 
inhibitors were added in 2003 and integrase inhibitors in 2007 (US Food and Drug 
Administration, 2008). 
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Table 1.1  Antiretroviral drugs 
 
Class of drug Activity / target Examples 
Nucleoside/nucleotide 
reverse transcriptase 
inhibitors (NRTIs)  
Prevent reverse transcription by 
inhibiting the reverse transcriptase 
enzyme; can also be incorporated into 
new viral DNA, causing DNA chain 
termination. 
 
zidovudine, 
lamivudine, abacavir, 
didanosine, stavudine, 
tenofovir 
Non-nucleoside 
reverse transcriptase 
inhibitors (NNRTIs) 
Inhibit reverse transcription directly 
by binding to the reverse transcriptase 
enzyme and interfering with enzyme 
activity.  
efavirenz, nevirapine 
Protease inhibitors 
(PIs) 
Inhibit the protease enzyme, which 
cleaves proteins for assembly into 
new viral particles. 
nelfinavir, saquinavir, 
ritonavir, atazanavir, 
lopinavir 
Integrase inhibitors  Inhibit the integrase enzyme, which is 
responsible for integration of the 
provirus into the host genome. 
raltegravir 
Fusion/entry 
inhibitors 
Interfere with binding, fusion or entry 
of HIV to the host cell by binding to 
targets such as chemokine receptors.  
enfuvirtide, maraviroc 
 
(Volberding et al., 2008; Weller & Williams, 2001) 
 
Zidovudine was the first drug to be licensed for treatment of HIV, and in 1994 was 
recommended for use in pregnancy (Public Health Service Task Force, 1994). 
Treatment with zidovudine alone delays disease progression but the benefits are 
short-lived. A combination of two drugs provides more effective viral suppression, 
and treatment with three or more drugs, or highly active antiretroviral therapy 
(HAART), usually from at least two different classes, is now standard. HAART 
traditionally consisted of two NRTIs and either a PI or an NNRTI, although the 
availability of new drug classes is leading to a wider range of possible regimens. 
Because the different classes of drugs target different stages of viral replication, 
treatment with combination therapy reduces the risk of the virus developing 
resistance to a given drug class. Current treatment guidelines in Europe and the UK 
recommend starting HAART once CD4 counts fall below 350 cells/µl, or an AIDS-
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defining condition is diagnosed (BHIVA, 2008; Panel on Antiretroviral Guidelines 
for Adults and Adolescents, 2008). 
1.3 HIV in pregnant women 
Antenatal prevalence 
In the UK, unlinked anonymous surveillance of HIV in pregnant women is carried 
out using neonatal blood samples that are routinely collected for newborn metabolic 
screening tests (Ades et al., 1991; Cortina-Borja et al., 2004). Residual samples are 
tested for the presence of HIV antibody, which reflects HIV seroprevalence in the 
mother due to the passive transplacental passage of maternal antibody to the fetus 
during pregnancy. The unlinked anonymous survey began in 1988, and in 2007 
covered 62% of births in England and Scotland, including London, the South East of 
England and most other metropolitan areas (Health Protection Agency, 2008; Nicoll 
et al., 1998). Samples are linked with birth registration records using the child’s date 
of birth and address, to obtain information on parental country of birth and area of 
residence; all personal identifiers are then permanently deleted (‘unlinked’) from 
laboratory records to preserve anonymity (Cortina-Borja et al., 2004).  
Unlinked anonymous surveys have shown a substantial rise in antenatal prevalence 
of HIV in the areas covered by the surveys over the last two decades. In London 
prevalence rose from 0.03% in 1988 to 0.19% in 1997 and 0.42% in 2006 (Nicoll et 
al., 1998; The UK Collaborative Group for HIV and STI Surveillance, 2005; The UK 
Collaborative Group for HIV and STI Surveillance, 2007). In the rest of England, 
prevalence remained low throughout the 1990s, but rose from 0.02% in 1997 to 
0.14% in 2006 (Figure 1.3) (The UK Collaborative Group for HIV and STI 
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Surveillance, 2007). The overall prevalence of HIV in women giving birth in 
England and Scotland more than doubled between 2000 and 2006 from 0.09% (about 
1 in 1140 women) to 0.23% (1 in 440 women) (The UK Collaborative Group for 
HIV and STI Surveillance, 2005; The UK Collaborative Group for HIV and STI 
Surveillance, 2007). HIV prevalence in the UK is highest among women born in sub-
Saharan Africa (2.1% in 2006) (Cortina-Borja et al., 2004), although this is notably 
lower than prevalence rates in sub-Saharan Africa, which are over 5% in most 
countries, and over 25% in many southern African countries (UNAIDS, 2008). HIV 
prevalence in UK-born women is much lower, but increased significantly between 
2000 and 2006, from 0.02% to 0.05% (The UK Collaborative Group for HIV and 
STI Surveillance, 2007). 
 
Figure 1.3 HIV prevalence among pregnant women in England and Scotland 
by area of residence  
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Prevalence obtained from unlinked anonymous survey of newborn infant dried blood spots; includes 
diagnosed and undiagnosed women. Adapted from Figure 1, published on the Health Protection 
Agency website, 2008 (www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/ 
1203084355122#f1, accessed 25 January 2009). 
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Antenatal testing and detection rates 
In most resource-rich countries, including those in Western Europe, pregnant women 
are now routinely offered an HIV test during pregnancy (Deblonde, Claeys, & 
Temmerman, 2007). In England, the Department of Health introduced a policy of 
routine offer and recommendation of antenatal HIV testing in 1999, to be 
implemented by the end of 2000 (NHS Executive, 1999). At the time, most units 
only provided HIV testing on request or for selected groups of women perceived to 
be at higher risk, but this approach was largely ineffective (Nicoll et al., 1998; 
Tookey et al., 1998). A target of 90% uptake of testing was set for the end of 2002, 
with the aim of diagnosing 80% of HIV-infected pregnant women. A similar 
universal testing policy was implemented in Ireland around the same time (Health 
Protection Surveillance Centre, 2007), and Scotland, Wales and Northern Ireland 
followed in 2002 and 2003 (Communicable Disease Surveillance Centre Northern 
Ireland, 2003; National Institute for Clinical Excellence, 2003; Scottish Executive 
Health Department, 2002). Uptake of antenatal testing rose rapidly following the 
introduction of the policy, and by 2003 almost all London antenatal units and around 
60% of units elsewhere in England were reporting over 80% uptake of testing 
(Figure 1.4) (Townsend, Cliffe, & Tookey, 2006).  
The proportion of HIV-infected pregnant women diagnosed before delivery can be 
estimated by aligning unlinked anonymous seroprevalence data with cases of 
diagnosed HIV infection in pregnancy reported to the National Study of HIV in 
Pregnancy in Childhood (NSHPC). Although individual cases cannot be linked, the 
alignment provides an estimate of the proportion of women detected through 
antenatal screening at a regional level. Before 1997, less than 25% of HIV-infected 
pregnant women were diagnosed before they delivered (Nicoll et al., 1998). By 1999 
detection rates had already risen to around 60%, and since 2003, following the 
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introduction of universal antenatal screening, rates of over 90% have been achieved 
(Figure 1.5) (The UK Collaborative Group for HIV and STI Surveillance, 2005; The 
UK Collaborative Group for HIV and STI Surveillance, 2007).  
 
Figure 1.4 Uptake of antenatal HIV testing over time in London and elsewhere 
in England, among units in which the routine offer policy had been 
implemented and for which adequate data were provided 
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Adapted from: Townsend CL, Cliffe S, Tookey PA. Uptake of antenatal HIV testing in the United 
Kingdom: 2000-2003. J Public Health (Oxf) 2006; 28(3): 248-252. By permission of Oxford 
University Press. 
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Figure 1.5 Estimated proportion of HIV-infected pregnant women diagnosed 
before delivery and of exposed infants becoming infected with HIV1, England & 
Scotland 
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Adapted from Figure 5, published on the Health Protection Agency website, 2008 
(www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1203084355122#f1, accessed 26 
January 2009). 
 
 
Pregnancy and HIV 
Before ART became widely available, many diagnosed HIV-infected women would 
not have considered parenthood; prognosis and life expectancy were poor, and the 
risk of a child being infected was around 15-20% in Europe (Duong et al., 1999; 
European Collaborative Study, 2001). HIV diagnosis was associated with a decline 
in pregnancy incidence and live birth rates (Stephenson & Griffioen, 1996; van 
Benthem et al., 2000) and an increase in termination rates (van Benthem et al., 
2000). As well as altering reproductive decisions, HIV infection may also affect the 
ability to conceive or to carry a pregnancy to term. Lower conception rates and 
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increased pregnancy loss compared with uninfected controls have been reported in 
some cohorts of infected women in Africa, although not in all (Allen et al., 1993; 
Gray et al., 1998; Nebie et al., 2001). Over the last decade, ART has led to dramatic 
reductions in morbidity and mortality, as well as in the risk of MTCT (European 
Collaborative Study, 2001; European Collaborative Study, 2005d; Mocroft et al., 
2003). Recent studies have shown that HIV-infected women are now more likely to 
desire children (Cliffe, 2005; Heard, Sitta, & Lert, 2007); there is also evidence that 
births to HIV-infected women have increased, and that fewer women are opting for 
terminations (European Collaborative Study, 2005b; Massad et al., 2004; van 
Benthem et al., 2000).  
Pregnancy itself does not appear to adversely affect the course of HIV disease 
(European Collaborative Study and the Swiss HIV Pregnancy Cohort, 1997; Minkoff 
et al., 2003; Saada et al., 2000), nor does short-course treatment in pregnancy, either 
in terms of progression to AIDS or death, or in terms of changes in CD4 cell count or 
HIV RNA viral load levels (Bardeguez et al., 2003; Martin et al., 2006; Tungsiripat, 
Drechsler, & Aberg, 2007). Declines in CD4 count in pregnancy have been reported, 
but appear to be due to haemodilution, and tend to resolve after delivery (Saada et 
al., 2000; Tuomala et al., 1997). Although evidence is limited, there does not appear 
to be a detrimental effect of short-course HAART or zidovudine monotherapy in 
pregnancy on subsequent response to treatment (Martin et al., 2006). 
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1.4 Mother-to-child transmission  
Mechanisms, timing and rates 
Mother-to-child transmission of HIV can take place in the antepartum, intrapartum 
and postpartum period and occurs through contact with infected maternal fluids and 
through breastfeeding (Newell, 1998). Although the placenta acts as an important 
barrier to HIV, in utero transmission can occur, probably as a result of transfusion of 
infected blood to the fetus through small tears in the placenta, or through placental 
disruption, for example by chorioamnionitis (Newell, 1998). Most perinatal HIV 
transmission occurs around the time of delivery, following exposure of the infant to 
maternal vaginal secretions and infected blood (Mofenson, 1997; Newell, 1998). 
Transmission also occurs postnatally through breastfeeding, which accounts for a 
third to half of perinatal infections in breastfeeding populations (Fowler & Newell, 
2002). In an individual patient meta-analysis, the rate of postnatal transmission after 
four weeks of age was estimated to be 8.9 per 100 child-years of breastfeeding (The 
Breastfeeding and HIV International Transmission Study (BHITS) Group, 2004). In 
the absence of prophylactic interventions, MTCT rates for HIV are estimated to 
range from 13% to 32% in resource-rich countries and from 25% to 48% in resource-
poor countries (Dabis et al., 1993), with differences attributed mainly to variation in 
breastfeeding duration. 
Factors shown to be associated with MTCT include maternal plasma HIV RNA viral 
load, CD4 count, mode of delivery, duration of ruptured membranes and gestational 
age at delivery (European Collaborative Study, 1996b; Stratton et al., 1999; Thorne 
& Newell, 2004b). HIV RNA viral load is the strongest predictor of MTCT, with a 
doubling of risk for each log10 increase in viral load (Cooper et al., 2002; European 
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Collaborative Study, 1999). Low CD4 count is also associated with an increased risk 
of transmission (European Collaborative Study, 1996b; European Collaborative 
Study, 2001). Differences in transmission by mode of delivery were first detected in 
observational studies in the early 1990s, in which elective caesarean section was 
found to be associated with a reduced risk of transmission compared with vaginal 
delivery (European Collaborative Study, 1994; European Collaborative Study, 1999; 
Moodley et al., 1994). This was confirmed in both a randomised clinical trial and a 
meta-analysis, which demonstrated a more than 50% reduction in transmission 
associated with planned pre-labour caesarean section (The European Mode of 
Delivery Collaboration, 1999; The International Perinatal HIV Group, 1999). In a 
meta-analysis, which included mostly untreated women, duration of ruptured 
membranes was associated with a 2% increase in transmission for each additional 
hour of ruptured membranes (The International Perinatal HIV Group, 2001). 
Prematurity was found to be a risk factor for transmission in early studies of women 
who were mostly untreated or on zidovudine alone (European Collaborative Study, 
1996b; European Collaborative Study, 1999; Kuhn et al., 1999). However, it is less 
clear whether premature delivery remains an independent predictor of transmission 
in HAART-treated women, particularly if viral load is suppressed (European 
Collaborative Study, 2005d; Warszawski et al., 2008). 
The primary intervention for reducing MTCT is ART, which is administered to the 
mother during pregnancy and delivery to reduce plasma HIV RNA viral load, and to 
the neonate as prophylaxis (Newell & Thorne, 2004). Elective caesarean section 
delivery and formula feeding are also now standard practice in resource-rich settings 
(BHIVA/CHIVA, 2008). This combined prevention approach led to overall declines 
in MTCT rates in resource-rich countries from around 20-25% to around 1-2% in the 
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late 1990s (Centers for Disease Control and Prevention, 2006; Cooper et al., 2002; 
Duong et al., 1999; European Collaborative Study, 2001), and rates of 1% or less 
have been reported in recent years (Dorenbaum et al., 2002; European Collaborative 
Study, 2005d; Peters et al., 2008; Warszawski et al., 2008). Widespread use of 
HAART has meant that the majority of women achieve low or undetectable HIV 
RNA viral load by the time of delivery, and it is now unclear whether planned 
caesarean section delivery confers any additional benefit for these women. Elective 
caesarean section may carry a higher risk of postpartum morbidity than vaginal 
delivery (Read & Newell, 2005), although possibly not in women on HAART 
(Duarte et al., 2006). Since 2005, guidelines have suggested that women on HAART 
who have uncomplicated pregnancies and an undetectable viral load may attempt a 
vaginal delivery, although there was limited evidence to support this 
recommendation. There is also uncertainty about the role of obstetric factors, such as 
duration of ruptured membranes and premature delivery, in relation to the risk of 
MTCT among women achieving viral suppression (European Collaborative Study, 
2005d; Jamieson et al., 2007; Newell & Thorne, 2004).  
Antiretroviral therapy in pregnancy 
In 1994, the beneficial effects of zidovudine in pregnancy were first demonstrated in 
the AIDS Clinical Trial Group (ACTG) 076 trial of women with CD4 counts above 
200 cells/µl, in which zidovudine was administered antenatally, starting between 14 
and 34 weeks gestation (median 28 weeks), intravenously in labour, and orally to the 
baby for the first six weeks of life (Connor et al., 1994). The transmission rate was 
two thirds lower in the intervention (8%) than in the control arm (25%). The benefits 
of zidovudine have also been demonstrated in a number of observational studies in 
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non-breastfeeding populations (Cooper et al., 2002; European Collaborative Study, 
2001; Kind et al., 1998; Mayaux et al., 1997). Subsequently, the addition of 
lamivudine, another NRTI, to the 076 protocol was shown to further reduce the 
transmission rate to 1.6% in the Agence Nationale de Recherche sur le Sida (ANRS) 
075 trial, but this was overshadowed by concerns about adverse events and drug 
resistance (Mandelbrot et al., 2001). There have been no clinical trials of HAART in 
pregnancy, partly due to the low transmission rates (<2%) achieved with 
combination therapy (Dorenbaum et al., 2002), but it has been shown in 
observational studies to have a greater effect on transmission rates than zidovudine 
alone. In the Women and Infants Transmission Study of around 1500 women in the 
United States (US), MTCT occurred in 10% of those taking zidovudine, 4% of those 
receiving dual therapy, and 1.2% of those on HAART (Cooper et al., 2002). In 
developed countries, HAART is now the standard of care for treatment in pregnancy, 
with transmission rates around 1% (European Collaborative Study, 2005d; 
Warszawski et al., 2008).  
In recent years, a substantial proportion of women have been conceiving on HAART 
(European Collaborative Study, 2005a; Watts et al., 2007). Current recommendations 
suggest that normal treatment should be continued after conception, with the 
exception of efavirenz (see page 42) (BHIVA/CHIVA, 2008; Perinatal HIV 
Guidelines Working Group, 2008). The majority of women diagnosed for the first 
time in pregnancy initiate treatment during the second or third trimester of 
pregnancy. Some women may already have depleted CD4 cell counts at diagnosis 
and require HAART for their own health, but for those diagnosed at an earlier stage 
of disease and initiating treatment purely for MTCT prophylaxis, less potent 
treatment options may be considered. Although zidovudine monotherapy is no longer 
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used for treatment of HIV-infected adults or children, it remains an option for MTCT 
prevention. Early studies suggested that when used in combination with elective 
caesarean section and no breastfeeding, zidovudine could reduce the risk of MTCT to 
below 1% (European Mode of Delivery Collaboration, 1999). The British HIV 
Association (BHIVA) Guidelines currently support this strategy for women who do 
not need HAART for their own health, have a pre-treatment viral load below 6000-
10,000 copies/ml and are willing to deliver by planned pre-labour caesarean section 
(BHIVA/CHIVA, 2008). Recommendations in the US are more cautious, suggesting 
that zidovudine monotherapy should only be considered in women with viral load 
<1000 copies/ml (Perinatal HIV Guidelines Working Group, 2008). There are 
limited data on the selective use of zidovudine monotherapy for preventing MTCT in 
women who do not require HAART, and no trials have addressed the relative 
efficacy of this approach compared with short-course HAART. In an audit that 
included 85 women who received zidovudine monotherapy in pregnancy, only a 
quarter had started HAART following pregnancy (at a median of 28 months follow-
up), and they were just as likely to have responded to treatment as those who had 
received short-course HAART (Martin et al., 2006).  
1.5 Safety and toxicity of antiretroviral therapy 
Despite the clear benefits of ART, a number of side effects can occur, including 
nausea, vomiting, diarrhoea and rash, as well as a range of metabolic toxicities 
(Herman & Easterbrook, 2001). Lipodystrophy, or wasting of peripheral fat, is one of 
the more common symptoms experienced by patients on antiretroviral drugs (Carr et 
al., 1998). More serious, acute toxicities can also occur: use of NRTIs can cause 
mitochondrial toxicity and has been shown to be associated with hyperlactataemia 
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(Brinkman et al., 1998; Gerard et al., 2000). In severe cases, toxicity can result in 
lactic acidosis, multi-organ failure and death. A number of reports of lactic acidosis 
in pregnant women have emerged, with several deaths (Luzzati et al., 1999; 
Mandelbrot et al., 2003; Sarner & Fakoya, 2002), and in 2001 the FDA issued a 
warning against the use of stavudine and didanosine in pregnancy; guidelines now 
recommend avoiding these drugs when pregnant (BHIVA/CHIVA, 2008; Coll et al., 
2002; Perinatal HIV Guidelines Working Group, 2008). 
Nevirapine, an NNRTI, was commonly used in first-line therapy along with 
zidovudine and lamivudine, but there is now growing evidence linking this drug to 
an increased risk of hepatotoxicity in adults, particularly women and those with CD4 
counts over 250 cells/µl (Baylor & Johann-Liang, 2004; Mazhude et al., 2002). 
Symptoms usually appear in the first few weeks of treatment and include hepatitis, 
liver failure and rash. In severe cases nevirapine exposure can cause Stevens-Johnson 
syndrome, a hypersensitivity reaction affecting the skin; a number of such cases, 
including several deaths, have been reported in pregnant women (Hitti et al., 2004; 
Joao et al., 2006; Lyons et al., 2003; Marazzi et al., 2006). Because the risk of 
hepatotoxicity is associated with less advanced immunosuppression, nevirapine is no 
longer recommended for pregnant women with CD4 counts above 250 cells/µl 
(BHIVA/CHIVA, 2008; Coll et al., 2002; Perinatal HIV Guidelines Working Group, 
2008).  
Prematurity 
Concerns about high rates of premature delivery in women on combination therapy 
were first raised in 1998 in a small Swiss study (Lorenzi et al., 1998). Since then, 
several other studies have reported similar findings (Boer et al., 2007; European 
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Collaborative Study, 2004a; Grosch-Woerner et al., 2008). It has been suggested that 
by reversing the immunological decline associated with HIV infection, ART could 
potentially be detrimental to the maintenance of pregnancy, which requires 
suppression of the pro-inflammatory component of the immune system (Fiore et al., 
2006). Nevertheless, several large-scale studies, mostly in the US, have failed to 
detect an association between ART and prematurity (Tuomala et al., 2002; Tuomala 
et al., 2005). Reasons for these conflicting findings remain unclear, but could relate 
to the limitations of observational data, including the inability to adjust for other risk 
factors for preterm delivery, the prevalence of which may differ between studies 
(Newell et al., 2007), and bias in treatment allocation (Tuomala & Yawetz, 2006). 
Studies in Europe 
Following the initial report from Switzerland, the association between ART and 
prematurity was confirmed first in a combined analysis of the European 
Collaborative Study (ECS) and the Swiss study, and subsequently in an updated ECS 
analysis, which showed a two-fold increase in prematurity among 1075 women on 
HAART compared with 704 women on monotherapy or dual therapy (European 
Collaborative Study, 2004a; European Collaborative Study and the Swiss Mother + 
Child HIV Cohort Study, 2000). Some smaller studies reported a lack of association 
between treatment and prematurity, probably due to methodological differences 
(Bucceri et al., 2002; Mandelbrot et al., 2001). More recently, a significant 
association between HAART and prematurity has been reported from Germany, the 
Netherlands and the UK (Boer et al., 2007; Grosch-Woerner et al., 2008; Martin & 
Taylor, 2007).  
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Studies in the United States 
Reports from the US have been conflicting, with initial reports suggesting no adverse 
effect of ART on timing of delivery. In an analysis of two clinical trials and five 
observational studies, prematurity rates were 15% in 533 women on combination 
therapy and 16% in 1590 women on monotherapy (Tuomala et al., 2002). This study 
did show a 3.5-fold increased risk of very low birth weight (<1500 g) associated with 
PI-containing combination therapy. A more recent analysis based on the Women and 
Infants Transmission Study in the US also reported a lack of association between 
ART and prematurity (Tuomala et al., 2005). However, in two other US studies, 
preterm delivery was significantly associated with PI-containing therapy (Cotter et 
al., 2006; Schulte et al., 2007).  
Other studies 
Few studies from outside Europe and the US have addressed the issue of ART and 
prematurity. In a South American study of 681 ART-treated women, unadjusted 
prematurity rates were 1.5 times higher in women on PI-based HAART compared 
with monotherapy or dual therapy, but the association was not significant (95% 
confidence interval [CI]: 0.6-3.4), possibly due to the small number of women on 
mono/dual therapy (n=94) (Szyld et al., 2006). Recently, published findings from a 
study of over 300 pregnant women in Côte d’Ivoire, showed over a two-fold increase 
in low birth weight (<2500 g) associated with HAART in pregnancy, compared with 
zidovudine alone or in combination with lamivudine (Ekouevi et al., 2008). 
Although gestational age was not available, and low birth weight was taken as a 
proxy, the association is likely due to prematurity.  
In an attempt to inform the debate about ART and prematurity, a meta-analysis was 
carried out by Kourtis and colleagues (Kourtis et al., 2007). Seven studies were 
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included in the comparison of combination therapy and monotherapy, and the 
authors concluded that there was no association with prematurity. However, they also 
found that longer duration of treatment and regimens that included a PI might 
increase the risk of prematurity. A significant degree of heterogeneity was noted 
between the studies, and questions remain about the appropriateness of merging the 
results (Patel, Thorne, & Newell, 2007).  
Other obstetric outcomes  
Pre-eclampsia  
There is some evidence that pre-eclampsia is less common in HIV-infected than 
uninfected women, probably because HIV suppresses the inflammatory responses 
which contribute to the pathology of pre-eclampsia (Hall, 2007; Stratton et al., 
1999). However, two studies have suggested that the use of HAART may reverse this 
effect: results from a cohort study of 214 women seen in two London hospitals 
demonstrated a significantly increased risk of pre-eclampsia among women on 
HAART (8/76) compared with untreated women (0/61) (Wimalasundera et al., 
2002). In another study, a sharp increase in cases of pre-eclampsia was reported for 
2001 to 2003, compared with data from 1985 to 2000, which the authors attributed to 
the increased use of HAART prior to pregnancy; women who were on HAART at 
conception were almost nine times more likely to develop pre-eclampsia than those 
who were not (Suy et al., 2006). 
Gestational diabetes 
Concerns about gestational diabetes have also been raised. Impaired glucose 
tolerance was reported in 8% of ART-treated women in a small retrospective study 
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(Chmait et al., 2002). A significant link between PIs and gestational diabetes was 
detected in the Pediatric AIDS Clinical Trials Group (PACTG) 316 trial, with rates 
of 4.6% in women on PIs compared with 1.7% in those not on PIs (Watts et al., 
2004a), and an increase over time in hospitalisations for gestational diabetes in HIV-
infected pregnant women in the US has also been reported (Kourtis et al., 2006). 
However, in two recent studies that explored the use of PIs and glucose intolerance, 
no association was detected (Hitti et al., 2007; Tang et al., 2006). 
Stillbirth 
In light of the proposed mechanisms underlying the association between ART and 
both pre-eclampsia and premature delivery, an increase in the risk of stillbirth might 
also be expected, particularly since pre-eclampsia is associated with an increased risk 
of fetal death (Sibai, Dekker, & Kupferminc, 2005). However, few studies have been 
large enough to investigate this association. In the study by Suy and colleagues 
described above, fetal death rates increased over time and were seven-fold higher in 
women on HAART before pregnancy than in those starting during pregnancy (Suy et 
al., 2006). No association between ART and stillbirth has been reported in any other 
study, although in all cases the number of stillbirths was small (Ekouevi et al., 2008; 
Tuomala et al., 2002; Tuomala et al., 2005; Watts et al., 2004a).  
Congenital abnormalities 
Animal studies have provided limited evidence for a teratogenic effect of 
antiretroviral drug exposure in pregnancy. In monkeys, spinal malformations have 
been observed in fetuses exposed to efavirenz (Nightingale, 1998); spinal anomalies 
in human infants exposed in utero have also been reported (De Santis et al., 2002; 
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Fundaro et al., 2002), and efavirenz is now contra-indicated in early pregnancy 
(BHIVA/CHIVA, 2008; Perinatal HIV Guidelines Working Group, 2008).  
Large-scale epidemiological studies have not shown any overall increase in 
abnormality rates associated with first trimester ART exposure (European 
Collaborative Study, 2005a; Watts et al., 2007), nor have other smaller European 
cohorts (Bucceri et al., 2002; Mandelbrot et al., 2001). In addition, the Antiretroviral 
Pregnancy Registry (APR), an international prospective monitoring system based in 
the US, has reported no increased risk of birth defects associated with exposures to 
several individual drugs with numbers large enough to detect a 1.5-fold (zidovudine 
and lamivudine) or two-fold (abacavir, efavirenz, lopinavir, nelfinavir, nevirapine, 
ritonavir, stavudine, and tenofovir) increase in risk (Antiretroviral Pregnancy 
Registry Steering Committee, 2008; Covington et al., 2004; Watts et al., 2004b). 
However, an increased prevalence of abnormalities (4.5%, 95% CI: 2.6-7.3%) was 
recently detected in 266 infants exposed to didanosine, compared with a population 
rate of 2.7% (Antiretroviral Pregnancy Registry Steering Committee, 2008). An 
increased rate of genital abnormalities (hypospadias) associated with first trimester 
antiretroviral exposure has also been reported (7 of 382 male infants, versus 2 of 892 
unexposed infants) (Watts et al., 2007); these findings have yet to be confirmed in 
other studies, and further investigation is required. Concerns were also raised in 
relation to combined exposure to ART and folate antagonists following a report from 
a retrospective multi-centre study in London (Jungmann et al., 2001), but the study 
included only nine infants with congenital abnormalities, and to date no other studies 
have raised similar concerns.  
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Other paediatric outcomes  
Exposure to antiretroviral drugs has been shown to produce short- to medium-term 
changes in haematological parameters in exposed infants, including anaemia and 
reductions in platelets, neutrophils and lymphocytes (Connor et al., 1994; Le 
Chenadec et al., 2003; Sperling et al., 1998). Reduced neutrophil and CD8+ 
lymphocyte counts have been shown to persist to at least eight years of age 
(European Collaborative Study, 2004b; European Collaborative Study, 2005c). 
However, the clinical significance of these observations is unclear; in a small study 
involving 16 children, no clinical symptoms were reported despite moderate-to-
severe toxicity based on absolute neutrophil counts (Bunders, Thorne, & Newell, 
2005). 
A high incidence of mitochondrial dysfunction has been reported in a cohort of ART-
exposed children in France (Barret et al., 2003; Blanche et al., 1999), and other cases 
have been reported from Italy and Spain (Noguera et al., 2003; Tovo et al., 2005). 
However, several studies in Europe and the US have failed to detect an increase in 
deaths in uninfected ART-exposed children (Bulterys et al., 2000; Dominguez et al., 
2000; European Collaborative Study, 2003; Lindegren et al., 2000; The Perinatal 
Safety Review Working Group, 2000). Although there is evidence from umbilical 
cord blood that mitochondrial damage can occur following exposure to ART in utero 
(Divi et al., 2004; Divi et al., 2007; Shiramizu et al., 2003), the actual risk of long-
term neurological disease remains unclear.  
Studies in animals and using human cord blood have also demonstrated the potential 
for genotoxic and carcinogenic effects of in utero ART exposure (Olivero et al., 
1997; Olivero et al., 1999; Olivero et al., 2002). Epidemiological studies have so far 
detected no increase in tumour incidence in children exposed to ART, with median 
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age at last follow-up ranging from two to four years (Culnane et al., 1999; European 
Collaborative Study, 2003; Hankin et al., 2007; Hanson et al., 1999). However, the 
potential for an increased risk of malignancies in later childhood or adulthood cannot 
be excluded.
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1.6 Rationale for this thesis and overview 
In the UK and Ireland, surveillance of HIV infection in pregnant women and children 
is carried out through the National Study of HIV in Pregnancy and Childhood 
(NSHPC). Through this unique surveillance system, information is collected 
prospectively on all pregnancies in HIV-infected women, and children are followed 
up through paediatricians to establish their infection status. Chapter 2 of this thesis 
provides an overview of the NSHPC and its methodology, and describes the other 
data sources used in this thesis.  
Although the various risk factors for MTCT were well described in the mid- to late 
1990s, HAART is now widely used in pregnancy and it is unclear whether factors 
such as vaginal delivery and prematurity remain associated with transmission in 
women with low or undetectable HIV RNA viral load. Furthermore, the impact of 
different strategies to prevent MTCT – for example, zidovudine monotherapy 
combined with elective caesarean section, or HAART combined with vaginal 
delivery – has not been investigated at a population level. The first part of Chapter 3 
covers the epidemiology of HIV in pregnant women in the UK and Ireland since 
1990, and in the second part of the chapter, MTCT rates are explored among women 
reported since 2000. 
Data collected through the NSHPC has also enabled adverse effects associated with 
treatment to be monitored. Questionnaires are routinely updated to address pertinent 
issues; for example, because of concerns raised about HAART and pre-eclampsia, 
information on pregnancy complications has been collected since 2004. These 
findings are reported in Chapter 4, along with an analysis of first trimester exposure 
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to ART and the risk of congenital abnormalities. Because of the large number of 
HIV-affected pregnancies reported in the UK and Ireland, and the fact that data are 
collected prospectively through two parallel systems (obstetric and paediatric), some 
of the limitations encountered in smaller studies or passive reporting systems are 
avoided. In the first part of Chapter 5, the association between HAART and 
prematurity is explored using NSHPC data. The aim of the second part of the chapter 
is to investigate the reasons for conflicting findings with regard to ART and 
prematurity, by comparing three studies with different methodologies, including one 
based in the US.  
Finally, in Chapter 6, Monte Carlo simulation models are used to compare the risks 
and benefits of ART in terms of pregnancy outcome and MTCT, and to quantify the 
ratio of risks to benefits for different treatment scenarios. Chapter 7 concludes with a 
full discussion of the findings, including their implications for policy and for future 
work in this field.  
Areas not addressed in this thesis 
Since no further information on HIV-infected women is collected through the 
NSHPC after delivery, this thesis could not address the impact of pregnancy or short-
course treatment on postpartum HIV disease progression. Uninfected children are not 
routinely followed up once their infection status is established, so it was not possible 
to investigate the potential consequences of in utero ART exposure for exposed 
children. Follow-up of uninfected exposed children reported to the NSHPC was 
carried out between 2002 and 2005 in the CHART (CHildren exposed to 
Antiretroviral Therapy) study by Hankin and colleagues (Hankin, 2006; Hankin et 
al., 2009).
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1.7 Key Points 
• Antiretroviral therapy is widely used for effective treatment of HIV disease, and 
for prevention of mother-to-child transmission (MTCT).  
• Prevalence of HIV in women giving birth in England and Scotland has increased 
significantly in recent years, rising from 0.09% in 2000 to 0.23% in 2006.  
• In the UK and Ireland, pregnant women are routinely offered an antenatal HIV 
test, and over 90% of infected women are now diagnosed by the time of delivery. 
•  MTCT can occur during pregnancy, at delivery and through breastfeeding, and is 
associated with high maternal HIV RNA viral load, CD4 cell count, duration of 
ruptured membranes and premature delivery.  
• The risk of MTCT can be reduced with antiretroviral therapy, elective caesarean 
section delivery and formula feeding; these interventions have led to a decline in 
rates of MTCT in resource-rich countries from around 20-25% in the early 1990s 
to 1-2% in recent years.  
• Most women now receive HAART in pregnancy and achieve low or undetectable 
HIV RNA viral load by the time of delivery. In this context, the contribution of 
other interventions and factors such as mode of delivery, duration of ruptured 
membranes and prematurity to MTCT risk has become less clear in recent years.  
• ART is associated with a number of adverse effects; in some studies, an 
association between HAART in pregnancy and preterm delivery has been 
reported.  
• Animal studies have suggested a potential risk of congenital abnormalities 
associated with ART exposure in early pregnancy, but so far no increased risk of 
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abnormalities has been detected in large-scale observational studies of children 
exposed to ART in utero.  
• Other adverse effects reported in ART-treated pregnant women include pre-
eclampsia, gestational diabetes, lactic acidosis, nevirapine-associated 
hepatotoxicity, and fetal death.  
• Quantifying the risk of HAART in relation to the benefits in an important step in 
better understanding the relationship between ART and adverse events, and in 
improving the management of HIV in pregnancy. 
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Chapter 2 Aims and methods 
2.1 Aim and objectives  
Aim 
To explore the association between antiretroviral therapy (ART) and pregnancy 
outcome in HIV-infected women in the UK and Ireland. 
Objectives 
1. To describe changes in the epidemiology of HIV in pregnant women over 
time, and estimate mother-to-child transmission rates according to risk factors 
and uptake of interventions. 
2. To explore the association between ART and pregnancy and perinatal 
outcomes (pre-eclampsia, prematurity, birth weight, perinatal death, 
congenital abnormalities), allowing for maternal characteristics. 
3. To explore differences in the association between ART and premature 
delivery in three observational studies (the National Study of HIV in 
Pregnancy and Childhood, the European Collaborative Study, and the 
Pediatric Spectrum of HIV Disease project), and to investigate the importance 
of methodology and analytical approach in explaining these differences. 
4. To model the risks and benefits of ART in terms of adverse pregnancy 
outcomes and mother-to-child transmission, using Monte Carlo simulation 
methods. 
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2.2 Data sources  
The National Study of HIV in Pregnancy and Childhood 
Surveillance of HIV and AIDS in pregnant women and children in the UK and 
Ireland is carried out through the National Study of HIV in Pregnancy and Childhood 
(NSHPC) (www.nshpc.ucl.ac.uk), based at the University College London (UCL) 
Institute of Child Health. The surveillance study relies mainly on two parallel, 
confidential reporting schemes, which aim to capture all diagnosed HIV-infected 
pregnant women accessing antenatal care, all HIV-infected children, and all infants 
born to infected women regardless of their own infection status (Figure 2.1).  
Obstetric scheme  
Obstetric HIV surveillance began in 1989 and is run under the auspices of the Royal 
College of Obstetricians and Gynaecologists (RCOG). Designated respondents 
(mostly midwives, obstetricians or genito-urinary physicians) responsible for all 
maternity units (n ~240) in the UK and Ireland are contacted quarterly and asked to 
report all pregnancies in HIV-infected women, regardless of the timing of HIV 
diagnosis or pregnancy outcome, using a standard reporting card (Appendix 2, page 
371). The surveillance scheme is active, meaning that a response is required even if 
no cases are seen, and response rates of 93-96% are achieved (Table 2.1). Data on 
each reported pregnancy are collected using a notification form (Appendix 2, page 
372) completed by the respondent. For pregnancies due to continue to term, a follow-
up form is sent near the time of delivery (Appendix 2, page 373). No names are 
collected, but obstetric reports are linked to previous pregnancies and paediatric 
reports using dates of birth and demographic details, and duplicates are excluded. 
Questionnaires are reviewed and updated periodically. 
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Figure 2.1 Overview of NSHPC surveillance scheme 
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Table 2.1 Pregnancies in HIV-infected women: reports made by December 
2008 through the obstetric reporting scheme 
 
Reporting period
Response rate (%) 
*
Number of 
confirmed cases
Not yet confirmed 
**
1989 - 1999 94-96 1360 0
2000 - 2002 95-96 2031 0
2003 93 1066 28
2004 93 1277 39
2005 93 1239 89
2006 94 1355 103
2007 96 1390 149
Jan - Mar 2008 94 325 55
Apr - Jun 2008 91 304 100
Jul - Sep 2008 80 193 148
 
 
* Response rate for return of initial reporting card. 
** Number of cases reported on initial card, but not confirmed by return of notification form. 
 
N.B. Response rates for the last two quarters are likely to increase as late reports are received. 
Updated tables appear quarterly on the NSHPC website: www.nshpc.ucl.ac.uk (‘Latest Summary 
Data’). 
 
 
Paediatric scheme 
Paediatric HIV surveillance began in 1986, and is run mainly through the British 
Paediatric Surveillance Unit (BPSU) of the Royal College of Paediatrics and Child 
Health (BPSU, 2008; Nicoll et al., 2000). Children with HIV infection and infants 
born to HIV-infected women are reported by paediatricians through the BPSU’s 
orange card scheme (Appendix 2, page 374), an active monthly reporting system for 
rare conditions of childhood. Notified cases are reported to the NSHPC, and 
paediatricians are asked to complete a notification form (Appendix 2, page 375). 
Some paediatric units responsible for large numbers of HIV-exposed children report 
directly to the NSHPC. Following the initial report, additional information is 
requested to ascertain infection status (Appendix 2, page 379), and infected children 
are followed up annually, mainly through the Collaborative HIV Paediatric Study 
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(CHIPS), a collaboration between the NSHPC, the Medical Research Council (MRC) 
Clinical Trials Unit, and the paediatric centres looking after the children. Laboratory 
reports of HIV in children under the age of 16 are also provided by the Health 
Protection Agency (HPA) in England and Wales and by Health Protection Scotland 
(HPS). All incoming reports, both from paediatric respondents and from the HPA 
and HPS, are checked against previously reported children using dates of birth and 
other identifiers to avoid duplicates.  
Data collection 
NSHPC data collection forms are regularly updated in order to include new questions 
and refine old questions (Table 2.2). Each version of the form is dated, and this is 
recorded on the database for each reported case.  
Information collected through the obstetric scheme includes maternal demographic 
details, mode of acquisition of HIV, time and place of HIV diagnosis, details of 
ART, recent laboratory investigations, and expected date of delivery. Ethnic origin is 
reported as white, black African, black Caribbean, Asian, Oriental, black other, 
mixed and other. HIV exposure categories include “from high prevalence area”, 
injecting drug use and HIV positive partner, with the option of specifying other 
exposures, such as receipt of transplant or blood product, occupational exposure, or 
sex work. Details of individual antiretroviral drugs taken in pregnancy are collected 
along with date (or gestation week) of initiation. Information on maternal clinical 
status is collected at the time of notification and at delivery. Maternal CD4 cell count 
has been collected since 1990, and HIV RNA plasma viral load since 1997; 
laboratory protocols and viral load assay types varied between hospitals and over 
time, but details are not routinely requested. Data collected at the time of delivery 
include date and mode of delivery, pregnancy complications, birth weight, 
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gestational age (recorded in completed weeks), sex of the infant and congenital 
abnormalities (identified by the time of notification, usually in the first few weeks of 
life). Information on maternal co-infections in pregnancy (including hepatitis C 
virus, hepatitis B virus and syphilis) has only been collected since July 2008, 
although some information on perinatal infections was available previously. 
Mode of delivery was collected from 1995 onwards (Table 2.2), with the following 
categories: vaginal, elective caesarean section or emergency caesarean section, as 
reported by the respondent. In 2002 the question was modified to distinguish 
between planned and unplanned vaginal delivery. Questions about pregnancy 
complications and rupture of membranes were added to the data collection forms in 
2004 and 2005, respectively (Table 2.2). Information on duration of ruptured 
membranes was added in 2007 and was therefore not available for analyses presented 
in this thesis. 
Paediatric forms are designed for both HIV-infected children and infants born to 
infected women; information sought includes mode of transmission or exposure, how 
the child was identified as infected or at risk of infection, maternal and paternal 
demographic characteristics, exposure to ART in fetal life and neonatally, perinatal 
details, laboratory investigations, clinical details and vital status. Although the 
paediatric and obstetric forms overlap in terms of the data collected, some 
information was only collected through one scheme (Table 2.3).
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Table 2.2 Changes to NSHPC data collection forms  
 
Variables Date added 
Maternal co-infections Jul 2008 
Planned mode of delivery (vaginal or elective caesarean section) May 2007 
Duration of ruptured membranes May 2007 
Reason for maternal treatment (prevention of mother-to-child 
transmission or also maternal health) 
Dec 2005 
Ruptured membranes (yes/no) Dec 2005 
Pregnancy complications (e.g. pre-eclampsia) Jun 2004 
Birth weight (added to obstetric form) Jun 2004 
Whether vaginal delivery was planned or unplanned  Mar 2002 
HIV RNA plasma viral load Sep 1997 
Mode of delivery Jan 1995 
 
N.B. CD4 cell count was requested throughout, but up to 1997 was reported for less than 50% of 
pregnancies.  
 
 
Table 2.3 Variables collected only through one of the NSHPC schemes 
 
Reported through: Variables 
Obstetric scheme only Maternal clinical status (HIV-related symptoms or AIDS) 
 
ART at conception 
 
Date of initiation of ART 
 
HIV RNA viral load 
 
CD4 cell count 
 
Pregnancy complications 
 
Rupture of membranes / duration of rupture of membranes 
 
Whether vaginal delivery was planned or unplanned  
Paediatric scheme only Infection status 
  
Birth weight (up to January 2004; subsequently through both) 
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Data management  
NSHPC data are managed in an Access 2003 database (Microsoft Corporation, 
Redmond, Washington, USA). All incoming reports are checked against previous 
reports, using dates of birth, to identify potential duplicates and match related cases: 
• Initial pregnancy notifications are checked to ensure they are not duplicate 
reports, and are linked with previous pregnancies.  
• Live births reported through the obstetric scheme are linked with paediatric 
cases. 
• Paediatric notifications are checked to ensure they are not duplicate reports, and 
are linked with pregnancy notifications and outcomes, and with siblings.  
Data quality is maintained through regular checks and data cleaning at different 
stages: 
• At the data entry phase, inconsistencies that are detected are checked with 
respondents (e.g. non-chronological dates, mismatches between data collected on 
obstetric and paediatric forms). 
• A series of Access queries (currently ~45), which detect inconsistencies and 
extreme values, are run on a quarterly basis; data entry errors are then corrected, 
and remaining inconsistencies are clarified with respondents. 
• Additional checks are carried out in Stata (Stata Corporation, College Station, 
Texas, USA) before each analysis, and new check queries are added periodically 
as a result.  
Datasets for analyses were extracted using Access queries, and obstetric and 
paediatric data were merged into a single dataset using R versions 2.1.2 to 2.8.0 (R 
Development Core Team, 2006). 
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Categories and definitions 
Variable definitions and groupings used across different analyses are described here. 
Details of categorisation relevant to specific analyses are shown in the corresponding 
chapters. 
Maternal characteristics 
Ethnic origin was grouped into three categories: white, black African and other. For 
most analyses, likely route of HIV acquisition was categorised as ‘injecting drug use’ 
or ‘non-injecting drug use’; the latter included all other routes, as well as those cases 
with no specified risk factors for HIV acquisition. Parity referred to the number of 
previous births, nulliparous meaning none and parous meaning one or more. Up to 
2001, parity referred only to previous live births, whereas from 2002 onwards, it 
included previous stillbirths.  
Maternal clinical and immunological characteristics 
Maternal clinical status: Women were classified as symptomatic if AIDS or HIV-
related symptoms were reported either at the time of first report or at delivery, and 
otherwise as asymptomatic (Centers for Disease Control and Prevention, 1992); in 
some analyses, clinical status at delivery was used. 
CD4 cell counts: Only CD4 cell counts measured in pregnancy were considered; 
those measured just after delivery were excluded, since changes in lymphocyte levels 
associated with haemodilution may occur (Tuomala et al., 1997). If multiple test 
results were reported, the one closest to delivery was selected. For some analyses, 
CD4 count was grouped according to commonly used categories: <200, 200-349, 
350-499 and ≥500 cells/µl. 
  59 
HIV RNA viral load: For most analyses, viral loads measured in pregnancy and up to 
seven days postpartum were considered, and the one closest to delivery was used. 
The only exception was the analysis in Chapter 5 (Section 5.2) on ART and 
prematurity in the NSHPC, in which viral loads measured at least one week after 
initiation of ART and up to 14 days postpartum were considered; the closest one to 
delivery was selected. Viral loads carried out just after delivery were considered 
because test results ‘closest to delivery’ were requested on the pregnancy outcome 
form, and in a small proportion of cases, the only test reported was carried out after 
delivery. When viral load was used as a continuous variable, it was log10 transformed 
(due to its non-normal distribution), and mid-points were used for values below the 
assay detection limits: for example, ‘<50 copies/ml’ was coded as 25 copies/ml, and 
‘<400 copies/ml’ as 200 copies/ml (Gray, Cortina-Borja, & Newell, 2004). For some 
analyses, viral load was classified as <50 copies/ml (undetectable), 50-999 copies/ml, 
1000-9999 copies/ml and ≥10,000 copies/ml, in order to distinguish between 
‘undetectable’ and ‘low but detectable’ viral load, as well as to enable rates of 
adverse outcomes to be shown at different viral load levels. The category ‘50-999 
copies/ml’ included a small number of tests reported as ‘<200 copies/ml’ or ‘<400 
copies/ml’, which are described in individual analyses. 
Antiretroviral therapy 
Exposure to ART in pregnancy was categorised according to the total number of 
drugs received: none, monotherapy (one drug), dual therapy (two drugs) or highly 
active antiretroviral therapy (HAART) (three or more drugs from any class). To 
explore the effect of different classes of drugs, regimens were categorised according 
to whether non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease 
inhibitors (PIs) were included, resulting in the following four categories: nucleoside 
reverse transcriptase inhibitors (NRTIs) only, NNRTI-containing regimens, PI-
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containing regimens, and NNRTI- and PI-containing regimens. Date or gestation 
week of initiation of ART was collected only through the obstetric scheme; in most 
cases, dates were provided, but where completed week of gestation was provided, 
this was recoded as the middle of that week (e.g. 26 completed weeks was recoded as 
26.5 weeks). Timing of ART exposure was classified as early if a woman started 
therapy prior to conception or in the first trimester (up to and including 12 completed 
weeks of gestation), and late if started after 12 weeks. 
Pregnancy outcome and delivery 
Spontaneous fetal death before 24 weeks gestation was defined as a miscarriage, and 
at 24 or more weeks gestation as a stillbirth (Royal College of Obstetricians and 
Gynaecologists, 2005). Perinatal death was defined as stillbirths and deaths in 
neonates occurring less than seven completed days from the time of birth 
(Confidential Enquiry into Maternal and Child Health, 2006). 
Gestational age was categorised as ≤32, 32-34, 35-36 and ≥37 weeks gestation; 
premature, or preterm, delivery was defined as delivery before 37 completed weeks 
gestation, and severe prematurity as delivery before 32 weeks gestation (Goldenberg 
et al., 2008). In addition, delivery before 35 weeks gestation was chosen as an 
additional cut-off to exclude ‘near-term’ infants born at 35 or 36 weeks (Wang et al., 
2004). Low birth weight was defined as <2500 g, and very low birth weight as <1500 
g (UNICEF/WHO, 2004). 
Elective caesarean section referred to scheduled caesarean section deliveries carried 
out before onset of labour or rupture of membranes; most were carried out for 
prevention of mother-to-child transmission, but additional reasons for elective 
caesarean section included twin pregnancy, breech presentation, previous caesarean 
section, maternal request and macrosomia (large baby) (Royal College of 
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Obstetricians and Gynaecologists, 2004). Emergency caesarean section deliveries 
included those carried out after rupture of membranes and/or onset of labour, as well 
as those carried out for other obstetric indications (e.g. pre-eclampsia, fetal distress, 
etc); if a delivery was reported as elective caesarean section, but rupture of 
membranes or labour was recorded, it was re-classified as an emergency.  
Congenital abnormalities 
Congenital abnormalities were classified using the World Health Organization’s 
International Classification of Diseases, 10th revision (World Health Organization, 
1992). For infants with multiple abnormalities reported, only the main one was 
included in the analysis. Detailed information on whether abnormalities were major 
or minor was not routinely collected; however, in order to estimate the prevalence of 
major abnormalities, the following were classified as minor: polydactyly, 
abnormalities of the feet, malformed ear, minor mouth abnormalities, macroglossia, 
undescended testes, accessory nipple, spinal hairy patch, strawberry naevus, 
birthmark, skin tag, and subclinical sub-ependymal cysts (see Table 4.13, page 141). 
These classifications were mostly consistent with those used by EUROCAT, the 
European congenital anomaly surveillance system (EUROCAT, 2005). Additional 
information is required for classification of talipes and polydactyly. As this was not 
available in the NSHPC, talipes was classified as major, and polydactyly as minor in 
these analyses. 
Infection status 
Non-breastfed infants were classified as ‘presumed uninfected’ if a negative HIV 
DNA or RNA PCR test after one month of age was reported and ‘confirmed 
uninfected’ following a subsequent negative PCR after three months of age or a 
negative HIV antibody test after 18 months of age. Infants were classified as 
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‘presumed infected’ if a positive PCR test was reported, and ‘confirmed infected’ if 
two positive PCR tests were reported, or if a positive antibody test after 18 months of 
age was reported. Surveillance definitions of infection status, which are sent to 
paediatric respondents, are shown in Appendix 2 (pages 377 and 380). Because 
preliminary results rarely conflict with later ones, and infants were mostly not 
breastfed, ‘presumed’ and ‘confirmed’ results were grouped in the analyses. PCR test 
results at birth were not routinely available, and in most cases it was not possible to 
establish timing of infant infection (whether in utero or at delivery). However, for 
infants with a PCR test result reported within the first 72 hours of life, those with a 
positive test were considered to have been infected in utero (Bryson et al., 1992). 
Ethics Approval 
The NSHPC is approved by the London Multi-centre Research Ethics Committee 
(MREC) (Reference: MREC/04/2/009, approved on 28 January 2004). In addition, as 
the surveillance is carried out in collaboration with the BPSU and the HPA, without 
individual patient consent, it is also covered by Section 60 of the Patient Information 
Advisory Group, under the Health and Social Care Act 2001. 
The European Collaborative Study 
The European Collaborative Study (ECS) is a prospective multi-centre cohort study 
of HIV-infected pregnant women, coordinated at the UCL Institute of Child Health 
in London (European Collaborative Study, 2007). The study was established in 1986 
(European Collaborative Study, 1988), and in 2006 included centres in 10 European 
countries (Belgium, Denmark, Germany, Italy, the Netherlands, Poland, Spain, 
Sweden, the Ukraine, and the UK). Women known to be HIV-infected when they 
become pregnant, and those diagnosed in pregnancy are invited to enrol in the study, 
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and informed consent is obtained. Local ethics approval is granted for each site. 
Information is collected at enrolment and during pregnancy, and children born to 
enrolled women are followed up according to standard protocols. Information 
collected includes maternal socio-demographic characteristics, likely route of HIV 
acquisition, obstetric history, use of ART, CD4 cell count, HIV RNA plasma viral 
load, and delivery and neonatal details (Appendix 3).  
Categories and definitions 
Ethnic origin in the ECS was categorised as white, black African or other. ART was 
categorised as none, monotherapy, dual therapy or HAART (three or more drugs), 
and HAART was categorised according to whether PIs or NNRTIs were included. 
History of injecting drug use was recorded. Gestational age was recorded in 
completed weeks. Mode of delivery was categorised as vaginal, elective caesarean 
section (before onset of labour or rupture of membranes) or emergency caesarean 
section. Maternal CD4 cell count and viral load tests were carried out locally, and 
those closest to delivery were selected. Children were classified as infected if a 
positive virological or serological marker of infection was detected, or if antibody 
persisted after 18 months of age; and as uninfected if they were antibody-negative 
and no virus or antigen had ever been detected. 
The Pediatric Spectrum of HIV Disease project 
The Pediatric Spectrum of HIV Disease (PSD) project was a prospective 
epidemiological review of newborn and paediatric medical records of HIV-exposed 
and HIV-infected live born infants in the United States, based at eight geographic 
sites from 1989 to 1997, and six sites from 1997 to 2004 (Figure 2.2). The study was 
run through the Centers for Disease Control and Prevention (CDC) in Atlanta, 
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Georgia. It was based in several hospitals in New York City and the District of 
Columbia, but had wider coverage in California, Massachusetts and North Carolina, 
and was considered population-based in those areas. In Texas and Puerto Rico, the 
study initially included single hospitals, but in 1997 was extended to cover others. 
The PSD was approved by the CDC Institutional Review Board, and was also 
reviewed and approved locally. Hospitals were visited by study personnel on a 
regular basis, and children were identified by contact with key practitioners, and by 
review of HIV laboratory logs and medical records. After initial data collection, 
records on each enrolled child were reviewed every six months. Data were collected 
mainly from paediatric medical notes, but maternal charts could also be reviewed if 
included in the paediatric records. Data were collected on standard forms (Appendix 
4) and entered into a CDC database at each site. Study personnel had periodic 
training on medical record abstraction and on any changes in the data collection 
methods (e.g. when HIV case definitions changed), and detailed form completion 
instructions were available.  
Data collected included maternal race/ethnicity and country of birth, presence of HIV 
symptoms at delivery, history of injecting drug use, antenatal ART, mode of 
delivery, birth weight and gestational age. Because the PSD was based on paediatric 
records, maternal age, HIV viral load and CD4 cell count were not available.  
Categories and definitions 
Ethnic origin was categorised as white (non-Hispanic), black (non-Hispanic), 
Hispanic, or other. Exposure to antenatal ART was categorised according to the 
number of drugs received: none, monotherapy, dual therapy or HAART; HAART 
was categorised according to whether or not a PI was included. Gestational age was 
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recorded in completed weeks. Mode of delivery was categorised as vaginal or 
caesarean section; information on whether caesarean sections were elective or 
emergency was only collected from 2003. Maternal clinical status was classified as 
symptomatic if AIDS or HIV-related symptoms were reported at delivery (Centers 
for Disease Control and Prevention, 1992). Infection status of the child was based on 
CDC classifications (Centers for Disease Control and Prevention, 1999). 
 
Figure 2.2  Pediatric Spectrum of HIV Disease (PSD) project sites 
 
 
N.B. San Francisco (Stanford) and North Carolina were sites until 1997 only.
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2.3 Comparative analysis of antiretroviral therapy and prematurity 
in three studies 
Dataset 
Singleton live born infants whose mothers were diagnosed with HIV before delivery 
were selected from the PSD, the ECS and the NSHPC. As there was some overlap 
between women enrolled in UK ECS centres and those reported through the NSHPC, 
these cases were excluded from the NSHPC dataset (n=200). Because information on 
stillbirths was not routinely collected in the PSD and ECS, stillbirths were also 
excluded from the NSHPC dataset. Infants with missing information on maternal 
ART were excluded from the PSD and ECS datasets, as were those with missing 
information on maternal ethnicity in the PSD. ECS centres in the Ukraine were 
excluded (n~2600 births), as they only joined the study in 2000 and included few 
women on HAART (~5%). In the ECS and NSHPC, it was possible to identify 
mothers who had more than one child during the study period, but information on 
repeat pregnancies was not available in the PSD. Data from the PSD, ECS and 
NSHPC were combined into one dataset in Stata version 10.0 (Stata Corporation, 
College Station, Texas, USA), in order to explore the association between ART and 
prematurity in the three studies. 
Statistical methods 
Heterogeneity between studies in the association between ART and prematurity was 
assessed using a χ2 test of homogeneity of odds ratios (Kirkwood & Sterne, 2003). 
Inclusion of covariates in logistic regression models was based on likelihood ratio 
tests. To allow for the effect of study site and mother (i.e. repeat pregnancies in the 
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same woman), generalized linear mixed effects were used (commands ‘xtlogit’ 
and ‘xtmelogit’ in Stata, for single and multilevel effects, respectively) (Rabe-
Hesketh, Skrondal, & Pickles, 2002). 
2.4 Statistical analysis 
Data analysis was carried out using Stata versions 8.0-10.0 (Stata Corporation, 
College Station, Texas, USA), or in R versions 2.1.2 to 2.8.0. (R Development Core 
Team, 2006). 
Categorical variables were compared using χ2 tests or Fisher’s exact tests if numbers 
in individual cells were small. Means were compared using t-tests, and medians 
using Kruskal-Wallis tests. Trends in medians were assessed using Cuzick’s non-
parametric test for trend across ordered groups (function ‘nptrend’ in Stata) 
(Cuzick, 1985). Univariable logistic regression models were fitted to obtain odds 
ratios (ORs), and multivariable models to adjust for potential confounders, and to 
obtain adjusted odds ratios (AORs) and 95% confidence intervals (CI). Ordinary 
logistic regression models were used to obtain p-values for trends in means or 
proportions. Likelihood ratio tests (LRTs) were used to compare nested logistic 
regression models. The LRT is a statistical test of the goodness-of-fit of one model 
compared with another. Interactions were explored using stratified Mantel-Haenszel 
ORs and tested using a χ2 test of homogeneity. Evidence of interaction was further 
investigated in logistic regression models.  
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2.5 Risk-benefit analysis of antiretroviral therapy in pregnancy 
In Chapter 6, results of a Monte Carlo simulation of the risks and benefits of ART 
are presented. Because the methodology diverges substantially from that used in 
other chapters, details are provided in the chapter itself.  
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2.6 List of analyses based on the NSHPC 
The NSHPC is an ongoing surveillance study, and datasets are compiled every three 
months. Analyses were carried out on the dataset that was most up-to-date at the time 
of analysis, as shown in Table 2.4.  
 
Table 2.4 List of NSHPC analyses 
 
Analysis Chapter Time period Cut-off Number included 
Pregnancies in HIV-
infected women  
3 1990-2006 Jun 2007 8327 pregnancies 
Mother-to-child 
transmission in the 
HAART era 
3 2000-2006 Jun 2007 5930 singleton 
infants 
ART and congenital 
abnormalities 
4 1990-2007 Jun 2008 8576 infants 
ART and 
stillbirth/neonatal death  
4 1990-2007 Jun 2008 8430 births 
ART and pre-eclampsia 4 2004-2007 Jun 2008 3852 pregnancies 
ART and prematurity  
- NSHPC analysis 
5 1990-2005 Jun 2006 5009 singleton 
infants 
ART and prematurity  
- comparative analysis 
5 1990-2006 Jun 2007 6665 singleton live 
born infants 
Mother-to-child 
transmission, early 
monotherapy 
comparison 
6 1990-2006 Jun 2007 4454 singleton 
infants (mono & 
HAART only) 
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Chapter 3 Pregnancies in HIV-infected women in the UK 
and Ireland  
Substantial changes in the epidemiology of HIV in Western Europe have occurred 
over the last two decades (Hamers & Downs, 2004). At the same time, advances in 
the prevention of mother-to-child transmission (MTCT) have led to a decline in 
transmission rates to less than 2% (European Collaborative Study, 2001; European 
Collaborative Study, 2005d). These developments are reflected in the profile of HIV-
infected pregnant women and their children in the UK and Ireland.  
In the first part of this chapter, trends in demographic characteristics, uptake of 
interventions, pregnancy outcome and MTCT in HIV-infected women in the UK and 
Ireland are described, in the context of changing guidelines for the management of 
HIV in pregnancy (BHIVA, 2001; BHIVA, 2005a; BHIVA/CHIVA, 2008). In the 
second part of the chapter, factors associated with MTCT are explored in infants 
born between 2000 and 2006, when effective antiretroviral therapy and universal 
antenatal HIV screening were widely available. Papers relating to these findings 
were published in 2008 and are shown in Appendix 2, pages 339 (Townsend et al., 
2008b) and 348 (Townsend et al., 2008a). 
3.1 Methods specific to this chapter 
All reported pregnancies in women diagnosed with HIV before delivery, delivering 
between 1990 and 2006, and reported to the National Study of HIV in Pregnancy and 
Childhood (NSHPC) by June 2007 were included. For calculation of overall MTCT 
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rates between 1990 and 2006, all live births were included, although second- and 
third-born twins and triplets were omitted to avoid duplication of information 
(European Collaborative Study, 1999; Warszawski et al., 2008). To explore specific 
risk factors for MTCT in 2000-2006, analyses were restricted to singleton live births, 
since complications are more common in multiple pregnancies (Rao, Sairam, & 
Shehata, 2004) and may alter the risk of transmission. Births were described by year 
of delivery and other pregnancy outcomes by year of ‘expected date of delivery’. To 
explore trends over time, years were grouped into five time periods according to 
availability of interventions (Table 3.1). Clinical status referred to HIV-related 
symptoms or AIDS occurring at any time in pregnancy (i.e. reported at initial 
notification or at delivery). 
Analyses were based on pregnancies, and some women were included more than 
once (see page 73). In the MTCT analysis covering 2000-2006, no woman had more 
than one infected child born in those years. 
 
Table 3.1 Time periods and availability of interventions relating to prevention 
of mother-to-child transmission 
 
Time period Intervention Reference 
1990-1993 Avoidance of breastfeeding (Dunn et al., 1992; Ziegler et al., 
1985) 
1994-1996 Zidovudine monotherapy (Connor et al., 1994) 
1997-1999 HAART; elective caesarean 
section 
 (Collier et al., 1996; European 
Collaborative Study, 1996b) 
2000-2003 
2004-2006 
Routine antenatal HIV screening (NHS Executive, 1999) 
 
HAART, highly active antiretroviral therapy. 
N.B. The period from 2000 to 2006 was split into two, due to the large number of pregnancies 
reported, and because of changes in uptake of HIV testing and interventions over this period.
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Reporting rates by geographical area were obtained by dividing the annual number of 
pregnancies in HIV-infected women reported in each country and English strategic 
health authority by the number of resident women aged 15 to 49 years, derived from 
mid-year 2000 census data for the UK (Office for National Statistics, 2000), and 
2002 census data for Ireland (Central Statistics Office Ireland, 2002). Maps were 
drawn using R version 2.4.1 (R Development Core Team, 2006). P-values in Tables 
3.2 and 3.3 were adjusted for multiple comparisons using a Bonferroni correction 
(Miller, 1981). 
Infection status was defined in Chapter 2 (page 61). The effect of excluding infants 
with missing information on infection status was explored in a sensitivity analysis 
(pages 106-107). The probability of being infected was imputed, based on variables 
that were significantly associated with transmission in the analysis, using the 
‘impute’ function in Stata. Relevant variables included: maternal antiretroviral 
therapy (ART) in pregnancy (none, monotherapy, dual therapy or highly active 
antiretroviral therapy [HAART]), mode of delivery (planned, unplanned or 
unspecified vaginal delivery, or elective or emergency caesarean section), gestational 
age (≤32, 32-34, 35-36 and ≥37 weeks), infant sex, and log10 HIV RNA viral load. 
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3.2 Pregnancies in HIV-infected women 
Between 1990 and 2006, 8327 pregnancies in 6788 HIV-infected women were 
reported; 5540 women had one pregnancy reported during the study period, 1010 
two, and 238 three or more. The annual number of reported pregnancies increased 
17-fold, from 82 in 1990 to 1394 in 2006, the steepest rise occurring between 1999 
and 2003 (Figure 3.1). There were 116 multiple births: in one twin pair one infant 
was stillborn, and there were two twin stillbirths (i.e. five stillborn infants 
altogether). Pregnancy outcomes included 6979 live births, 77 stillbirths, 329 
miscarriages and 519 terminations (Table 3.2). There were 423 pregnancies with 
other or unknown outcomes, which included two maternal deaths (one suicide and 
one death from HIV encephalopathy, both of which occurred in the mid 1990s) and 
23 ectopic pregnancies (all ending before 13 weeks gestation); 110 women were 
known to have left the British Isles before delivery and another 109 were otherwise 
lost to follow-up. At the time of analysis (June 2007), information on pregnancy 
outcome was still pending on 179 pregnancies due to end in 2004-2006 (Table 3.2). 
The proportion of pregnancies in nulliparous women increased significantly from 
12% in 1990-1993 to 35% in 2004-2006.
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Figure 3.1 Number of pregnancy reports by year of delivery, according to 
whether maternal diagnosis occurred before or during pregnancy.  
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EDD, expected date of delivery.  
* (NHS Executive, 1999; Townsend, Cliffe, & Tookey, 2006).  
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Table 3.2 Pregnancy characteristics by time period 
 
  
1990-1993         
(n=376) 
1994-1996      
(n=325) 
1997-1999      
(n=576) 
2000-03      
(n=3041) 
2004-06      
(n=4009) 
Total 
(n=8327) 
p-value 
(trend) 
Characteristic (8327 pregnancies) n % n % n % n % n % n   
Pregnancy outcome (n=8327)             
Live birth 235 62.5 260 80.0 456 79.2 2623 86.3 3405 84.9 6979 <0.005 
Stillbirth  1 0.3 2 0.6 7 1.2 24 0.8 43 1.1 77 >0.50 
Miscarriage 15 4.0 5 1.5 32 5.6 119 3.9 158 3.9 329 >0.50 
Termination of pregnancy 111 29.5 48 14.8 70 12.2 155 5.1 135 3.4 519 <0.005 
Other / outcome not known * 14 3.7 10 3.1 11 1.9 120 3.9 268 6.7 423 NA 
Timing of diagnosis (n=8327)  
 
 
 
 
 
 
 
 
 
  
Before this pregnancy 279 74.2 220 67.7 357 62.0 1242 40.8 2117 52.8 4215 <0.002 
During this pregnancy 97 25.8 105 32.3 219 38.0 1799 59.2 1892 47.2 4112 <0.002 
Parity (n=6569)  
 
 
 
 
 
 
 
 
 
  
Nulliparous (no previous births) 5 11.9 48 19.4 105 20.4 881 35.1 1136 34.9 2175 <0.002 
Parous (≥1 previous birth) 37 88.1 200 80.6 409 79.6 1629 64.9 2119 65.1 4394 <0.002 
Region of pregnancy report (n=8321**)             
London 191 50.8 210 65.0 437 76.0 1728 56.9 1803 45.0 4369 NA 
England outside London 65 17.3 51 15.8 72 12.5 823 27.1 1711 42.7 2722 NA 
Scotland, Wales, Northern Ireland 91 24.2 49 15.2 30 5.2 90 3.0 166 4.1 426 NA 
Ireland 29 7.7 13 4.0 36 6.3 397 13.1 329 8.2 804 NA 
  
* Includes 179 pregnancies due to end in 2004-2006 for which outcome was still pending at the time of analysis (June 2007); trend test not appropriate for this group.  
** Excludes six infants born in the Channel Islands.  
NA, not applicable. P-values are for trends over time, comparing each category against all others combined, and were obtained using logistic regression and adjusted for 
multiple comparisons using a Bonferroni correction. 
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Demographic characteristics of HIV-infected women 
There were marked changes over time in the demographic profile of HIV-infected 
pregnant women (Table 3.3). The proportion of all women reported to have probably 
acquired HIV through injecting drug use or from a drug-using partner declined 10-
fold, from around half in 1990-1993 to less than 5% in 2004-2006 (Table 3.3). 
Meanwhile the proportion of women born in sub-Saharan Africa increased from 
under half in 1990-1993 to almost 80% in 2004-2006, with a corresponding change 
in maternal ethnic origin (Table 3.3). There was also a statistically significant rise in 
the proportion of women born in Asia, from 0% (0/214) in 1990-1993 to 2.2% 
(87/3912) in 2004-2006 (trend: p=0.003). As a proportion of all women with either 
country of birth or ethnicity reported, those born in the Caribbean or of black 
Caribbean ethnicity increased from 1.4% (4/293) in 1990-1993 to 3.7% (147/3989) 
in 2004-2006 (trend: p=0.051). Among women who were born abroad, information 
on date of arrival in the British Isles was only available for 55.6% (3735/6714); 
among these, median time between arrival and delivery was 3.3 years (interquartile 
range [IQR]: 1.4-6.1 years). Seven women were known to have acquired infection 
vertically from their own mothers; all delivered (n=5) or terminated their pregnancy 
(n=2) between 2004 and 2006, and were aged between 15 and 20 years at the time of 
delivery or expected date of delivery; four were born in the British Isles.  
Median maternal age at delivery increased over time, from 27.2 years (IQR: 24.4-
30.1 years) in 1990-1993 to 30.2 years (IQR: 26.4-34.0 years) in 2004-2006 (trend 
for grouped years, p<0.001). Mean maternal age in the UK as a whole has increased 
steadily over time, rising from 26.2 years in 1983 to 28.6 years in 2001 among UK-
born women, and 27.3 years to 31.7 years in East African women (Collingwood, 
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2004). There was no evidence of a significant increase over time in the proportion of 
teenage pregnancies (those in women under the age of 20), which was 2.8% (10/358) 
in 1990-1993, 3.9% (22/571) in 1997-1999, and 3.4% (134/3982) in 2004-2006 
(trend: p=0.276). In the general population in the UK, the proportion of babies born 
to women under 18 fluctuated between two and three percent between 1976 and 2000 
(Maher & Macfarlane, 2004). 
Up to 1999, the majority of pregnancies were in women who already knew their HIV 
status before they became pregnant (67.0%, 856/1277) (Figure 3.1, page 74, and 
Table 3.2). As universal antenatal HIV screening was introduced throughout the 
British Isles, the proportion of women diagnosed during pregnancy rose to 60.1% 
(1566/2606) between 2001 and 2003, and then declined subsequently (Figure 3.1). 
The corresponding increase in women diagnosed before pregnancy was probably 
partly due to women diagnosed antenatally in the early years of routine screening 
becoming pregnant again in later years. Indeed, among women who knew their HIV 
status at conception (and with information on where their diagnosis was made), the 
proportion diagnosed in a previous pregnancy doubled from 18.0% (24/133) in 2000 
to 36.1% (181/502) in 2006 (trend: p<0.001). Overall, 2.9% (120/4112) of antenatal 
diagnoses were made in the last two weeks of pregnancy, by which time the 
opportunity to reduce the risk of MTCT with maternal ART was substantially 
reduced. 
The prevalence of AIDS or HIV-related symptoms in pregnancy remained stable at 
over 20% between 1990 and 1999 (trend, p=0.850), then declined from 18% (46/252) 
in 1999 to 12% (47/390) in 2000 (p=0.040), remaining at a stable 11% thereafter 
(trend from 2000 to 2006: p=0.846).
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Table 3.3 Maternal characteristics by time period 
 
  
1990-1993         
(n=376) 
1994-1996      
(n=325) 
1997-1999      
(n=576) 
2000-03      
(n=3041) 
2004-06      
(n=4009) 
Total 
(n=8327) 
p-value 
(trend) 
Characteristic (8327 pregnancies) n % n % n % n % n % n   
Exposure category (n=8327)  
 
 
 
 
 
 
 
 
 
  
Injecting drug use-associated * 185 49.2 94 28.9 91 15.8 168 5.5 125 3.1 663 <0.003 
Other ** 191 50.8 231 71.1 485 84.2 2873 94.5 3884 96.9 7664 <0.003 
Region of birth (n=8009)             
UK / Ireland 105 49.1 101 32.8 143 25.0 450 15.0 496 12.7 1295 <0.004 
Europe (excluding UK / Ireland) 9 4.2 13 4.2 21 3.7 69 2.3 121 3.1 233 >0.50 
Sub-Saharan Africa 93 43.5 179 58.1 381 66.6 2309 76.9 3076 78.6 6038 <0.004 
Elsewhere 7 3.3 15 4.9 27 4.7 175 5.8 219 5.6 443 0.016 
Ethnic origin (n=8157)             
White 167 57.6 127 39.3 150 26.1 427 14.1 492 12.5 1363 <0.003 
Black African 115 39.7 183 56.7 388 67.5 2357 78.0 3140 79.5 6183 <0.003 
Other 8 2.8 13 4.0 37 6.4 236 7.8 317 8.0 611 <0.003 
Age at delivery (n=8244)  
 
 
 
 
 
 
 
 
 
  
14-24 years 107 29.9 63 19.9 101 17.7 557 18.5 704 17.7 1532 <0.003 
25-34 years 235 65.6 234 73.8 379 66.4 1940 64.3 2463 61.9 5251 <0.003 
≥35 years 16 4.5 20 6.3 91 15.9 519 17.2 815 20.5 1461 <0.003 
Clinical status in pregnancy (n=7253)  
 
 
 
 
 
 
 
 
 
  
Asymptomatic 258 78.2 210 74.7 428 80.6 2413 89.0 3026 89.0 6335 <0.003 
HIV-related symptoms or AIDS 72 21.8 71 25.3 103 19.4 299 11.0 373 11.0 918 <0.003 
 
* Includes women whose partners acquired HIV through injecting drug use (n=195). ** Includes women with missing exposure information.  
P-values are for trends over time, comparing each category against all others combined, and were obtained using logistic regression and adjusted for multiple comparisons 
using a Bonferroni correction. 
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Geographic patterns in pregnancy reporting 
There were changes over time in the origin of pregnancy reports within the UK and 
Ireland. The proportion of pregnancies reported from London increased significantly 
from about 50% in 1990-1993 to 76% in 1997-1999 (trend: p<0.001) (Table 3.2, 
page 75). Subsequently, although the number of reports from London continued to 
rise until 2004, when they stabilised, the proportion reported from elsewhere in 
England increased significantly from 12.5% in 1997-1999 to 42.7% in 2004-2006 
(trend: p<0.001) (Table 3.2). Figure 3.2 shows annual reporting rates (number of 
reports per million women aged 15-49 years) across the UK and Ireland in four time 
periods. By 2004-2006, rates in most areas of the UK were similar to those in 
London in 1990-1999. In Ireland, reporting rates stabilised following a substantial 
rise in the number of reports from only 13 in 1999 to almost 150 in 2003.  
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Figure 3.2 Pregnancy reporting rates in the UK and Ireland by time period 
and country/region 
 
 
N.B. Reporting rates were obtained by dividing the annual number of reported pregnancies in HIV-
infected women by the number of resident women aged 15 to 49 years, derived from 2000 census data 
for the UK (Office for National Statistics, 2000), and 2002 census data for Ireland (Central Statistics 
Office Ireland, 2002).
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Terminations and miscarriages 
The proportion of reported pregnancies ending in termination decreased 10-fold from 
around 30% in 1990-1993 to 3% in 2004-2006 (Table 3.2). Termination was 2.6 
times more common in women diagnosed with HIV before pregnancy than in those 
diagnosed antenatally (OR=2.65, 95% CI: 2.18-3.23, p<0.001). However, similar 
declines occurred in both groups: termination rates fell from 34.7% in 1990-1993 to 
4.1% in 2004-2006 among women diagnosed before pregnancy (trend: p<0.001), and 
from 20.2% to 2.7% among those diagnosed during pregnancy (trend: p<0.001). 
There was no association between HIV exposure category or maternal age and 
termination after adjusting for year and timing of diagnosis in multivariable logistic 
regression analysis (p>0.50 in both cases). Median gestational age at termination was 
10 weeks (IQR: 9-13 weeks) for women diagnosed before pregnancy, and 15 weeks 
(IQR: 12-19 weeks) for those diagnosed during pregnancy (p<0.001). About 30% 
(101/335) of previously diagnosed women having terminations were taking ART at 
conception. Three terminations were carried out after 24 weeks: one at 25 weeks for 
major congenital heart defects, one at 30 weeks for anencephaly, and one at 29 
weeks because of concerns about the woman’s mental health.  
Four percent (329/8327) of reported pregnancies resulted in a miscarriage; 80.9% 
(266/329) occurred before 20 weeks gestation, 10.3% (34/329) at 20-21 weeks and 
8.8% (29/329) at 22-23 weeks. The overall rate of reported miscarriage remained 
constant over time (trend: p=0.951), as did the rate of late miscarriages (≥ 20 weeks) 
(trend: p=0.890). 
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Live births and stillbirths 
The following results refer to the 85% pregnancies (7056/8327) resulting in a live 
birth (n=6979) or stillbirth (n=77). 
Antiretroviral therapy 
Changes in the use of ART over time are shown in Figure 3.3. Following the 
introduction of zidovudine for the prevention of MTCT in 1994 (Connor et al., 
1994), uptake of ART (mostly monotherapy) increased rapidly. Although 
monotherapy has continued to be offered in some circumstances, as indicated in the 
British HIV Association (BHIVA) Guidelines (BHIVA, 2001; BHIVA, 2005a; 
BHIVA/CHIVA, 2008), it was overtaken by HAART in the late 1990s. By 2006, 
98.4% (1092/1110) of diagnosed pregnant women received ART at some time in 
pregnancy, 94.5% (1032/1092) of whom received HAART and 4.4% (48/1092) 
monotherapy (Figure 3.3).  
The type of HAART regimens changed over time, with an increase in the use of 
protease inhibitors (PIs) among HAART-treated women, which doubled from 36.1% 
(43/119) in 1999 to 73.2% (755/1032) in 2006 (p<0.001) (Figure 3.3). This pattern 
was probably associated with toxicity concerns relating to use of nevirapine (up until 
then the most commonly used non-nucleoside reverse transcriptase inhibitor 
[NNRTI]) among women with CD4 counts above 250 cells/µl (Lyons et al., 2003). 
Evidence supporting this includes higher median CD4 counts in women on PIs in 
2006 than those on other HAART regimens (420 cells/µl versus 330 cells/µl, 
p<0.001). Women on PIs were also more likely to have been diagnosed during, 
rather than before, pregnancy (48.1%, 363/755, versus 28.9%, 80/277, p<0.001). 
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Figure 3.3  Antiretroviral therapy and mother-to-child transmission rates (with 
95% confidence intervals) by year of delivery 
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PI, protease inhibitor; MTCT, mother-to-child transmission.
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Among pregnancies in previously diagnosed women, timing of initiation of ART 
(before or during pregnancy) was available for 87.3% (2942/3369); once 
combination therapy became available, the proportion on treatment at conception 
rose rapidly and then stabilised at around 45% (1188/2544) between 1999 and 2006 
(trend: p=0.936). Information on reason for treatment was available only in 2006: 
among women who initiated HAART during pregnancy, 69.2% (258/373) did so 
only to prevent MTCT, with no difference according to whether maternal diagnosis 
was before (69.3%, 104/150) or during pregnancy (69.1%, 154/223, p=0.955). 
CD4 counts and viral load 
As the uptake of HAART increased, significant overall improvements in CD4 count 
and viral load occurred. CD4 count in pregnancy was reported for 75.9% 
(4901/6459) of births between 1998 and 2006, at a median of 29 days before delivery 
(IQR: 14-55 days). In later years, CD4 tests tended to be closer to delivery, at a 
median of 28 days (IQR: 13-53 days) before delivery in 2005-2006, compared with 
37 days (IQR: 15.5-83.5 days) in 1998-1999 (trend for individual years: p<0.001). 
Median CD4 count increased significantly, from 315 cells/µl (IQR: 225-425 cells/µl) 
in 1998 to 395 cells/µl (IQR: 270-570 cells/µl) in 2006 (trend, p<0.001). 
Viral load was reported for 78.8% (5092/6459) of births between 1998 and 2006, at a 
median of 24 days before delivery (IQR: 10-45 days). As with CD4 tests, there was a 
decline in median time between viral load tests and delivery from 27 days (IQR: 14-
69 days) in 1998-1999 to 22 days (IQR: 10-42 days) in 2005-2006 (trend for 
individual years: p<0.001). A small proportion of viral load tests were reported as 
‘less than 200’ (n=57) or ‘less than 400’ copies/ml (n=110), due to the detection 
limits of the assays used; these were recoded as 100 and 200 copies/ml, respectively. 
The proportion with viral load <50 copies/ml increased from 29.0% (27/93) in 1998 
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to 69.0% (609/882) in 2006 (trend: p<0.001). Median viral load decreased from 1992 
copies/ml (IQR: <50-8400 copies/ml) in 1998 to <50 copies/ml (IQR: <50-99 
copies/ml) in 2006 (trend: p<0.001).  
Mode of delivery 
Most deliveries between 1995 and 2006 were by elective caesarean section (56.4%, 
3717/6593). As evidence emerged about the beneficial effects of elective caesarean 
section in reducing the risk of MTCT (European Collaborative Study, 1994; The 
European Mode of Delivery Collaboration, 1999), the proportion of elective 
caesarean sections increased from 38.3% (36/94) in 1997 to a high of 66.4% 
(144/217) in 1999 (trend: p<0.001) (Figure 3.4). Subsequently, the proportion of 
women delivering by elective caesarean section declined gradually to around 50% 
(555/1136) in 2006, as advice on the option of vaginal delivery for women with 
undetectable viral load evolved (BHIVA, 2001; BHIVA, 2005a). Vaginal deliveries 
increased from 16.6% (36/217) to 28.3% (321/1136) between 1999 and 2006 (trend: 
p<0.001), mostly due to a rise in planned vaginal deliveries (Figure 3.4). The 
proportion of emergency caesarean sections increased from 17.1% (37/217) in 1999 
to 22.9% (260/1136) in 2006 (trend: p=0.001); among these, the proportion occurring 
at 37 weeks gestation or later increased from 48.6% (18/37) in 1999 to 60.6% 
(155/256) in 2006 (trend: p=0.021), suggesting that an increasing proportion of 
emergency caesarean sections occurred as a result of attempted vaginal deliveries.  
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Figure 3.4 Mode of delivery by year 
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N.B. Information on mode of delivery was only collected from 1995 onwards. Information on whether 
vaginal deliveries were planned was collected from 2002 onwards, but only from obstetric 
respondents.
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Gestational age, birth weight, stillbirth and neonatal death 
Median gestational age was 38 weeks (IQR: 38-39 weeks); 14.2% (975/6874) of 
deliveries were premature (<37 weeks), and 3.6% very premature (<32 weeks). 
Median birth weight was 3050 g (IQR: 2720-3370 g); 14.1% (827/5865) of infants 
were of low birth weight (<2500 g) and 3.1% (179/5865) of very of low birth weight 
(<1500 g). There were no significant trends over time in the proportion of infants 
who were premature (p=0.564), very premature (p=0.182), of low birth weight 
(p=0.197) or of very low birth weight (p=0.340). In the general population in the UK, 
around 6% of babies are born prematurely and a similar proportion are of low birth 
weight, with no significant trends over time (Maher & Macfarlane, 2004; Moser, 
Stanfield, & Leon, 2008). 
There were 77 stillbirths (11 per 1000 births) and 30 neonatal deaths (4 per 1000 live 
births). Mortality rates were explored in two time periods (because of small numbers 
in individual years): the stillbirth rate was similar in 1990-1999 (10 per 1000 births, 
10/961) and 2000-2006 (11 per 1000 births, 67/6095, p=0.871). Likewise, there was 
no significant difference in neonatal mortality rates between the two time periods, 
although numbers were small: 3 per 1000 live births (3/951) in 1990-1999, and 4 per 
1000 live births (27/6028) in 2000-2006 (p=0.562). In the UK overall, the stillbirth 
rate has remained constant since the mid-1990s, at 5.3 per 1000 births, while 
neonatal mortality rates declined from 3.9 to 3.4 per 1000 between 2000 and 2006 
(Confidential Enquiry into Maternal and Child Health, 2008). 
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3.3 Mother-to-child transmission  
Trends over time (1990-2006) 
Infection status was reported for 86.9% (6063/6979) of live births between 1990 and 
2006 (those with unreported infection status in 2000-2006 are discussed on page 89). 
Counting twins as one birth (none were discordant), the overall MTCT rate declined 
significantly from 18.5% in 1990-1993 (35/189, 95% CI: 13.3-24.8%) to 1.0% 
(29/2832, 95% CI: 0.7-1.5) in 2004-2006, with a high of 24.1% (13/54, 95% CI: 
13.5-37.6%) in 1993 and a low of 0.8% (6/768, 95% CI: 0.3-1.7%) in 2006 (Figure 
3.3, page 83). Breastfeeding status was reported for 86.6% (5251/6063) of mothers; 
the proportion who breastfed their infants declined from 2.9% (5/172) in 1990-1993 
to 0.5% (12/2286) in 2004-2006 (trend: p=0.001).  
Transmission rates in the HAART era (2000-2006) 
Antenatal testing for HIV has been routinely offered and recommended in England 
since 2000 and in the whole of the UK and Ireland since 2003 (National Institute for 
Clinical Excellence, 2003; Townsend, Cliffe, & Tookey, 2006). Since 2000 over 
80% of HIV-infected pregnant women have been diagnosed by the time of delivery 
(The UK Collaborative Group for HIV and STI Surveillance, 2006), and of these, 
over 90% received ART in pregnancy (Figure 3.3, page 83). To explore risk factors 
for transmission during a period when most HIV-infected women were diagnosed 
before delivery, and uptake of ART was high, data on singleton infants born between 
2000 and 2006 were analysed. Multiple births were excluded from this analysis 
(n=98); none of the twins or triplets were infected (0/165). Some mothers (n=689) 
 89 
had two or more pregnancies reported between 2000 and 2006, but none had more 
than one infected child born during those years. 
Maternal characteristics  
Most mothers were black African (79%), received antenatal HAART (82%) and 
delivered by elective caesarean section (57%) (Table 3.4). Median maternal age at 
delivery was 29.8 years (IQR: 26.2-33.6 years; n=5882). Median birth weight was 
3051 g (IQR: 2740-3380 g).  
Among the 186 women who were untreated in pregnancy, 50 were known to have 
declined treatment; of the remainder, 43 had been diagnosed late in pregnancy (i.e. 
less than two weeks prior to delivery) and another 18 had delivered prematurely (12 
at <32 weeks, 6 at 33-37 weeks). Among women on HAART, 24.1% (1075/4469) 
had started treatment before pregnancy (for their own health), and median gestational 
age at initiation for those starting in pregnancy was 25.9 weeks (IQR: 22.4-28.9 
weeks). Initiation of zidovudine monotherapy occurred at a median of 28.0 weeks 
gestation (IQR: 25.4-30.0 weeks), significantly later than initiation of HAART 
(p<0.001). Median viral load (nearest to delivery) was <50 copies/ml (IQR: <50-184 
copies/ml) among women on HAART and 355 copies/ml (IQR: 54-1977 copies/ml) 
in those on monotherapy; viral load tests were carried out at a median of 70 days 
(IQR: 35-119 days) and 42 days (IQR: 11-65 days) after initiation of HAART and 
monotherapy, respectively.  
Infants with unreported infection status 
Infection status was missing for 13.1% (779/5930) of infants at time of analysis. This 
was partly due to reporting delay in recent years: infection status was missing for 
32.1% (360/1120) of infants born in 2006, but for only 8.7% (419/4810) of those 
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born between 2000 and 2005. Reasons for unreported infection status were as 
follows:  
1. Birth was only reported through obstetric scheme (no paediatric notification) 
(54.0%, 421/779); 
2. Paediatric follow-up pending (28.4%, 221/779); 
3. Child lost to follow-up (11.4%, 89/779); 
4. Child left UK/Ireland before infection status established (3.5%, 27/779); 
5. Child died before infection status established (most deaths were in premature 
children or those with congenital abnormalities) (2.7%, 21/779). 
Children with unreported infection status did not differ significantly from those with 
known infection status in terms of maternal HIV exposure group, clinical status or 
mode of delivery, but more were born at <32 weeks gestation (5.0%, 38/758, versus 
2.3%, 115/5002, p<0.001), to untreated women (5.9%, 43/733, versus 2.8%, 
143/5027, p<0.001), and to women with viral load ≥1000 copies/ml (21.8%, 
130/596, versus 18.7%, 764/4096, p=0.061). These factors tended to be associated: 
for example, untreated women tended to have higher viral loads, and premature 
delivery was one of the reasons for remaining untreated at delivery. These children 
were therefore at higher risk of infection than children for whom infection status was 
reported, an issue that will be explored later (page 106).  
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Table 3.4 Characteristics of mother-child pairs for deliveries in 2000-2006 
 
 
 Characteristic (n=5930)   n % 
Maternal ethnic origin (n=5875) White 775 13.2 
 
Black African 4630 78.8 
 
Other 470 8.0 
Region of birth (n=5831) British Isles 825 14.1 
 
Sub-Saharan Africa 4531 77.7 
 
Elsewhere 475 8.2 
HIV exposure group (n=5930) Non-injecting drug use * 5689 95.9 
 
Injecting drug use-associated ** 241 4.1 
Clinical status (n=5134) Asymptomatic 4606 89.7 
 
HIV symptoms or AIDS 528 10.3 
HIV RNA viral load (n=4692) Undetectable (<50 copies/ml) 2648 56.4 
 
50-999 copies/ml 1150 24.5 
 
1000-9999 copies/ml 509 10.8 
 
≥10,000 copies/ml 385 8.2 
CD4 count (n=4539) ≥500 cells/µl 1595 35.1 
 
350-499 cells/µl 1158 25.5 
 
200-349 cells/µl 1241 27.3 
 
<200 cells/µl 545 12.0 
Antiretroviral therapy (n=5760) Untreated 186 3.8 
 
Monotherapy  712 12.3 
 
Dual therapy 136 2.3 
 
HAART 4726 81.6 
Mode of delivery (n=5901) Elective caesarean section 3368 57.1 
 
Emergency caesarean section 1223 20.7 
 
Vaginal delivery 1310 22.2 
 
     - planned  745 12.6 
 
     - unplanned 176 3.0 
 
     - unspecified 389 6.6 
Gestational age (n=5760) ≥37 weeks 5029 87.3 
 
35-36 weeks 360 6.2 
 
32-34 weeks 218 3.8 
 
<32 weeks 153 2.7 
Sex of infant (n=5903) Male 2978 50.4 
  Female 2925 49.6 
 
* Includes women with missing exposure information. ** Includes women who acquired HIV from a 
drug-using partner.  
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Infants with reported infection status 
Infection status of the 5151 infants for whom information was provided is shown in 
Table 3.5; 15% of uninfected children and 25% of infected children had insufficient 
results at the time of analysis to definitively confirm their infection status (according 
to the definitions in Chapter 2). Infants with presumed infection status were also 
included in the analysis to avoid reducing the sample size, and because confirmatory 
test results hardly ever contradict initial ones (in the NSHPC, this has happened on 
only two or three occasions over the last 10 years; PA Tookey & J Masters, personal 
communication).  
 
Table 3.5 Infection status according to receipt of confirmatory results  
 
Infection status n % 
Uninfected   
Confirmed  4328 85.0 
Presumed  762 15.0 
Infected   
Confirmed  46 75.4 
Presumed  15 24.6 
Total   
Confirmed  4374 84.9 
Presumed  777 15.1 
 
Overall mother-to-child transmission rates 
The overall transmission rate was 1.2% (61/5151, 95% CI: 0.9-1.5%). There was a 
general trend towards lower transmission rates in later years, although it was not 
statistically significant for individual years (p=0.151) (Table 3.6), or when 
comparing 2000-2002 (1.6%, 23/1456) with 2003-2006 (1.0%, 38/3695, p=0.069). 
Transmission was not significantly associated with maternal region of birth or HIV 
exposure group (Table 3.6). HIV-related symptoms and CD4 cell counts were not 
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associated with transmission, although there was a slight non-significant trend 
towards increased transmission at lower CD4 counts (Table 3.6); the lack of 
association with HIV symptoms is most likely due to small numbers (only seven 
transmissions in the symptomatic group). Transmission was slightly higher in black 
African women (1.4%) than in white women (0.4%), although this association was 
borderline significant (p=0.054). Factors that were significantly associated with 
transmission in univariable analysis included no maternal ART, vaginal delivery 
(particularly if unplanned), emergency caesarean section, prematurity (<32 weeks 
gestation), female sex and detectable viral load (Table 3.7). Restricting the 
univariable analyses to the subset included in the multivariable models (shown later) 
did not substantially alter any of the unadjusted odds ratios (data not shown). Table 
3.8 shows all infants (and proportion infected) by maternal ART and mode of 
delivery. Numbers in many of the groups were too small to enable accurate 
transmission rates to be estimated. Comparison of the most common combinations of 
ART and mode of delivery are described later (for example, page 103).
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Table 3.6 Maternal characteristics and mother-to-child transmission rates  
 
 Maternal characteristics 
(n=5151*) 
MTCT 
rate 
(%) 
(n infected  
/ 
 n total) OR  (95% CI) p-value 
Year of delivery (n=5151)     
2000 1.5 (5 / 327)   -  
2001 1.6 (8 / 485)   -  
2002 1.6 (10 / 644)   -  
2003 1.0 (9 / 901)   -  
2004 1.0 (10 / 989)   -  
2005 1.2 (13 / 1045)   - trend 
2006 0.8 (6 / 760)   - 0.151 
Ethnic origin (n=5104)     
White 0.4 (3 / 692) 1.00  
Black African 1.4 (54 / 3990) 3.15  (0.98-10.11) 0.054 
Other 0.9 (4 / 422) 2.20  (0.49-9.87) 0.304 
Region of birth (n=5074)     
British Isles 0.7 (5 / 740) 1.00  
Sub-Saharan Africa 1.4 (54 / 3915) 2.06  (0.82-5.16) 0.125 
Elsewhere 0.5 (2 / 419) 0.71  (0.14-3.65) 0.677 
HIV exposure group (n=5151)     
Non-injecting drug use 1.2 (60 / 4937) 1.00  
Injecting drug use-associated ** 0.5 (1 / 214) 0.38  (0.05-2.77) 0.341 
Clinical status (n=4456)     
Asymptomatic 1.1 (45 / 3994) 1.00  
HIV-related symptoms or AIDS 1.5 (7 / 462) 1.35  (0.61-3.01) 0.463 
CD4 cell count (n=3962)     
≥500 cells/µl 0.8 (11 / 1389) 1.00  
350-499 cells/µl 1.1 (11 / 1011) 1.38  (0.60-3.19) 0.454 
200-349 cells/µl 1.0 (11 / 1080) 1.29  (0.56-2.98) 0.553 
<200 cells/µl 1.5 (7 / 482) 1.85  (0.71-4.79) 0.208 
 
* Infants with infection status reported. 
** Includes HIV acquisition from a drug-using partner.   
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Table 3.7  Treatment and pregnancy characteristics and mother-to-child 
transmission rates  
 
 Risk factors (n=5151*) 
MTCT 
rate (%) 
(n 
infected / 
n total) OR  (95% CI) p-value 
Antiretroviral therapy (n=5027)     
HAART 1.0 (40 / 4120)   
Dual therapy 0.8 (1 / 126) 0.82  (0.11-5.98) 0.841 
Monotherapy 0.5 (3 / 638) 0.48  (0.15-1.56) 0.224 
None 9.1 (13 / 143) 10.2  (5.33-19.53) <0.001 
Missing 3.2 (4 / 124)   
Mode of delivery (n=5131)     
Elective caesarean section 0.8 (23 / 2953)   
Emergency caesarean section 1.6 (17 / 1056) 2.08  (1.11-3.92) 0.023 
Vaginal delivery 1.9 (21 / 1122) 2.43  (1.34-4.41) 0.003 
     - planned 1.1 (7 / 618) 1.46  (0.62-3.42) 0.384 
     - unplanned 5.7 (9 / 157) 7.75  (3.52-17.04) <0.001 
     - unspecified 1.4 (5 / 347) 1.86  (0.70-4.93) 0.211 
Missing 0.0 (0 / 20)   
HIV viral load (n=4096)     
Undetectable (<50 copies/ml) 0.1 (3 / 2309)   
50-999 copies/ml 1.2 (12 / 1023) 9.12  (2.57-32.4) 0.001 
1000-9999 copies/ml 1.4 (6 / 429) 10.90  (2.70-43.8) 0.001 
≥10,000 copies/ml 6.0 (20 / 335) 48.8  (14.4-165.2) <0.001 
Missing 1.9 (20 / 1055)   
Gestational age (n=5002)     
≥37 weeks 1.0 (45 / 4383)   
35-36 weeks 1.0 (3 / 315) 0.93  (0.29-3.00) 0.899 
32-34 weeks 2.1 (4 / 189) 2.08  (0.74-5.86) 0.164 
<32 weeks 6.1 (7 / 115) 6.25  (2.75-14.17) <0.001 
Missing 1.3 (2 / 149)   
Sex of infant (n=5141)     
Male 0.9 (22 / 2580)   
Female 1.5 (39 / 2561) 1.80  (1.06-3.04) 0.029 
Missing 0.0 (0 / 10)     
 
* Infants with infection status reported. 
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Table 3.8  Number of infants and proportion infected by maternal ART and mode of delivery 
 
  Caesarean section   Vaginal delivery   All deliveries 
 Elective Emergency   Planned Unplanned Unspecified     
  Total Infected Total Infected   Total Infected Total Infected Total Infected   Total Infected 
ART n n % n n %   n n % n n % n n %   n n % 
HAART 2286 17 0.7 877 15 1.7  559 4 0.7 122 4 3.3 263 0 0.0  4107 40 1.0 
Dual therapy 69 1 1.4 18 0 0.0  13 0 0.0 2 0 0.0 23 0 0.0  125 1 0.8 
Monotherapy  464 0 0.0 108 0 0.0  37 1 2.7 9 1 11.1 19 1 5.3  637 3 0.5 
Untreated 52 3 5.8 34 2 5.9  8 2 25.0 24 4 16.7 25 2 8.0  143 13 9.1 
Missing 82 2 2.4 19 0 0.0   1 0 0.0 0 0 - 17 2 11.8   119 4 3.4 
Total  2953 23 0.8 1056 17 1.6   618 7 1.1 157 9 5.7 347 5 1.4   5131* 61 1.2 
 
* 20 infants with missing information on mode of delivery are excluded from this table, as none were infected.  
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Multivariable analysis 
Because the overall transmission rate was low, there were issues with small numbers, 
particularly when adjusting for multiple risk factors. Other than mode of delivery and 
ART, only variables that were significant to p<0.10 in a likelihood ratio test (LRT) 
were included. In the main multivariable logistic regression model adjusting for 
ART, mode of delivery, gestational age and sex, neither the inclusion of CD4 count 
nor maternal ethnic group significantly improved the model (LRT, p=0.490 and 
p=0.145, respectively). Because of the association between ART and viral load, 
separate models were developed including and excluding viral load.  
In the main model, which included ART, mode of delivery, gestational age and sex 
(but not viral load) (n=4892; Table 3.9), being untreated (AOR=9.08, p<0.001) was 
the strongest risk factor for transmission, and girls were more likely to be infected 
than boys (AOR=1.91, p=0.023). Prematurity (<32 weeks) was a significant risk 
factor for transmission in the multivariable model (AOR=3.55, p=0.010); however, 
of the seven women who had infected infants born at <32 weeks gestation, all were 
either untreated (n=3) or treated for less than three weeks (range: 1-19 days), and all 
but one delivered vaginally. Duration of treatment was not included in this model, 
since this variable did not apply to untreated women. The association between mode 
of delivery and transmission varied by type of therapy (Table 3.8, page 96), but could 
not be explored adequately using interaction terms, due to small numbers in many of 
the cells (Table 3.8); instead, separate analyses by type of ART are presented later. 
It was unclear why girls were more likely to be infected than boys. There was no 
evidence of a differential effect of sex by treatment (any versus none, test of 
homogeneity of ORs, p=0.333) or mode of delivery (test of homogeneity of ORs, 
p=0.951) in this population. There was no evidence of increased fetal death in boys: 
 98 
in fact, girls were twice as likely to be stillborn as boys (0.98%, 29/2954, versus 
0.50%, 15/2993, p=0.031); however, sex was not reported for a third (21/65) of 
stillbirths in 2000-2006.  
Planned versus unplanned vaginal delivery 
In the multivariable model, vaginal delivery was associated with a non-significant 
1.8-fold increase in transmission compared with elective caesarean section 
(AOR=1.82, p=0.076). Information on whether vaginal deliveries were planned or 
unplanned was available for 69.1% (775/1122). After adjusting for ART, gestational 
age and sex, unplanned vaginal delivery was associated with a significantly increased 
risk of transmission (AOR=4.16, 95% CI: 1.66-10.41, p=0.002) compared with 
elective caesarean section, but planned vaginal delivery was not (AOR=1.56, 95% 
CI: 0.65-3.72, p=0.319).  
Viral load 
Viral load was reported for 79.5% (4096/5151) of women, but for significantly fewer 
untreated than treated women (49.7%, 71/143, versus 82.3%, 4021/4884, p<0.001), 
and infected than uninfected infants (67.2%, 41/61, versus 79.7%, 4055/5090, 
p=0.024); possible reasons for these patterns include a lack of opportunity for viral 
load testing in women who present for the first time in labour, and the fact that 
women who decline ART are likely to refuse viral load testing as well, although no 
evidence was available to support either of these suggestions. Closest viral load to 
delivery was measured at a median of 23 days before delivery (IQR: 10-44 days). 
MTCT increased with increasing viral load, and the association was more 
pronounced in women who had vaginal deliveries or emergency caesarean sections 
than in those who delivered by elective caesarean section (Figure 3.5). In 
multivariable analysis (n=4084) controlling for ART, mode of delivery, gestational 
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age and sex, each log10 increase in viral load was associated with a 2.4-fold increase 
in transmission (AOR=2.41, p<0.001) (Table 3.9).  
In the multivariable model that included viral load, lack of ART (AOR=3.17, 
p=0.023) and vaginal delivery (AOR=2.40, p=0.033) were strongly associated with 
transmission, but gestational age and sex were not (Table 3.9). Adjusting for viral 
load led to a reduction in the AOR for very premature delivery (<32 weeks) from 
3.55 (Model 1) to 2.35 (Model 3), suggesting that at least some of the association 
between prematurity and transmission was explained by high viral loads in women 
who delivered prematurely. This is consistent with the observation that the mothers 
of all seven infected infants born at <32 weeks were on treatment for less than three 
weeks (or not at all). On the other hand, the reduction in the AOR for the association 
between female sex and MTCT from 1.91 (Model 1) to 1.58 (Model 3), and loss of 
statistical significance, was mainly due to the exclusion of 808 mother-child pairs 
with no viral load information. Indeed, the reduction in the AOR occurred when the 
analysis was restricted to cases with viral load reported, but without adjusting for 
viral load (Table 3.9, Model 2). 
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Table 3.9 Adjusted odds ratios for mother-to-child transmission  
 
 
Model 1: all cases (n=4892), 
viral load not included 
Model 2: cases with viral load 
reported (n=4084), not 
adjusting for viral load 
Model 3: cases with viral load 
reported (n=4084), adjusting 
for viral load 
  
n  
(model 
1) AOR  95% CI p-value 
n 
 (models  
2 & 3) AOR  95% CI p-value AOR  95% CI p-value 
Antiretroviral therapy            
HAART 4012 1.00   3399 1.00   1.00   
Dual therapy 120 0.86 0.12-6.33 0.883 75 1.60 0.21-11.98 0.647 1.71 0.22-13.03 0.606 
Monotherapy  629 0.56 0.17-1.82 0.334 539 0.72 0.22-2.38 0.587 0.57 0.17-1.91 0.366 
None 131 9.08 4.54-18.16 <0.001 71 8.58 3.34-22.03 <0.001 3.17 1.17-8.59 0.023 
Mode of delivery            
Elective caesarean section 2797 1.00   2399 1.00   1.00   
Emergency caesarean section 1023 1.67 0.80-3.48 0.172 847 1.48 0.62-3.57 0.380 1.89 0.79-4.52 0.153 
Vaginal delivery 1072 1.82 0.94-3.53 0.076 838 1.82 0.84-3.93 0.128 2.40 1.08-5.35 0.033 
Gestational age            
≥37 weeks 4288 1.00   3584 1.00   1.00   
35-36 weeks 306 0.84 0.25-2.81 0.773 255 0.82 0.19-3.60 0.788 0.49 0.11-2.23 0.359 
32-34 weeks 185 1.63 0.54-4.94 0.390 153 1.73 0.47-6.34 0.405 1.17 0.32-4.29 0.816 
<32 weeks 113 3.55 1.36-9.30 0.010 92 4.38 1.48-12.99 0.008 2.35 0.77-7.20 0.134 
Sex of infant            
Male 2447 1.00   2053 1.00   1.00   
Female 2445 1.91 1.09-3.33 0.023 2031 1.52 0.80-2.87 0.198 1.58 0.82-3.04 0.170 
HIV RNA viral load            
Per log10 increase     4084       2.41 1.91-3.05 <0.001 
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Figure 3.5 Mother-to-child transmission rates (with 95% confidence intervals) 
by HIV viral load and mode of delivery  
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Breastfeeding 
Although HIV-infected women in the UK and Ireland are recommended to formula 
feed, breastfeeding was reported in 0.6% (29/4399) of infants with information 
provided. Three of these infants were infected, all of whom were born to untreated 
women. Two of the women had declined ART: one breastfed for over three months, 
and the other’s baby was HIV negative at three months and subsequently 
seroconverted. The third woman had an antenatal HIV test during pregnancy, but the 
result was not communicated until after delivery; she breastfed for one week, and her 
baby had a positive DNA PCR test at three weeks of age.  
Transmission following HAART 
The MTCT rate for women on HAART was 1.0% (40/4120) (Table 3.5). Logistic 
regression models were developed to explore risk factors for MTCT in this group, 
but statistical power to detect differences between subgroups was very limited, due to 
the small number of transmissions. Furthermore, planned, unplanned and unspecified 
vaginal deliveries had to be combined to avoid omission of subgroups from the 
models. MTCT rates were not significantly different whether HAART included an 
NNRTI (0.9%, 18/1959), a PI (1.1%, 20/1795, p=0.625), both an NNRTI and a PI 
(0.8%, 2/258), or neither (0%, 0/108, p=0.847). Comparing PI with non-PI regimens, 
there was no difference in MTCT rates after adjusting for mode of delivery, sex and 
log10 viral load (AOR=1.27, 95% CI: 0.61-2.62, p=0.521; n=3399). Severe 
prematurity (<32 weeks) was not a significant risk factor for transmission among 
women on HAART, after adjusting for mode of delivery (vaginal, elective or 
emergency caesarean section) and sex (AOR=1.32, 95% CI: 0.30-5.82, p=0.714; 
n=4012), and was therefore omitted from the models.  
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Timing and duration of HAART 
HAART at conception was associated with a significantly lower risk of transmission 
than HAART started during pregnancy (0.1%, 1/928, versus 1.3%, 39/2967, 
p=0.001), even after adjusting for mode of delivery and sex (AOR=0.08, 95% CI: 
0.01-0.58, p=0.013; n=3880). Adjusting for log10 viral load reduced the magnitude 
and significance of the association (AOR=0.18, 95% CI: 0.02-1.35, p=0.096; 
n=3394).  
Of the 3192 women who started HAART during pregnancy, date of initiation was 
available for 2643 (83%); those who transmitted (n=34) started later than those who 
did not (median gestational age at initiation: 30.1 weeks, IQR: 27.4-32.6 weeks, 
versus 25.9 weeks, IQR: 22.4-28.7 weeks, p<0.001). In multivariable analysis, each 
additional completed week of treatment corresponded to a 17% (AOR=0.83, 95% CI: 
0.77-0.89, p<0.001; n=2639) reduction in the risk of transmission after adjusting for 
mode of delivery and sex, and a 10% (AOR=0.89, 95% CI: 0.83-0.96, p=0.003; 
n=2475) reduction after adjusting for log10 viral load as well as mode of delivery and 
sex. Most of the decline in transmission occurred in the first six weeks of treatment, 
with a 43% reduction for each additional week of ART during this period 
(AOR=0.57, 95% CI: 0.34-0.96, p=0.036; n=278), after adjusting for mode of 
delivery, sex and log10 viral load. 
Elective caesarean section versus planned vaginal delivery 
Among women on HAART, there was no statistically significant difference in 
MTCT rates between elective caesarean section (0.7%, 17/2286) and planned vaginal 
delivery (0.7%, 4/559; AOR=1.24, 95% CI: 0.34-4.52, p=0.746, adjusted for sex and 
log10 viral load). Results were similar if women on treatment for less than 14 days 
were excluded (AOR=1.34, 95% CI: 0.36-5.04, p=0.663), but as with other analyses 
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among women on HAART, statistical power was limited. Because the BHIVA 
Guidelines suggest offering planned vaginal deliveries only to women with 
suppressed viral load on HAART (BHIVA, 2005a), the proportion of women with 
undetectable viral load was higher in those who had planned vaginal deliveries 
(79.0%, 417/528) than in those who had elective caesarean sections (58.7%, 
1135/1934, p<0.001). MTCT rates were higher in women on HAART who had 
emergency caesarean sections (1.7%, 15/877) or unplanned vaginal deliveries (3.3%, 
4/122) compared with those who had elective caesarean section deliveries (p=0.027 
and p=0.019, respectively).  
HAART and undetectable viral load 
Only three transmissions were reported among 2117 infants born to women on 
HAART with undetectable viral load (0.1%, 95% CI: 0.0-0.4%); duration of HAART 
among the mothers who transmitted ranged from 6 to 14 completed weeks. Two of 
the infants were born by elective caesarean section (0.2%, 2/1135) and one by 
planned vaginal delivery (0.2%, 1/417); none were premature. Two of the three 
infants (one born vaginally) had positive HIV PCR tests within 72 hours of birth, 
suggesting that they were infected in utero rather than at the time of delivery (Bryson 
et al., 1992). The other infant had no PCR tests reported in the first three days of life, 
and timing of infection was therefore unknown.  
Transmission despite interventions 
Eighteen other women had infected infants despite HAART and either planned 
vaginal delivery or elective caesarean section. Ten of them received less than two 
weeks of treatment and/or had high viral loads near delivery (range: 8500-285,000 
copies/ml). In addition, problems with adherence or denial were reported in a few 
cases, although information was not specifically requested.  
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There were six transmissions from women with low but detectable viral load (50-999 
copies/ml); two had planned vaginal deliveries and four had elective caesarean 
sections. There was no statistically significant difference in transmission rates 
between planned vaginal delivery (2.5%, 2/81) and elective caesarean section (0.8%, 
4/471, p=0.215) among women with low but detectable viral load, although due to 
limited statistical power, it was not possible to exclude an effect. Two of these six 
infected infants had positive HIV PCR tests within 72 hours of birth, suggesting in 
utero transmission (both were born by elective caesarean section). The remaining 
two of the eighteen women received HAART for at least one month, but no viral 
loads were reported. Information on neonatal prophylaxis was provided for 20 of the 
21 infants infected despite maternal HAART and planned vaginal or elective 
caesarean section delivery, and all were treated; nine with monotherapy (one 
zidovudine, one didanosine), three with dual therapy (zidovudine and nevirapine), 
and eight with triple therapy (mostly combivir and nevirapine). Eighteen infants had 
breastfeeding status reported, and none were breastfed. 
Transmission following zidovudine monotherapy 
The mothers of 638 infants received prophylactic zidovudine monotherapy in 
pregnancy. The majority of these pregnancies were managed in accordance with the 
BHIVA Guidelines (BHIVA, 2001; BHIVA, 2005a): most of the women had CD4 
counts above 200 cells/µl (99% [524/530] including 85% [451/530] above 350 
cells/µl) and viral load <10,000 copies/ml (95.7%, 517/540); most (78%) viral loads 
were measured after initiation of treatment. Seventy three percent (464/637) of 
women delivered by elective caesarean section. 
Three infants were infected (0.5%, 95% CI: 0.1-1.4%); all three mothers were treated 
with zidovudine for less than one month, had detectable viral load (range: 474-3000 
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copies/ml) and delivered vaginally (contrary to BHIVA recommendations). The 
transmission rate following monotherapy and elective caesarean section was 0% 
(0/464, 95% CI: 0-0.8%), with a median viral load of 400 copies/ml (IQR: 61-1992 
copies/ml); this transmission rate was not significantly different from that following 
HAART and planned vaginal delivery (0.7%) or elective caesarean section (0.7%, 
Fisher’s exact test: p=0.150). The transmission rate following monotherapy and 
emergency caesarean section was 0% (0/116, 95% CI: 0-3.4%), with a median viral 
load of 597 copies/ml (IQR: 84-3195 copies/ml); 37% (40/108) of emergency 
caesarean sections were carried out at <37 weeks gestation, including 5% (5/108) at 
<32 weeks.  
Multiple births 
Including all twin and triplet births, or all twin and triplet infants, did not 
substantially alter the overall MTCT rate (Table 3.10). 
 
Table 3.10 Mother-to-child transmission rates according to inclusion or 
exclusion of twins and triplets 
 
  Total 
n 
infected 
MTCT 
rate (%) 95% CI 
Singleton infants only 5151 61 1.18 0.89-1.48 
Singletons and first twins/triplets 5233 61 1.17 0.87-1.46 
All infants 5316 61 1.15 0.86-1.43 
 
Adjustment for unreported infection status 
Potential bias introduced by excluding infants with unreported infection status was 
investigated by computing likely infection status based on maternal treatment and 
viral load category. MTCT rates by treatment and viral load are shown in Table 3.11. 
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Because viral load was unavailable for 50% of untreated women and for almost all 
women with missing treatment information, the estimated number of additional 
infected infants in these two groups was calculated using the overall transmission 
rate for each group (without taking into account viral load): rates were 9.1% for 
untreated women and 3.2% for those with missing treatment information. Among 
treated women, transmission rates at different viral load levels were available and 
were used in the calculations (Table 3.11). Using these transmission rates to compute 
likely infection status, an estimated 1.4% (11/779) of children with unreported 
infection status would be infected. The overall transmission rate would remain 1.2% 
(72/5930, 95% CI: 1.0-1.5%).  
A similar result was obtained by imputing probability of infection in Stata, based on 
ART, mode of delivery (with vaginal delivery classified as planned or unplanned), 
gestational age groups, infant sex, and log10 viral load. The estimated number of 
additional infections using this method was 10, with the estimated overall 
transmission rate remaining 1.2% (71/5930, 95% CI: 0.9-1.5%).
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Table 3.11 Mother-to-child transmission rates by maternal antiretroviral 
therapy and viral load, and estimated number of additional infections among 
children with unreported infection status 
 
ART
Viral load 
(copies/ml)
Infected 
(n )
Total 
(n )
Actual 
MTCT 
rate (%)
MTCT 
rate used 
(%)
Un-reported 
infection 
status (n )
Estimated 
additional 
infected (n )
No <50 0 9 0.0
50-999 0 20 0.0
1000-9999 0 14 0.0
≥10000 6 28 21.4
Missing 7 72 9.7
Total 13 143 9.1 9.1 43 4
Yes <50 3 2299 0.1 0.1 337 0
50-999 12 1003 1.2 1.2 124 1
1000-9999 6 414 1.4 1.4 72 1
≥10000 14 305 4.6 4.6 41 2
Missing 9 863 1.0 1.0 116 1
Total 44 4884 0.9
Missing <50 0 1 0.0
50-999 0 0 -
1000-9999 0 1 0.0
≥10000 0 2 0.0
Missing 4 120 3.3
Total 4 124 3.2 3.2 46 1
Total 61 5151 1.2 779 11
Numbers too small - overall MTCT rate 
used in calculation
Numbers too small - overall MTCT rate 
used in calculation
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3.4 Key points 
• The number of pregnancies in diagnosed HIV-infected women in the UK and 
Ireland increased from around 100 per year in the early 1990s to over 1200 per 
year from 2005 onwards. 
• The demographic profile of HIV-infected pregnant women changed substantially 
over this period, with a shift in likely route of HIV infection from injecting drug 
use to exposure in areas of high HIV prevalence, especially sub-Saharan Africa. 
• The proportion of women diagnosed antenatally increased in the years following 
the introduction of routine screening, from less than 40% before 2000, to 60% in 
2000-2003.  
• The number of pregnancy reports made to the NSHPC increased over time in all 
parts of the British Isles. The proportion of pregnancies reported from England 
outside London rose substantially from 13% in 1997-1999 to 43% in 2004-2006.  
• The proportion of pregnancy terminations decreased 10-fold between the early 
1990s and 2004-2006.  
• Uptake of ART increased to 98% in 2006, after zidovudine became available in 
1994, and over 80% of women in recent years were on HAART at some time in 
pregnancy.  
• Between 1999 and 2006, the proportion of planned vaginal deliveries rose 
gradually from 17% to 28%, and the proportion of emergency caesarean sections 
rose from 17% to 23%. 
• MTCT rates declined from a high of 24% in 1993 to 1% in 2004-2006.  
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• Independent risk factors for transmission in 2000-2006 (when HAART was 
widely available) included lack of maternal ART, vaginal delivery (particularly if 
unplanned), female sex, and prematurity (<32 weeks). Viral load remained 
strongly associated with MTCT.  
• The risk of transmission was reduced in women who started HAART before 
pregnancy (AOR=0.18), compared with those starting during pregnancy. Earlier 
initiation of HAART was associated with a significant reduction in the risk of 
transmission (AOR=0.90 per week of treatment) in women who started treatment 
in pregnancy.  
• There was no statistically significant difference in MTCT rates according to the 
management strategies outlined in the BHIVA Guidelines: HAART with elective 
caesarean section (0.7%), HAART with planned vaginal delivery (0.7%), or 
zidovudine monotherapy with elective caesarean section (0%). 
• Only three transmissions were reported among 2117 infants born to women on 
HAART with viral load <50 copies/ml, and two were likely infected in utero.  
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Chapter 4 Antiretroviral therapy, pregnancy 
complications and congenital abnormalities  
The increasing use of antiretroviral therapy (ART) in pregnancy following its success 
in reducing mother-to-child transmission (MTCT) rates has naturally prompted 
concerns about potential adverse effects. By reducing HIV RNA viral load and 
allowing CD4 cell recovery, ART leads to immunological changes which may 
disrupt those occurring naturally in pregnancy (Fiore et al., 2006), potentially leading 
to undesirable outcomes such as pre-eclampsia, premature labour or fetal death 
(European Collaborative Study, 2004a; Suy et al., 2006). In recent years, a 
substantial minority of women have been on highly active antiretroviral therapy 
(HAART) at conception and throughout pregnancy, raising additional concerns about 
possible teratogenic effects associated with fetal exposure in the first trimester of 
pregnancy, at the time of organogenesis. 
Information on pregnancy outcome (miscarriage, stillbirth and neonatal death) and 
congenital abnormality has been routinely collected through the National Study of 
HIV in Pregnancy and Childhood (NSHPC) since its inception. In addition, in 
response to concerns raised about ART and pre-eclampsia (Suy et al., 2004; Suy et 
al., 2006), information on pregnancy complications, including pre-eclampsia, was 
collected from mid-2004 onwards.  
In this chapter the association between ART and adverse pregnancy and perinatal 
outcomes is explored; the first section addresses stillbirths and neonatal deaths; the 
second section, pregnancy complications; and the third section, congenital 
abnormalities, particularly in relation to timing of ART exposure. Information on 
congenital abnormality rates in the NSHPC between 1990 and 2003 was initially 
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published in 2006 (Townsend et al., 2006) (Appendix 2, page 365). An updated 
analysis using data for 1990 to 2007 was published in 2009 (Townsend et al., 2009) 
(Appendix 2, page 333) and relates to results shown here. The association between 
ART and premature delivery will be explored in detail in Chapter 5.  
4.1 Methods 
In this chapter, clinical status refers to HIV-related symptoms or AIDS occurring at 
any time in pregnancy. 
Stillbirth and neonatal death 
Analysis of stillbirth and neonatal death was based on births between 1990 and 2007, 
reported to the NSHPC by June 2008; twin births were included and were defined as 
a stillbirth if one or both twins died. Because the lowest stillbirth rate was in women 
on monotherapy, this group was chosen as the baseline for comparison by type of 
ART. 
Pregnancy complications 
Analysis of pregnancy complications was restricted to pregnancies delivered between 
2004 and 2007, for which information on complications was sought. Information was 
collected from obstetric respondents only, and was recorded on the database as 
reported. Details of laboratory tests and criteria for establishing diagnosis were not 
available. Known risk factors for pre-eclampsia on which information was available 
through the NSHPC were maternal age, clinical status and multiple pregnancy (Sibai, 
Dekker, & Kupferminc, 2005). Since the dataset was restricted to pregnancies 
delivered between 2004 and 2007, only a small proportion (6%, 210/3567) were 
second or third pregnancies in women already reported with one pregnancy during 
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that period. Only six women had pregnancy complications reported in two 
pregnancies included in the dataset, so logistic regression analyses were not adjusted 
for repeat pregnancies. In these analyses, monotherapy was chosen as the baseline 
for comparison of type of ART, due to the small number of pregnancies (n=53) in 
untreated women. 
Congenital Abnormalities 
This analysis included all infants (live born, stillborn, twins and triplets) born 
between 1990 and 2007 in the UK and Ireland to women diagnosed before delivery 
and reported to the NSHPC by June 2008. Congenital abnormality rates and 95% 
confidence intervals (CI) were calculated, overall and by timing and type of ART in 
pregnancy. First trimester ART exposure was classified according to class, but not 
number, of antiretroviral drugs included (since few women were on monotherapy or 
dual therapy in early pregnancy). The four ART categories were: nucleoside reverse 
transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor 
(NNRTI), protease inhibitor (PI), or both NNRTI and PI; regimens in the latter three 
categories could also include NRTIs. Because of specific concerns (detailed in 
Chapter 1), abnormality rates were calculated for infants exposed to efavirenz or 
didanosine in early pregnancy, and the rate of hypospadias was explored by ART 
exposure. Potential confounders on which information was available included 
maternal ethnicity, age, injecting drug use (as the reported route of HIV acquisition) 
and clinical status (EUROCAT, 2004).  
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4.2 Stillbirths and neonatal deaths 
Out of the 8430 births reported for 1990-2007, 92 were stillbirths, and there were 30 
neonatal deaths. Three women had two stillbirths reported during the study period, 
but none had more than one infant who died neonatally. The stillbirth rate was 10.9 
per 1000 births (92/8430) (95% CI: 8.8-13.4), compared with a UK population rate 
of 5.3 per 1000 births (95% CI: 5.1-5.5) in 2006 (Confidential Enquiry into Maternal 
and Child Health, 2008). The neonatal mortality rate was 3.6 per 1000 live births 
(30/8338) (95% CI: 2.4-5.1), in line with population rates of 3.9 per 1000 (95% CI: 
3.7-4.0) in 2000 and 3.4 per 1000 (95% CI: 3.3-3.6) in 2006 (Confidential Enquiry 
into Maternal and Child Health, 2008). Fifteen of the neonatal deaths occurred before 
the seventh day of life; the perinatal mortality rate was 12.7 per 1000 births 
(107/8430) (95% CI: 10.4-15.3).  
For over half the stillbirths, details were provided on likely cause of death (Table 
4.1). Reasons reported included placental problems (insufficiency, abruption) (15.2% 
of all stillbirths), perinatal infections (8.7%), congenital abnormalities (7.6%) and 
pre-eclampsia (5.4%) (Table 4.1). In the general population, congenital abnormality 
is reported as the most common cause of stillbirth (15%), followed by antepartum 
haemorrhage (10%), intrapartum causes (7%), pre-eclampsia (4%) and infection 
(2%) (Confidential Enquiry into Maternal and Child Health, 2006). Because 
information is not specifically requested on cause of death in the NSHPC, it is 
possible that reasons were identified in some of the cases where no information was 
supplied, although in general, at a population level, about half of all stillbirths remain 
unexplained (Confidential Enquiry into Maternal and Child Health, 2006).  
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Table 4.1 Reasons or complications reported for stillbirths 
 
Reason / complication reported n % 
Placental insufficiency or abruption 14 15.2 
Perinatal infection 8 8.7 
Congenital abnormality 7 7.6 
Pre-eclampsia 5 5.4 
Hypertension or proteinuria 5 5.4 
Multiple pregnancy  3 3.3 
Delivery complications 2 2.2 
Maternal death near delivery 1 1.1 
No apparent cause identified 6 6.5 
Intrauterine death, no further details 10 10.9 
No details supplied 31 33.7 
Total 92 100.0 
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Stillbirth rates by maternal and pregnancy characteristics are shown in Table 4.2. 
Multiple pregnancy was associated with a 2.7-fold increased risk of stillbirth, and 
CD4 count <200 cells/µl with a two-fold increase. Untreated women were almost 
nine times more likely than women on monotherapy to have a stillborn child 
(p<0.001), although in this analysis this was mainly because these stillbirths occurred 
very early, most likely before treatment could be initiated; 10 out of 14 occurred at 
<32 weeks gestation, including eight at <28 weeks gestation.  
Stillbirth was four times more likely in women on HAART than in those on 
monotherapy (p=0.019). In multivariable analysis (n=6345), adjusting for CD4 cell 
count and multiple pregnancy, HAART remained associated with stillbirth, although 
this was only borderline significant, likely due to the small number of stillbirths in 
some of the cells (adjusted odds ratio [AOR]=3.13, 95% CI: 0.98-10.00, p=0.055). In 
the multivariable model, CD4 count <200 cells/µl was significantly associated with 
stillbirth compared with CD4 ≥500 cells/µl (AOR=1.79, 95% CI: 1.03-3.13, 
p=0.041) but the association with multiple pregnancy was no longer significant 
(AOR=2.37, 95% CI: 0.73-7.67, p=0.150, for multiple versus singleton pregnancies); 
since the AOR was similar to the odds ratio (OR), the lack of statistical significance 
was likely due to small numbers.
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Table 4.2 Stillbirth rates and unadjusted odds ratios by maternal 
demographic and pregnancy characteristics 
 
Total n % OR ( 95% CI)
Timing of diagnosis (n=8320)
Before this pregnancy 4222 51 1.2 1.00
During this pregnancy 4098 41 1.0 0.83 (0.55-1.25) 0.366
Exposure category (n=8430)
Non-injecting drug use 8050 89 1.1 1.00
Injecting drug use 380 3 0.8 0.71 (0.22-2.26) 0.564
Ethnic group (n=8351)
White 1317 12 0.9 1.00
Black African 6375 71 1.1 1.22 (0.66-2.26) 0.518
Other 659 9 1.4 1.51 (0.63-3.59) 0.356
Age at delivery (n=8365)
<20 years 276 3 1.1 0.95 (0.29-3.11) 0.926
20-24 years 1232 12 1.0 0.85 (0.43-1.65) 0.625
25-29 years 2698 31 1.1 1.00
30-34 years 2587 26 1.0 0.87 (0.52-1.48) 0.613
35-39 years 1347 15 1.1 0.97 (0.52-1.80) 0.920
≥40  years 225 5 2.2 1.96 (0.75-5.08) 0.169
Parity (live/stillbirths) (n=5477)
0 1973 24 1.2 1.00
1 1810 18 1.0 0.82 (0.44-1.51) 0.516
2 976 11 1.1 0.93 (0.45-1.90) 0.833
3 or more 718 9 1.3 1.03 (0.48-2.23) 0.938
Clinical status (n=7385)
Asymptomatic 6574 78 1.2 1.00
HIV symptoms or AIDS 811 13 1.6 1.36 (0.75-2.45) 0.312
CD4 cell count (n=6351)
≥500 cells/µl 2154 21 1.0 1.00
350-499 cells/µl 1714 25 1.5 1.50 (0.84-2.70) 0.171
200-349 cells/µl 1717 17 1.0 1.02 (0.53-1.93) 0.962
<200 cells/µl 766 16 2.1 2.17 (1.12-4.17) 0.021
Multiple pregnancy (n=8430)
Singleton 8288 88 1.1 1.00
Twin / triplet 142 4 2.8 2.70 (0.98-7.46) 0.055
ART (n=8171)
Untreated 574 14 2.4 8.82 (2.52-30.81) 0.001
Monotherapy 1061 3 0.3 1.00
Dual therapy 223 2 0.9 3.19 (0.53-19.21) 0.205
HAART 6313 70 1.1 4.01 (1.26-12.76) 0.019
- without PI 2714 38 1.4 5.01 (1.54-16.26) 0.007
- with PI 3585 32 0.9 3.18 (0.97-10.39) 0.056
p -valuePregnancy complication
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4.3 Pregnancy complications 
All complications 
The following analysis is restricted to 3852 pregnancies delivered between 2004 and 
2007. This subset comprised 45.7% (3852/8430) of all reported births, and 80% 
(3852/4820) of all births between 2004 and 2007; of the 968 births between 2004 and 
2007 for which information on complications was not sought, 40% (383/968) were 
reported on an earlier version of the data collection form (which did not solicit the 
information required), and 60% (585/968) through paediatric respondents only (who 
were not asked to provide the information). The question on pregnancy 
complications was completed for 92.6% of pregnancies (3567/3852), and of those, 
problems were reported in 7.7% (275/3567) (Table 4.3). The most commonly 
reported problems were pre-eclampsia (2.1% overall), hypertension (1.3%) and 
gestational diabetes (0.9% overall) (Table 4.3). Rates were generally lower than 
expected, with pre-eclampsia occurring in 2-7% of pregnancies in the general 
population (Sibai, Dekker, & Kupferminc, 2005), and gestational diabetes in about 
3.5% (National Institute for Clinical Excellence, 2008). Pregnancy outcomes 
included 64 multiple pregnancies, 40 stillbirths, and 11 neonatal deaths. 
Missing information on pregnancy problems 
Information on pregnancy complications was missing for 7.4% (285/3852) of 
pregnancies; these were more likely to be in women who acquired HIV through 
injecting drug use (14.1%, 10/71, versus 7.3%, 275/3781, p=0.030), in untreated 
women (15.9%, 10/63, versus 7.1%, 268/3766, p=0.008) and in those with lower 
CD4 count (8.9%, 33/369, for CD4<200 cells/µl, versus 5.3%, 68/1277, for CD4 
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≥500 cells/µl, p=0.011). There was no significant association between availability of 
information and any other variable (timing of diagnosis, ethnic group, maternal age, 
parity, clinical status, mode of delivery or multiple pregnancy). 
Pregnancy and perinatal outcomes  
Compared with pregnancies with no complications reported, those with problems 
were more likely to result in emergency caesarean section delivery (51% versus 
21%), premature delivery (46% versus 11%), stillbirth (7% versus 0.5%), and an 
infant with a congenital abnormality (5% versus 2%) (Table 4.4). Pregnancy 
complications were reported in 53.0% of stillbirths (18/34), and 2 of 10 pregnancies 
resulting in a neonatal death. 
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Table 4.3 Prevalence of pregnancy complications in the NSHPC 
 
Category Pregnancy complication n % 
None  3292 92.3 
Hypertensive conditions Hypertension 48 1.3 
 
Pregnancy-induced hypertension 17 0.5 
 
Proteinuria 2 0.1 
 
Pre-eclampsia * 72 2.0 
 
HELLP syndrome 2 0.1 
 
Pre-eclampsia and gestational diabetes 2 0.1 
Diabetes Diabetes 4 0.1 
 
Gestational diabetes **  30 0.8 
Obstetric complications Placental problems 20 0.6 
 
Oligohydramnios/low liquor 4 0.1 
 
Polyhydramnios 7 0.2 
 
Post-partum haemorrhage 3 0.1 
 
Intra-uterine growth retardation 15 0.4 
Haematological problems Anaemia 7 0.2 
 
Thrombocytopaenia/low platelets 5 0.1 
 
Thrombosis (DVT/embolism) 5 0.1 
Liver / cholesterol Abnormal LFTs/liver abnormalities 6 0.2 
 
Obstetric cholestasis 10 0.3 
 
Cholesterol problems 2 0.1 
Other Nephrotic syndrome/renal failure 4 0.1 
  
Other specified problems *** 10 0.3 
Total   3567 100.0 
 
DVT, deep vein thrombosis; HELLP, haemolysis, elevated liver enzymes or low platelet counts; LFT, 
liver function tests.  
* The overall rate of pre-eclampsia (2.1%) included women who also had gestational diabetes 
reported (n=2), and those with HEELP syndrome (n=2). ** Likewise, the overall rate of gestational 
diabetes (0.9%) included women who also had pre-eclampsia reported.  
*** Including antepartum bleeding/haemorrhage (n=4), abdominal pain (n=2), oesophageal varices, 
motor neurone palsy, fibroid uterus, thyrotoxicosis, seizure. 
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Table 4.4  Pregnancy and perinatal characteristics by report of pregnancy 
complications  
 
  No complications Complications 
  % n % n 
p-value 
(exact) 
Outcome (n=3567) 
     
Live birth 99.5 3276 93.5 257  
Stillbirth 0.5 16 6.5 18 <0.001 
Mode of delivery (n=3562) 
     
Elective caesarean section 51.6 1698 28.0 77  
Emergency caesarean section 21.4 704 51.3 141  
Vaginal 27.0 889 19.3 53 <0.001 
Gestational age (n=3567) 
     
≥37 weeks 89.3 2939 53.8 148  
35-36 weeks 5.5 182 17.5 48  
32-34 weeks 2.9 94 12.0 33  
<32 weeks 2.3 77 16.7 46 <0.001 
Birth weight (n=3470) 
     
≥2500 g 85.5 2815 52.0 143  
1500-2499 g 9.7 319 27.3 75  
<1500 g 2.1 70 17.5 48 <0.001 
Sex of child (n=3552) 
     
Male 50.7 1670 46.2 127  
Female 48.8 1608 53.5 147 0.148 
Congenital abnormality (n=3536) 
     
No 97.5 3209 90.9 250  
Yes 1.9 63 5.1 14 0.001 
Child's HIV infection status (n=2817) 
    
Uninfected 78.4 2580 77.1 212  
Infected 0.8 25 0.0 0 0.254 
Neonatal death (n=3567) 
     
No 99.8 3284 99.3 273  
Yes 0.2 8 0.7 2 0.177 
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Risk factors for pregnancy complications 
Pregnancy complications (of any kind) were more common in women who were 
older (14% for women over 44, versus 4% for those under 20 years of age), 
symptomatic (14%, versus 7% in asymptomatic women), had CD4 counts <200 
cells/µl (12%, versus 7% for CD4 ≥500 cells/µl) or a history of three or more 
previous births (12%, versus 7% for nulliparous women), as well as in multiple 
pregnancies (19% versus 7.5%) (Table 4.5). Pregnancy complication rates were also 
higher in women on HAART regimens that did not contain PIs, compared with 
monotherapy (OR=1.85), although this was only of borderline significance 
(p=0.052).  
Variables that were significantly associated with pregnancy complications in 
univariable analysis were included in a multivariable logistic regression model. 
Maternal age, clinical status, CD4 cell count and multiple pregnancy were all 
significantly and independently associated with pregnancy complications, after 
adjusting for all other factors including parity and ART (Table 4.6). After adjusting 
for these other variables, in particular maternal age, parity was no longer a risk factor 
for pregnancy complications. Non-PI HAART was also no longer significantly 
associated with pregnancy problems; the OR for non-PI HAART versus 
monotherapy was reduced after adjusting for both HIV-related symptoms (AOR=1.3, 
adjusting only for symptoms) and CD4 count (AOR=1.3, adjusting only for CD4 
count), suggesting that the observed effect was due to confounding by maternal 
clinical factors associated with type of ART. Indeed, very few women on 
monotherapy were symptomatic (1.7%, 4/235), and among those on HAART, 
symptoms were more common in women on non-PI-based HAART (14.2%, 
143/1004) than in those on PI-based HAART (7.9%, 193/2428, p<0.001). 
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Among women on HAART the risk of pregnancy complications was higher in those 
who were on treatment at the time of conception than in those who started HAART 
in pregnancy (11.2%, 103/917, versus 6.5%, 151/2310; OR=1.81, 95% CI: 1.39-2.35, 
p<0.001). Because timing of treatment only applied to women on HAART, this 
variable could not be included in the main multivariable model. However, in a 
separate model restricted to women on HAART (n=2523), pregnancy complications 
remained significantly associated with HAART at conception after adjusting for 
maternal age, parity, clinical status, CD4 cell count and multiple pregnancy: 
AOR=1.79 (95% CI: 1.30-2.46, p<0.001). This association was mainly due to 
increased rates of hypertensive conditions (including pre-eclampsia) in women on 
HAART at conception (5.7%, 52/917) compared with those on HAART later (3.3%, 
77/2310, p=0.002). The association was reduced and no longer significant after 
excluding hypertensive conditions (AOR=1.48, 95% CI: 0.94-2.32, p=0.087), 
although this could have been due to smaller numbers.
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Table 4.5  Pregnancy complication rates and unadjusted odds ratios by 
maternal demographic and pregnancy characteristics 
 
Total n % OR ( 95% CI)
Timing of diagnosis (n=3564)
Before this pregnancy 1939 164 8.5 1.00
During this pregnancy 1625 111 6.8 0.79 (0.62-1.02) 0.070
Exposure category (n=3567)
Non-injecting drug use 3506 272 7.8 1.00
Injecting drug use 61 3 4.9 0.61 (0.19-1.98) 0.414
Ethnic group (n=3561)
White 444 33 7.4 1.00
Black African 2803 222 7.9 1.07 (0.73-1.57) 0.723
Other 314 20 6.4 0.85 (0.48-1.51) 0.572
Age at delivery (n=3567)
<20 years 118 5 4.2 0.67 (0.27-1.71) 0.405
20-24 years 464 25 5.4 0.87 (0.54-1.39) 0.555
25-29 years 1071 66 6.2 1.00
30-34 years 1108 88 7.9 1.31 (0.94-1.83) 0.106
35-39 years 682 74 10.9 1.85 (1.31-2.62) 0.000
≥40  years 124 17 13.7 2.42 (1.37-4.27) 0.002
Parity (live/stillbirths) (n=2913)
0 1132 86 7.6 1.00
1 965 68 7.0 0.92 (0.66-1.28) 0.630
2 496 39 7.9 1.04 (0.70-1.54) 0.853
3 or more 320 38 11.9 1.64 (1.09-2.45) 0.016
Clinical status (n=3529)
Asymptomatic 3206 228 7.1 1.00
HIV symptoms or AIDS 323 45 13.9 2.11 (1.50-2.98) <0.001
CD4 cell count (n=3361)
≥500 cells/µl 1209 81 6.7 1.00
350-499 cells/µl 933 69 7.4 1.11 (0.80-1.55) 0.532
200-349 cells/µl 883 67 7.6 1.14 (0.82-1.60) 0.434
<200 cells/µl 336 40 11.9 1.88 (1.26-2.81) 0.002
Multiple pregnancy (n=3567)
Singleton 3509 264 7.5 1.00
Twin / triplet 58 11 19.0 2.88 (1.47-5.61) 0.002
ART  (n=3538)
Untreated 53 4 7.5 1.40 (0.43-4.53) 0.573
Monotherapy 218 12 5.5 1.00
Dual therapy 38 2 5.3 0.95 (0.20-4.44) 0.952
HAART 3229 254 7.9 1.47 (0.81-2.66) 0.209
- without PI 946 92 9.7 1.85 (0.99-3.44) 0.052
- with PI 2283 162 7.1 1.31 (0.72-2.40) 0.379
p -valuePregnancy complication
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Table 4.6 Pregnancy problems: unadjusted and adjusted odds ratios by 
maternal characteristics 
 
    Univariable (n=2749) ** Multivariable (n=2749) *** 
  n OR ( 95% CI) p-value AOR ( 95% CI) p-value 
Age at delivery        
per year 2749 1.06 (1.03-1.09) <0.001 1.05 (1.02-1.08) <0.001 
Parity (live/stillbirths)        
0 1075 1.00   1.00   
1 902 0.86 (0.61-1.22) 0.403 0.76 (0.53-1.09) 0.136 
2 467 1.01 (0.67-1.52) 0.956 0.77 (0.50-1.18) 0.225 
3 or more 305 1.62 (1.07-2.45) 0.022 1.13 (0.72-1.79) 0.588 
Clinical status        
Asymptomatic 2484 1.00   1.00   
Symptomatic * 265 2.04 (1.39-2.99) <0.001 1.65 (1.10-2.45) 0.014 
CD4 count        
≥500 cells/µl 986 1.00   1.00   
350-499 cells/µl 769 0.98 (0.67-1.42) 0.912 0.90 (0.62-1.32) 0.587 
200-349 cells/µl 720 1.16 (0.81-1.67) 0.425 0.99 (0.68-1.44) 0.959 
<200 cells/µl 274 2.11 (1.38-3.22) 0.001 1.70 (1.09-2.64) 0.019 
Multiple pregnancy        
Singleton 2702 1.00   1.00   
Twin / triplet 47 2.88 (1.38-6.05) 0.005 2.74 (1.29-5.84) 0.009 
Type of ART        
Untreated 27 3.21 (0.91-11.26) 0.069 3.01 (0.85-10.66) 0.088 
Monotherapy 175 1.00   1.00   
Dual therapy 25 1.60 (0.33-7.89) 0.561 1.26 (0.25-6.33) 0.781 
HAART 2522 1.58 (0.80-3.14) 0.191 1.27 (0.63-2.56) 0.497 
- without PI 717 2.19 (1.07-4.46) 0.031 1.65 (0.79-3.42) 0.181 
- with PI 1805 1.35 (0.67-2.70) 0.399 1.16 (0.57-2.34) 0.687 
 
* HIV-related symptoms or AIDS 
** Univariable analysis for cases included in the multivariable model (n=2749) 
*** Multivariable analysis based on ART variable with PI and non-PI HAART; the combined 
HAART category was added separately. 
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Pre-eclampsia 
Pre-eclampsia was reported in 2.1% (76/3567) of pregnancies, which is on the low 
end of the 2-7% range reported for the wider population (Sibai, Dekker, & 
Kupferminc, 2005). Seventy percent (53/76) of pregnancies with pre-eclampsia were 
delivered prematurely, including 27% (20/76) before 32 weeks, and pre-eclampsia 
was present in 11% (53/480) of all premature deliveries. In five percent (4/76) of 
pregnancies with pre-eclampsia, the outcome was a stillbirth; none of the live born 
infants died neonatally.  
Pre-eclampsia rates were higher in women with known risk factors, but this was not 
statistically significant for maternal age, parity and multiple pregnancy, probably due 
to small numbers (Table 4.7). Pre-eclampsia rates were higher in women who were 
symptomatic (p=0.041) or had CD4 counts <200 cells/µl (p=0.063 for comparison 
with CD4≥200 cells/µl, and p=0.038 for comparison with CD4≥500 cells/µl). Pre-
eclampsia was not significantly associated with type of ART overall (Table 4.7). 
Because of specific concerns about pre-eclampsia risk in women on HAART at 
conception (Suy et al., 2004), the association between type and timing of HAART 
and pre-eclampsia was explored. Crude pre-eclampsia rates were 2.7% (12/424) in 
women on PI-based HAART at conception, 2.9% (14/466) in those on non-PI 
HAART at conception, 2.8% (13/466) in those starting a non-PI regimen in 
pregnancy, and 1.6% (30/1843) in those starting a PI regimen in pregnancy.  
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Table 4.7 Pre-eclampsia rates and unadjusted odds ratios by maternal 
demographic and pregnancy characteristics 
 
 
Total n % OR ( 95% CI) p -value
Timing of diagnosis (n=3564)
Before this pregnancy 1939 47 2.4 1.00
During this pregnancy 1625 29 1.8 0.73 (0.46-1.17) 0.190
Exposure category (n=3567)
Non-injecting drug use 3506 76 2.2 NA
Injecting drug use 61 0 0.0 NA
Ethnic group (n=3561)
White 444 8 1.8 1.00
Black African 2803 62 2.2 1.23 (0.59-2.59) 0.581
Other 314 6 1.9 1.06 (0.36-3.09) 0.913
Age at delivery (years) (n=3567)
<20 years 118 1 0.8 0.41 (0.05-3.05) 0.382
20-24 years 464 9 1.9 0.94 (0.43-2.06) 0.884
25-29 years 1071 22 2.1 1.00
30-34 years 1108 27 2.4 1.19 (0.67-2.10) 0.547
35-39 years 682 13 1.9 0.93 (0.46-1.85) 0.829
≥40  years 124 4 3.2 1.59 (0.54-4.69) 0.401
Parity (live/stillbirths) (n=2913)
0 1132 33 2.9 1.00
1 965 15 1.6 0.53 (0.28-0.97) 0.041
2 496 10 2.0 0.69 (0.34-1.40) 0.300
3 or more 320 7 2.2 0.74 (0.33-1.70) 0.484
Clinical status (n=3529)
Asymptomatic 3206 63 2.0 1.00
HIV symptoms or AIDS 323 12 3.7 1.92 (1.03-3.61) 0.041
CD4 cell count (n=3361)
≥500 cells/µl 1209 23 1.9 1.00
350-499 cells/µl 933 18 1.9 1.01 (0.54-1.89) 0.964
200-349 cells/µl 883 16 1.8 0.95 (0.50-1.81) 0.880
<200 cells/µl 336 13 3.9 2.08 (1.04-4.14) 0.038
Multiple pregnancy (n=3567)
Singleton 3509 73 2.1 1.00
Twin / triplet 58 3 5.2 2.57 (0.79-8.40) 0.119
ART  (n=3538)
Untreated 53 1 1.9 1.03 (0.11-9.40) 0.980
Monotherapy 218 4 1.8 1.00
Dual therapy 38 1 2.6 1.45 (0.16-13.30) 0.745
HAART 3229 69 2.1 1.17 (0.42-3.23) 0.765
- without PI 946 27 2.9 1.57 (0.54-4.54) 0.403
- with PI 2283 42 1.8 1.00 (0.36-2.82) 0.996
Pre-eclampsia
 
 
NA, not applicable. 
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HAART started before pregnancy was less likely to contain PIs (47.2%, 463/980) 
than HAART started during pregnancy (79.7%, 1980/2484, p<0.001), reflecting the 
selective use of nevirapine (an NNRTI) for women with CD4 counts <250 cells/µl. 
PI-based HAART started in pregnancy was initiated slightly later (median 24.7 
weeks, IQR: 21.9-28.0 weeks) than non-PI HAART (23.5 weeks, IQR: 20.6-27.1 
weeks, p<0.001). 
Multivariable logistic regression models were fitted, adjusting for known risk factors 
on which information was available. Because of the small numbers involved, parity 
and CD4 count were recoded as binary variables (any or no previous live/stillbirth(s); 
CD4 count <200 cells/µl or ≥ 200 cells/µl) and maternal age was included as a 
continuous variable. CD4 count <200 cells/µl was associated with a two-fold 
increase in pre-eclampsia compared with CD4 count ≥200 cells/µl, and having had 
one or more previous deliveries was associated with a significantly lower risk of pre-
eclampsia (AOR=0.55) (Table 4.8). Clinical status and multiple pregnancy were not 
significantly associated with pre-eclampsia. The risk of pre-eclampsia was 1.7 times 
higher in women on non-PI-based HAART compared with PI-based HAART, and 
1.6-fold higher if HAART was initiated prior to conception, but neither association 
was statistically significant (Table 4.8). Despite the fact that these two associations 
were driven by the low pre-eclampsia rate in women starting PI-based HAART in 
pregnancy, there was no statistically significant evidence of interaction between type 
and timing of HAART (test of homogeneity of ORs: p=0.345) although this could be 
due to the limited power of the test.  
Although PI-based HAART was started later in pregnancy, the (non-significant) 
association between type of HAART and pre-eclampsia remained after adjusting for 
gestation week at initiation (AOR=2.01, 95% CI: 0.91-4.44, p=0.085; n=1759). 
Starting HAART later was associated with a 6% decrease in the risk of pre-eclampsia 
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(AOR=0.94, 95% CI: 0.88-1.00, p=0.069) for each week of gestation, after adjusting 
for type of regimen, parity and CD4 count (excluding clinical status and multiple 
pregnancy). There was, however, weak evidence of an interaction between CD4 
count and HAART: the association between pre-eclampsia and both type and timing 
of HAART were apparent only in women with CD4 counts above 200 cells/µl (test 
of homogeneity of ORs: p=0.152 and p=0.107 for type and timing of ART, 
respectively) (Table 4.9). In multivariable analysis restricted to women on HAART 
with CD4 counts ≥200 cells/µl and including type and timing of HAART and parity 
(n=2272), HAART at conception was associated with a significant 2.3-fold increase 
in pre-eclampsia compared with HAART later in pregnancy (95% CI: 1.16-4.55, 
p=0.017); the association with non-PI HAART was reduced in magnitude and not 
significant (AOR=1.63, 95% CI: 0.84-3.19, p=0.152). 
Similar results were obtained when the outcome included cases of pregnancy-
induced hypertension (n=16) or any hypertension (n=58). The only important 
difference was a significant association with maternal age (AOR=1.05 per year, 95% 
CI: 1.01-1.10, p=0.010) when any hypertension was included, consistent with the 
known correlation between age and blood pressure (Ong et al., 2007). 
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Table 4.8  Unadjusted and adjusted odds ratios for pre-eclampsia in women 
on HAART 
 
    Univariable (n=3231) Multivariable (n=2522) 
  n OR ( 95% CI) p-
value AOR ( 95% CI) 
p-
value 
Type of HAART 
    
   
- with PI 2283 1.00   1.00   
- without PI 946 1.57 (0.96-2.56) 0.072 1.75 (0.95-3.22) 0.072 
HAART initiation 
       
During pregnancy 2310 1.00   1.00   
Before pregnancy 917 1.54 (0.94-2.52) 0.087 1.62 (0.91-2.88) 0.099 
Maternal age 
       
Per year 3231 1.02 (0.98-1.06) 0.381 1.02 (0.97-1.08) 0.378 
Parity (live/stillbirths) 
       
0 1035 1.00   1.00   
1 or more 1609 0.66 (0.39-1.10) 0.114 0.50 (0.28-0.90) 0.020 
Clinical status 
       
Asymptomatic 2885 1.00   1.00   
HIV symptoms or AIDS 317 1.99 (1.05-3.75) 0.034 1.46 (0.71-3.01) 0.302 
CD4 count  
       
≥200 cells/µl 2758 1.00   1.00   
<200 cells/µl 326 1.78 (0.92-3.45) 0.086 2.09 (1.04-4.17) 0.037 
Multiple pregnancy 
       
Singleton 3176 1.00   1.00   
Twin / triplet 55 2.72 (0.83-8.93) 0.099 1.96 (0.45-8.47) 0.366 
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Table 4.9 Type and timing of HAART and pre-eclampsia: rates and 
unadjusted odds ratios stratified by CD4 cell count 
 
    
Pre-
eclampsia     
  n n % OR ( 95% CI) p-value 
CD4≥200 cells/µl       
Type of HAART  
  
   
- with PI 1969 30 1.5 1.00   
- without PI 789 23 2.9 1.94 (1.12-3.36) 0.018 
HAART initiation 
      
During pregnancy 1997 31 1.6 1.00   
Before pregnancy 760 22 2.9 1.89 (1.09-3.29) 0.024 
CD4<200 cells/µl       
Type of HAART 
      
HAART with PI 233 8 3.4 1.00   
HAART without PI 93 3 3.2 0.94 (0.24-3.61) 0.925 
HAART initiation 
      
During pregnancy 186 6 3.2 1.00   
Before pregnancy 140 5 3.6 1.11 (0.33-3.72) 0.864 
 
Gestational diabetes 
Gestational diabetes was reported in only 0.8% of pregnancies (30/3567, Table 4.3), 
and in a higher proportion of women on non-PI HAART (1.4%, 13/946) than PI-
based HAART (0.7%, 17/228) although the difference was not statistically 
significant (p=0.090) and may have been due to confounding (for example, by 
clinical factors associated with treatment). However, the small number of cases 
precluded multivariable analysis.
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4.4 Congenital abnormalities 
Rates of congenital abnormalities were explored in infants born between 1990 and 
2007. A total of 8576 infants were reported, including 95 who were stillborn and 288 
twins or triplets. Information was available from both paediatric and obstetric 
sources for 79% (6631/8242) of infants, but the remainder were reported only 
through the obstetric (10%, 704/8242) or paediatric (11%, 907/8242) scheme. 
Information on congenital abnormality was available for 96.1% (8242/8576) of 
infants.  
Infants with missing information on congenital abnormality 
The 3.9% of infants with no information on congenital abnormality (n=334) were 
more likely than those with information available to be born before 2000 (44%, 
146/334, versus 10%, p<0.001). They were therefore more likely than those with 
information reported to be born to untreated women (28%, 87/308, versus 6%, 
p<0.001), and to symptomatic women (16%, 45/275, versus 11%, p=0.004). They 
were also more likely to be preterm (25%, 80/323 versus 15%, p<0.001). Infants with 
missing information on congenital abnormalities were more likely to be stillborn 
(9.6%, 32/334, versus 0.8%, 63/8242, p<0.001); however, in general, delivery and 
perinatal information is poorly completed for stillbirths. Furthermore, in 40% of 
these stillbirths, it was unlikely that a congenital abnormality was present, either 
because the death was specifically reported as having no apparent cause (n=2) or 
because the death was attributed to another probable cause, including infection (n=2), 
pregnancy complications such as pre-eclampsia or placental abruption (n=6), twin-
to-twin transfusion (n=2) or maternal liver failure (n=2). Overall, infants with 
missing information on congenital abnormality were no more likely than those with 
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information provided to have early ART exposure (15%, 44/289, versus 22%, 
p=0.478). 
Maternal and pregnancy characteristics and ART 
Among infants with information on congenital abnormalities reported (n=8242), 
ninety percent were born between 2000 and 2007 (Table 4.10). Three quarters were 
born to black African women, and 15% had mothers born in the UK or Ireland. 
Maternal region of birth and ethnic group were highly collinear: 82.5% (998/1210) of 
white women were born in the UK or Ireland, and 97.6% (6012/6162) of black 
African women were born in sub-Saharan Africa. Median maternal age at delivery 
was 30.0 years (interquartile range [IQR]: 26.3-33.8 years). Median gestational age 
was 38 weeks (IQR 37-39 weeks) and median birth weight was 3040 g (IQR 2700-
3360 g). Median age at last follow up was six months (IQR: 3-15 months). 
Information on timing of ART exposure was available for 92.6% (7633/8242) of 
infants; for those where information was missing, this was mostly (88%, 538/609) 
because reports were only obtained from paediatric respondents, who were not asked 
to provide this information. Less than a quarter of infants (22.4%, n=1708) had early 
in utero exposure, with the majority exposed later on (Table 4.10). Among first 
trimester regimens, most (52.9%) contained NNRTIs.  
Congenital abnormalities 
Altogether 232 infants out of 8242 were reported to have at least one congenital 
abnormality (2.8%, 95% CI: 2.5-3.2%), a quarter (59/232) of whom had only minor 
abnormalities (defined in Chapter 2, page 61, and shown in Table 4.13, page 141). 
The congenital abnormality rate excluding minor defects was 2.1% (95% CI: 1.8-
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2.4%). All other abnormality rates shown here refer to major and minor 
abnormalities combined. Nineteen infants had more than one abnormality reported. 
There were seven twin pregnancies where at least one twin had an abnormality, 
including one where both twins were affected (hydronephrosis). Abnormalities were 
reported in 11% (7/63) of stillborn infants. Nine infants with the following 
abnormalities were reported to have died neonatally: Down's syndrome, Trisomy 18, 
heart defects (n=3), achondroplasia, holoprosencephaly, dysmorphic features, 
intestine malrotation. Among the 194 live born infants with abnormalities, for whom 
HIV infection status was established, three (1.5%) were infected; one with a major 
heart abnormality, one with hydrocephalus, and one with congenital hip dislocation. 
Congenital abnormality rates were marginally lower in infants born to black African 
mothers (2.6%) than in those born to white mothers (3.6%, p=0.051), and higher 
among infants whose mothers were symptomatic (4.1% versus 2.7%, p=0.029) 
(Table 4.10). Infants with abnormalities were more likely to be delivered prematurely 
(4.0% versus 2.6%, p=0.012) and to be of low birth weight. Abnormality rates were 
significantly higher in boys (3.3%) than in girls (2.2%, p=0.003), although if genital 
abnormalities (all of which were in boys) were excluded, the difference became non-
significant (2.8%, 115/4101, versus 2.2%, 91/4079, p=0.098). There was also a 
statistically significant excess of limb abnormalities (almost all polydactyly) in boys 
(0.6%, 25/4123), compared with girls (0.2%, 7/4079, p=0.002).
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Table 4.10 Rates and unadjusted odds ratios for congenital abnormalities by 
maternal, infant, and treatment characteristics 
 
Characteristics (n=8242) Total Congenital abnormality  
  n % n  % OR  (95% CI) p-value 
Time period (n=8242)        
1990-1999 833 10.1 31 3.7 1.00   
2000-2007 7409 89.9 201 2.7 0.72 (0.49-1.06) 0.970 
Maternal characteristics         
Ethnic origin (n=8171)        
White 1285 15.7 46 3.6 1.00   
Black African 6244 76.4 162 2.6 0.72 (0.51-1.00) 0.051 
Black other 326 4.0 13 4.0 1.12 (0.60-2.10) 0.726 
Other 316 3.9 10 3.2 0.88 (0.44-1.76) 0.719 
Region of birth (n=8057)        
UK/ Ireland 1245 15.5 46 3.7 1.00   
Sub-Saharan Africa 6128 76.1 161 2.6 0.70 (0.50-0.98) 0.039 
Elsewhere 684 8.5 22 3.2 0.87 (0.52-1.45) 0.586 
Age at delivery (n=8184)        
<25 years 1471 18.0 40 2.7 1.00   
25-34 years 5154 63.0 147 2.9 1.05 (0.74-1.50) 0.786 
≥ 35 years 1559 19.0 43 2.8 1.01 (0.66-1.57) 0.948 
HIV exposure group (n=8242)        
Non-injecting drug use 7876 95.6 219 2.8 1.00   
Injecting drug use 366 4.4 13 3.6 1.29 (0.73-2.28) 0.384 
Clinical status (n=7235)        
Asymptomatic 6451 89.2 174 2.7 1.00   
HIV-related symptoms/AIDS 784 10.8 32 4.1 1.54 (1.05-2.25) 0.029 
Infant characteristics        
Sex (n=8202)        
Male  4123 50.3 137 3.3 1.00   
Female 4079 49.7 91 2.2 0.66 (0.51-0.87) 0.003 
Gestational age (n=8056)        
≥37 weeks 6874 85.3 182 2.6 1.00   
<37 weeks 1182 14.7 47 4.0 1.52 (1.10-2.11) 0.012 
Birth weight (n=7153)        
≥2500 g 6067 84.8 158 2.6 1.00   
<2500 g 1086 15.2 45 4.1 1.62 (1.15-2.27) 0.005 
Treatment characteristics        
Timing of ART exposure(n=7633)       
Not treated in pregnancy 498 6.5 14 2.8 1.00   
Late (2nd/3rd trimester) 5427 71.1 147 2.7 0.96 (0.55-1.68) 0.893 
Early (1st trimester) 1708 22.4 53 3.1 1.11 (0.61-2.01) 0.739 
Treatment class in 1st trimester (n=1697)       
NRTI only 148 8.7 8 5.4 2.08 (0.92-4.72) 0.080 
NNRTI  898 52.9 24 2.7 1.00   
PI  553 32.6 17 3.1 1.16 (0.61-2.17) 0.654 
NNRTI & PI 98 5.8 3 3.1 1.15 (0.34-3.89) 0.822 
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There was no significant difference in the unadjusted abnormality rate by ART 
exposure, which was 2.8% in unexposed infants, 2.7% in those with late exposure, 
and 3.1% in those with early ART exposure (p=0.690) (Table 4.10). After adjusting 
for potential confounders (maternal ethnicity, age at delivery, injecting drug use and 
clinical status) neither late (AOR=0.96, 95% CI: 0.54-1.71, p=0.889) nor early ART 
exposure (AOR=1.01, 95% CI: 0.54-1.88, p=0.972) was significantly associated with 
congenital abnormality, compared with no exposure (n=7179) (Table 4.11). In 
adjusted analysis, abnormalities remained significantly lower in black African 
women compared with white women (AOR=0.66) and significantly higher in 
symptomatic women compared with asymptomatic women (AOR=1.51). Because of 
collinearity, analyses were not adjusted for maternal region of birth. If early exposure 
was instead compared with no early exposure, the difference in abnormality rates 
(3.1% versus 2.7%) remained non-significant: OR=1.14 (95% CI: 0.84-1.57, 
p=0.395), AOR=1.05 (95% CI: 0.75-1.47, p=0.776). 
Class of ART was reported for 99.4% (1697/1708) of infants exposed in the first 
trimester. Because monotherapy and dual therapy were uncommon in early 
pregnancy (<3%, 48/1697), regimens were classified according to class of 
antiretrovirals rather than number of drugs. Class of regimen was not significantly 
associated with congenital abnormalities (p=0.363) (Table 4.10). Although the rate in 
infants exposed only to NRTIs was higher than for other drug classes, these infants 
were more likely to be reported in earlier years and therefore to be born to women 
who were young, white, symptomatic and/or had acquired HIV through injecting 
drug use (as shown in Chapter 3). In multivariable analysis (n=1679), PI-containing 
regimens were not associated with an increase in congenital abnormalities compared 
with NNRTI-containing regimens (AOR=1.09, 95% CI: 0.58-2.07, p=0.789), after 
adjusting for maternal ethnicity, age, injecting drug use and clinical status. Likewise, 
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in the same model there was no significantly increased risk associated with exposure 
to NRTI-containing regimens (AOR=1.94, 95% CI: 0.84-4.50, p=0.123) or to 
NNRTI- and PI-containing regimens (AOR=1.15, 95% CI: 0.34-3.92, p=0.823). Four 
infants in the PI group were also exposed to fusion inhibitors in the first trimester, 
but none had abnormalities reported.  
 
Table 4.11 Unadjusted and adjusted odds ratios for congenital abnormalities 
 
    Univariable (n=7179) * Multivariable (n=7179) 
  n OR ( 95% CI) p-
value AOR ( 95% CI) 
p-
value 
ART exposure and timing 
 
      
Not treated in pregnancy 447 1.00   1.00   
Late (2nd/3rd trimester) 5043 0.88 (0.50-1.53) 0.644 0.96 (0.54-1.71) 0.889 
Early (1st trimester) 1689 1.00 (0.55-1.82) 0.995 1.01 (0.54-1.88) 0.972 
Ethnic origin        
White 1105 1.00   1.00   
Black African 5471 0.67 (0.48-0.96) 0.028 0.66 (0.45-0.98) 0.039 
Black other 318 1.08 (0.57-2.04) 0.815 1.12 (0.58-2.15) 0.735 
Other 285 0.83 (0.40-1.72) 0.607 0.83 (0.39-1.75) 0.624 
Age at delivery        
<25 years 1264 1.00   1.00   
25-34 years 4516 1.14 (0.78-1.68) 0.504 1.19 (0.80-1.76) 0.392 
≥ 35 years 1399 1.07 (0.67-1.71) 0.779 1.08 (0.66-1.75) 0.758 
HIV exposure group        
Other risk 6891 1.00   1.00   
Injecting drug use 288 1.36 (0.73-2.53) 0.326 0.96 (0.48-1.94) 0.912 
Clinical status        
Asymptomatic 6404 1.00   1.00   
HIV-related symptoms/AIDS 775 1.54 (1.05-2.27) 0.027 1.51 (1.02-2.25) 0.041 
 
* Univariable analysis for infants included in the multivariable model.
 138 
Efavirenz and didanosine 
A total of 220 infants were exposed to efavirenz, 205 (93.2%) in early pregnancy; of 
those exposed early, 2.4% (5/205) had abnormalities reported (undescended testes 
[n=2], hip dislocation [n=2], hypertrophic pyloric stenosis). This rate did not differ 
significantly from the rate in infants with first trimester ART exposures other than 
efavirenz (3.2%, 48/1503, p=0.672). There were 284 exposures to didanosine, 174 
(61.3%) in the first trimester; of those infants with early didanosine exposure, 3.4% 
(6/174) had abnormalities reported (Down’s syndrome, heart defect [n=2], 
hydronephrosis, jejunal atresia, foot abnormality); again, this rate did not differ 
significantly from the rate for other first trimester ART exposures (3.1%, 47/1534, 
p=0.816). However, there was sufficient power (>80%) to detect only about a 2.5-
fold increase in risk associated with didanosine or efavirenz exposure. There were no 
abnormalities reported in infants exposed to efavirenz (n=15) or didanosine (n=110) 
later in pregnancy. 
Type of abnormalities 
No category of abnormality was significantly associated with first trimester 
exposure, although power to detect an association was limited due to small numbers 
(Table 4.12). Of the 12 cases of hypospadias, all were in infants exposed to 
zidovudine-containing regimens (0.18%, 12/6711); however, the rate did not differ 
significantly from the rate in infants exposed to zidovudine-sparing regimens (0%, 
0/792, p=0.262). Timing of ART was reported for 11 of these infants: two had early 
exposure (2/1708, 0.12%; or 2/856 boys, 0.23%), and nine late (9/5427, 0.17%; 
9/2693 boys, 0.33%), with no statistically significant difference between the two 
groups (p=1.00). Individual abnormalities by timing of treatment are shown in Table 
4.13. There was no clear excess in any particular abnormality in infants with early 
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exposure, except for renal dilatation, which was reported in 0.18% (3/1708) of 
infants exposed to ART in the first trimester, but only 0.02% (1/5929) of unexposed 
infants, a difference which was just statistically significant (Fisher’s exact test, 
p=0.037). However, given the number of different abnormalities (and consequently 
the number of statistical tests carried out in order to compare rates in all the different 
groups), this finding should be treated with caution, particularly since it was based on 
only four infants with the abnormality. 
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Table 4.12  Reported category of congenital abnormality by timing of ART exposure 
 
          Timing of ART exposure 
 
 Total 
Total with 
timing 
information* None 
Late (2nd/3rd 
trimester) 
Early (1st 
trimester) 
Type of abnormality  n  (%) n  (%) n  (%) n  (%) n  (%) p value ** 
Nervous system 17 0.21 16 0.21 1 0.20 11 0.20 4 0.23 0.767 
Ear, face, neck & eye 5 0.06 4 0.05 0 0.00 3 0.06 1 0.06 1.000 
Heart & circulatory 30 0.36 25 0.33 0 0.00 16 0.29 9 0.53 0.144 
Respiratory system 4 0.05 3 0.04 1 0.20 2 0.04 0 0.00 1.000 
Cleft palate/lip 7 0.08 7 0.09 1 0.20 5 0.09 1 0.06 1.000 
Digestive system 18 0.22 18 0.24 1 0.20 11 0.20 6 0.35 0.262 
Genital organs 22 0.27 19 0.25 3 0.60 11 0.20 5 0.29 0.594 
Urinary system 20 0.24 19 0.25 1 0.20 11 0.20 7 0.41 0.163 
Musculoskeletal 40 0.49 38 0.50 2 0.40 27 0.50 9 0.53 0.846 
Limbs 32 0.39 30 0.39 3 0.60 23 0.42 4 0.23 0.279 
Integument 11 0.13 10 0.13 0 0.00 7 0.13 3 0.18 0.474 
Chromosomal 21 0.25 20 0.26 1 0.20 16 0.29 3 0.18 0.594 
Other & unspecified anomalies 2 0.02 2 0.03 0 0.00 1 0.02 1 0.06 0.397 
Type not specified 3 0.04 3 0.04 0 0.00 3 0.06 0 0.00 1.000 
Total congenital abnormalities  232 2.81 214 2.80 14 2.81 147 2.71 53 3.10   
Total infants 8242   7633   498   5427   1708     
 
* Excludes 18 infants with abnormalities for whom information on timing of treatment was not available. 
** Fisher’s exact test for comparison of first trimester exposure with late or no exposure.
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Table 4.13 Reported congenital abnormalities (grouped by category) by timing 
of ART exposure 
 
 
Early ART 
exposure  
Early ART 
exposure 
Abnormality by WHO category No Yes Abnormality by WHO category No Yes 
Total infants  5929 1708       
Total abnormalities 161 53 Genital organs    
Nervous system    Hypospadias 9 2 
Hydrocephalus 5 1 Undescended testes * 5 2 
Sub-ependymal cysts * 0 1 Ambiguous genitalia 0 1 
Spina bifida 2 2 Urinary    
Cerebral atrophy 1 0 Hydronephrosis 7 3 
Absent corpus callosum 1 0 Urethral/bladder problem 1 0 
Holoprosencephaly 1 0 Renal dilatation 1 3 
Microcephaly 1 0 Dysplastic kidney 3 1 
Dandy-Walker syndrome 1 0 Musculoskeletal    
Eye, ear, face, neck    Skeletal problems/hemivertebrae 1 1 
Malformed ear * 1 0 Exomphalos 0 1 
Ptosis of eye 1 0 Talipes 17 3 
Minor mouth abnormalities * 0 1 Spinal hairy patch * 0 1 
Duane's syndrome 1 0 Abnormalities of feet * 1 1 
Heart & circulatory    Hip dislocation 4 2 
Heart defects (unspecified) 3 1 Cleidocranial dysostosis 1 0 
Pulmonary stenosis 3 0 Caffeys syndrome 1 0 
Heart (Ebstein's anomaly) 0 1 Diaphragmatic hernia 1 0 
Heart (patent ductis arteriosus) 3 2 Achondroplasia 1 0 
Heart (septal defects) 4 4 Osteodystrophy  1 0 
Stenosis of aortic valve 1 0 Gastroschisis 1 0 
Heart (Tetralogy of Fallot) 1 0 Limbs    
Heart (truncus arteriosus) 0 1 Extra digits * 26 3 
Heart (cardiomyopathy) 1 0 Larsen syndrome 0 1 
Respiratory    Integument    
Lung abnormality 1 1 Accessory nipples * 2 0 
Stridor (laryngeal) 1 1 Strawberry naevus * 4 0 
Cyst adenomatoid malformation 1 1 Skin tag * 1 1 
Cleft palate/lip    Birthmark * 0 2 
Cleft palate and/or hare lip 6 1 Chromosomal    
Digestive    Down's syndrome 13 2 
Biliary atresia 1 0 Trisomy 18 3 0 
Bowel obstruction/abnormalities 5 2 Chromosomal anomaly 1 0 
Jejunal atresia 2 1 Turner's syndrome 0 1 
Anal polyp 1 0 Other & unspecified    
Macroglossia * 1 0 Prader-Willi syndrome 0 1 
Duodenal atresia 0 1 Beckwith-Wiedemann syndrome 1 0 
Hypertrophic pyloric stenosis 0 1 Type not specified    
Intestine malrotation 1 1 Unspecified congenital anomaly 2 2 
Imperforate anus 1 0 Dysmorphic features 1 1 
 
* Abnormalities classified as minor.  
N.B. Excludes 18 congenital abnormalities (6 minor) in infants with missing information on timing of 
maternal ART.
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Abnormalities in terminated pregnancies 
In addition to abnormalities in live born and stillborn infants, 21 congenital 
abnormalities were reported in 549 terminated pregnancies (1990-2007); these were 
anencephaly (n=4), Down’s syndrome (n=5), other chromosomal anomaly (n=3), 
exomphalos, enlarged cerebral ventricles, cleft lip/palate, hydronephrosis, bowel 
abnormality, heart defect, spina bifida, achondroplasia, and renal agenesis. These 21 
terminations were carried out between 12 and 30 weeks gestation, and only five 
(three Down’s syndrome) were in women who were on treatment (HAART) in early 
pregnancy. The overall abnormality rate including these 21 terminations was 3.1% 
(253/8263, 95% CI: 2.7-3.5).
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4.5 Key Points 
• The stillbirth rate was 10.9 per 1000 births (95% CI: 8.8-13.4 per 1000 births), 
and was three times higher in women on HAART (11 per 1000) than in women 
on monotherapy (3 per 1000) after adjusting for other risk factors. 
• Pregnancy complications (other than stillbirth and prematurity) were reported in 
7.7% (285/3852) of pregnancies, and were more common in older women and 
those with HIV-related symptoms or low CD4 count (<200 cells/µl), as well as in 
multiple pregnancies.  
• Pre-eclampsia was reported in 2% of pregnancies, and was significantly 
associated with type and timing of HAART: a lower rate of pre-eclampsia (1.6%) 
was reported in women who initiated PI-based HAART in pregnancy, compared 
with those who were on HAART at conception (2.9%) or those who initiated 
non-PI-based HAART in pregnancy (2.8%). 
• Among women starting HAART in pregnancy, later initiation of HAART was 
associated with a 6% decrease in pre-eclampsia for each gestation week without 
HAART. 
• The congenital abnormality rate in 8242 infants born in the UK or Ireland to 
HIV-infected women (1990-2007) was 2.8% (95% CI: 2.5-3.2%). 
• Congenital abnormality rates were not associated with timing of in utero ART 
exposure, nor with class of first trimester ART exposure. 
• Despite reports of increased abnormality rates associated with early efavirenz or 
didanosine exposure, no such association was detected in this population, nor was 
any association detected between early ART exposure and rates of hypospadias.
 144 
Chapter 5 Antiretroviral therapy and premature delivery  
Evidence suggesting an increased risk of premature, or preterm, delivery associated 
with highly active antiretroviral therapy (HAART) in pregnancy has been 
accumulating in recent years (Boer et al., 2007; Cotter et al., 2006; European 
Collaborative Study, 2004a). Studies in the United States (US), however, have 
produced conflicting results, with some finding no association between treatment and 
preterm delivery (Tuomala et al., 2002; Tuomala et al., 2005), and others suggesting 
a possible association with protease inhibitor (PI)-containing HAART (Cotter et al., 
2006; Schulte et al., 2007). Reasons for these conflicting findings have remained 
unclear, although several methodological issues have been highlighted including 
differences in populations, type of data collected and analytical approach, as well as 
the inability to control for other known risk factors for prematurity in some studies 
(Tuomala & Yawetz, 2006).  
The first part of this chapter addresses the association between antiretroviral therapy 
(ART) and premature delivery in the UK and Ireland, using data from the National 
Study of HIV in Pregnancy and Childhood (NSHPC) (related publication shown in 
Appendix 2, page 357) (Townsend et al., 2007). In the second part of the chapter, 
data from the NSHPC are compared with data from the European Collaborative 
Study (ECS), and the Pediatric Spectrum of HIV Disease project (PSD) in the US. 
Differences between the studies are investigated, including the role of methodology, 
population characteristics and analytical approach in explaining any variation 
between studies in the observed association between ART and prematurity.  
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5.1 Methods specific to this chapter 
Because multiple pregnancy is a risk factor for prematurity (Slattery & Morrison, 
2002), all analyses in this chapter were restricted to singleton births. The association 
between ART and gestational age was explored using a categorical variable for 
prematurity, defined as delivery at <37 weeks gestation (Goldenberg et al., 2008). 
Because elective caesarean section deliveries for prevention of mother-to-child 
transmission are usually scheduled at 38 weeks gestation (BHIVA, 2005a; 
BHIVA/CHIVA, 2008; Coll et al., 2002; Perinatal HIV Guidelines Working Group, 
2005), categorising gestational age as <37 weeks avoided the methodological 
complication of a change over time in the proportion of elective caesarean section 
deliveries.  
Odds ratios (ORs) were adjusted for known risk factors for prematurity on which 
information was available; these included maternal injecting drug use (IDU), clinical 
status and ethnic group (Aveyard et al., 2002; Institute of Medicine, 2006; Patel et 
al., 2004; Schulte et al., 2007; Slattery & Morrison, 2002). A U-shaped association 
between maternal age and premature delivery has also been reported, with younger 
(<20 years of age) and older mothers (>35 years of age) being at increased risk of 
preterm delivery (Slattery & Morrison, 2002); it was therefore appropriate to include 
maternal age as a categorical variable.  
NSHPC analysis 
The NSHPC analysis was based on all singleton live births and stillbirths delivered 
between 1990 and 2005, in women diagnosed as HIV-infected before delivery and 
reported through the obstetric scheme by March 2006. In most analyses, 
monotherapy and dual therapy were combined, due to the relatively small number of 
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pregnancies in women on dual therapy (n=157, 3%). Timing of initiation of 
treatment was classified as before pregnancy or in the first trimester (up to 12 
completed weeks gestation); second trimester (13-26 completed weeks gestation); or 
third trimester (after 26 weeks gestation). Year of delivery was grouped according to 
availability of ART: 1990-1993 (pre-ART); 1994-1999 (monotherapy and 
introduction of HAART); 2000 onwards (HAART and selective monotherapy for 
women with low viral load). Maternal clinical status was defined as any HIV-related 
symptoms or AIDS reported at any time in pregnancy (Centers for Disease Control 
and Prevention, 1992).  
In order to assess differences in birth weight between groups independently of 
gestational age, a z-score (standard deviation from the population mean) was 
calculated for each birth weight according to gestational age and gender, using 
British 1990 population standards (Cole, Freeman, & Preece, 1998). Z-scores were 
obtained using LMSgrowth, a Microsoft Excel add-in available at 
www.healthforallchildren.co.uk (Accessed 26 January 2009), which employs the 
LMS method (Cole & Green, 1992). This method summarises growth reference data 
with three curves representing the median (M), the coefficient of variation (S) and 
the skewness (L) as they change with age.  
To allow for repeat pregnancies in the same woman, generalized linear mixed effects 
were used to fit logistic regression models accounting for random effects attributed 
to the mother (command ‘xtlogit’ in Stata) (Rabe-Hesketh, Skrondal, & Pickles, 
2002). Only random effects on the intercept of the linear predictor were considered; 
these act as a subject-specific risk baseline corresponding to unobserved, mother-
specific variables. Due to improvements in the estimation criteria for ‘xtlogit’ 
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between Stata versions 9.0 and 10.0, results presented here differ slightly from 
published findings (Townsend et al., 2007). 
5.2 ART and prematurity in the NSHPC 
The association between ART and prematurity was first explored in pregnancies 
reported to the NSHPC. Between 1990 and 2005, a total of 5009 singleton births 
were reported, with an overall prematurity rate of 13.3% (667/5009). Seventy 
pregnancies (1.3%) had inadequate information on type or timing of ART (before or 
during pregnancy), and were excluded; these did not differ from those for which 
treatment information was available in terms of prematurity, but a higher proportion 
occurred before 2000 (34% versus 17%, p<0.001). Because of the changes over time 
in demographic characteristics (described in Chapter 3), white women (27% versus 
17%, p=0.023) and women with IDU-acquired infection (12% versus 5%, p<0.001) 
were over-represented in this group.  
Pregnancies in treated and untreated women 
There were clear baseline differences between ART-treated and untreated women, 
and between women on monotherapy or dual therapy (mono/dual therapy) and those 
on HAART (Table 5.1), reflecting concurrent changes in the characteristics of HIV-
infected women over time along with trends in ART use in pregnancy (Chapter 3). 
There were also differences in availability of test results between the three groups; 
for example, CD4 count was available for 88.0% (2977/3384) of women on HAART 
and 76.2% (808/1061) of those on mono/dual therapy, but for only 41.3% (204/494) 
of untreated women.  
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Pregnancies in untreated women 
There were 494 pregnancies in untreated women. As these were more likely to have 
occurred in the earlier years than pregnancies in treated women, they were more 
likely to be in white women (33.7%, 164/486, versus 14.6%, 650/4443, p<0.001) and 
in women with IDU-acquired infection (20.0%, 99/494, versus 3.4%, 149/4449).  
The prematurity rate in untreated women was 15.6% (77/494) and increased over 
time, from 11.0% (20/181) in 1990-1993, to 16.7% (26/156) in 1994-1999 and 
19.7% (31/157) in 2000-2005 (p=0.004). Two of the main reasons for being 
untreated in the latter period (when over 95% of women received ART in pregnancy) 
were late diagnosis and premature delivery; in 2000-2005, 22.3% (35/157) of 
untreated women were diagnosed with HIV within two weeks of delivery, compared 
with only 1.0% (41/3950) of treated women (p<0.001). Furthermore, among women 
who delivered prematurely in 2000-2005, diagnosis was within two weeks of 
delivery in 29% (9/31) of untreated women but only 2% (9/522) of treated women 
(p<0.001). Because of biases introduced by these changes over time, these 
pregnancies in untreated women were not an appropriate comparison group for those 
in women on HAART.  
Pregnancies in ART-treated women 
Most of the 4445 pregnancies with ART exposure were in black African women, and 
few were in women with IDU-acquired infection (Table 5.1). Median maternal age at 
delivery was 29.7 years (range: 14.8-47.4 years, interquartile range [IQR]: 26.2-33.6 
years).
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Table 5.1 Demographic characteristics by category of antiretroviral therapy 
received in pregnancy  
 
Untreated 
(n =494)
Mono/dual 
therapy (n =1061) HAART (n =3384)
HAART vs. 
mono/dual
n % n % n % χ2 p -value
Ethnic origin (n=4929)
White 164 (33.7) 211 (19.9) 439 (13.0)
Black African 303 (62.3) 763 (72.0) 2647 (78.2)
Other 19 (3.9) 86 (8.1) 297 (8.8) <0.001
Age at delivery (n=4937)
<25 years 124 (25.2) 239 (22.5) 572 (16.9)
25-34 years 334 (67.7) 681 (64.2) 2161 (63.9)
≥35 years 35 (7.1) 140 (13.2) 651 (19.2) <0.001
Exposure category (n=4939)
Injecting drug use 99 (20.0) 68 (6.4) 81 (2.4)
Other* 395 (80.0) 993 (93.6) 3303 (97.6) <0.001
Timing of diagnosis (n=4939)
Before pregnancy 253 (51.2) 397 (37.4) 1606 (47.5)
During pregnancy 241 (48.8) 664 (62.6) 1778 (52.5) <0.001
Parity (n=4352)
Nulliparous 69 (22.0) 318 (33.8) 1082 (34.9)
Parous 244 (78.0) 624 (66.2) 2015 (65.1) 0.505
Clinical status (n=4895)
Asymptomatic 418 (86.2) 962 (91.5) 2919 (86.9)
HIV symptoms or AIDS 67 (13.8) 89 (8.5) 440 (13.1) <0.001
CD4 count (n=3989)
≥500 cells/µl 63 (30.9) 387 (47.9) 895 (30.1)
200-499 cells/µl 110 (53.9) 372 (46.0) 1628 (54.7)
<200 cells/µl 31 (15.2) 49 (6.1) 454 (15.3) <0.001
HIV RNA viral load (n=3257)
<50 copies/ml 12 (11.2) 163 (30.6) 1772 (67.7)
51-999 copies/ml ** 22 (20.6) 213 (40.0) 625 (23.9)
1000-9999 copies/ml 31 (29.0) 133 (25.0) 133 (5.1)
>10,000 copies/ml 42 (39.3) 23 (4.3) 88 (3.4) <0.001
Mode of delivery (n=4676)
Elective caesarean section 83 (29.3) 702 (68.1) 1996 (59.4)
Emergency caesarean section 55 (19.4) 144 (14.0) 689 (20.5)
Vaginal 145 (51.3) 185 (17.9) 677 (20.1) <0.001
Year of delivery  (n=4939)
1990-93 181 (36.6) 14 (1.3) 0
1994-99 156 (31.6) 317 (29.9) 164 (4.8)
2000-05 157 (31.8) 730 (68.8) 3220 (95.2) <0.001
Maternal and pregnancy 
characteristics (n =4939)
 
 
N.B. Excludes 70 pregnancies with missing information on type or timing of ART. 
* Includes exposure in area of high HIV prevalence, blood transfusion, and other/unknown risk.  
** Includes viral loads reported as ‘<200 copies/ml’ or ‘<400 copies/ml’ (n=85; 1 untreated, 21 
mono/dual therapy, 63 HAART).
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Most deliveries were by elective caesarean section (Table 5.1), and median 
gestational age was 38 weeks (IQR: 38-39 weeks). Compared with HAART, 
mono/dual therapy was associated with being younger, white, and acquiring HIV 
through IDU (Table 5.1); this again related to issues of timing, with monotherapy 
having been available earlier than HAART (Chapter 3, Figure 3.3, page 83). 
Mono/dual therapy was also associated with higher viral load, probably because 
HAART is more effective than monotherapy or dual therapy at reducing viral load. 
However, HAART was associated with lower CD4 cell count, possibly because 
women with low baseline CD4 count would have been put on HAART if it was 
available.  
Most women took HAART in pregnancy; HAART more frequently included a non-
nucleoside reverse transcriptase inhibitor (NNRTI) than a PI (Table 5.2). Over a 
quarter of women on HAART were on treatment early in pregnancy (Table 5.2), 
whereas most women taking mono/dual therapy started later (94.9%, 1007/1061). Of 
the 914 women on HAART early, 41 started it during the first trimester, at a median 
of 11 weeks (IQR: 7-12 weeks). Among those starting treatment later in pregnancy, 
timing of ART initiation was available for 92.9% (3477/3744) of pregnancies: 
women on mono/dual therapy started treatment slightly but significantly later than 
women on HAART (median gestation, 28.1 weeks versus 26.2 weeks, p<0.001). 
However, the proportion of pregnancies in which treatment was initiated within the 
last two weeks of pregnancy did not differ by type of ART (HAART: 4.7%, 
113/2385, mono/dual therapy: 4.5%, 43/951, p=0.789), even among women who 
delivered prematurely (HAART, 12.0%, 38/317; mono/dual, 11.0%, 10/91, p=0.794). 
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Table 5.2 Use of antiretroviral therapy 
 
  Total Premature 
Antiretroviral therapy (n=4445) n % n % 
Type of ART (n=4445)   
  
Monotherapy 904 (20.3) 97 (10.7) 
Dual therapy * 157 (3.5) 10 (6.4) 
HAART 3384 (76.1) 476 (14.1) 
Type of HAART (n=3384)   
  
- with NRTIs only  69 (2.0) 6 (8.7) 
- with NNRTI(s) 1831 (54.1) 261 (14.3) 
- with PI(s) 1256 (37.1) 169 (13.5) 
- with PI(s) & NNRTI(s) 228 (6.7) 40 (17.5) 
Timing of HAART (n=3299)**   
  
Before pregnancy / first trimester *** 914 (27.7) 150 (16.4) 
Second trimester 1287 (39.0) 188 (14.6) 
Third trimester 1098 (33.3) 129 (11.7) 
 
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase 
inhibitor; PI, protease inhibitor. 
 
* Of the 157 dual therapy regimens, three included one PI, and one included two PIs.  
** Excludes 85 pregnancies in which HAART was started during pregnancy, but no dates were given.  
*** Includes 41 pregnancies in which HAART was initiated during the first trimester. 
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Prematurity rates and risk factors 
The overall prematurity rate in ART-treated pregnancies was 13.1% (583/4445, 95% 
CI: 12.1-14.2%); 51.8% (302/583) of premature deliveries were at <35 weeks, 
including 23.3% (136/583) at <32 weeks. There was no trend in the rate of premature 
delivery (<37 weeks) over time (p=0.759). Prematurity was not significantly 
associated with maternal age (Table 5.3), even when age was broken down into 
smaller age groups: rates were 11.3% (17/150) in women under 20 years of age, and 
13.7% (14/102) in those over 39 years of age, compared with 12.4% (186/1496) in 
women aged 25-29 years (p=0.696 and p=0.703 respectively). There was no 
association between prematurity and maternal ethnic group, but acquisition of HIV 
through IDU, and HIV-related symptoms in pregnancy were associated with a 
significantly increased risk of prematurity (Table 5.3).  
The prematurity rate was 10.7% in pregnancies with monotherapy exposure, 6.4% in 
those with dual therapy exposure and 14.1% with HAART exposure (Table 5.2). As 
there were only a small number of women on dual therapy, and the prematurity rate 
was not significantly different from those on monotherapy (p=0.094), these two 
groups were combined; the prematurity rate in the combined group was 10.1% 
(107/1061) (Table 5.3).  
HAART was associated with a significantly increased risk of prematurity compared 
with mono/dual therapy in univariable analysis (OR=1.46) (Table 5.3); including a 
random effect term to control for repeat pregnancies led to a slight increase in the 
OR, to 1.61. ORs were then adjusted for known risk factors, on which information 
was available (clinical status, IDU-acquired infection, ethnic group and maternal 
age); ethnic group and maternal age were included despite not being significant in 
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univariable analysis, to enable comparison with other studies (e.g. European 
Collaborative Study, 2004a; Schulte et al., 2007). In multivariable analyses, the 
association between HAART and prematurity remained significant (AOR=1.63, 
p=0.001), and all ORs were very similar in the unadjusted and adjusted models 
(Table 5.3). There were no significant interactions between ART and any of the 
covariates included in the models.
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Table 5.3 Rates, unadjusted and adjusted odds ratios for premature delivery 
 
% Univariable
Univariable - adjusted for 
repeat pregnancies
Multivariable - adjusted for 
repeat pregnancies (n =4407)
n premature OR  ( 95% CI) p -value OR  ( 95% CI) p -value AOR  ( 95% CI) p -value
Antiretroviral therapy
Mono/dual therapy 1061 10.1 1.00 1.00 1.00
HAART 3384 14.1 1.46 (1.17-1.82) 0.001 1.61 (1.21-2.15) 0.001 1.63 (1.22-2.19) 0.001
Ethnic origin   
White 650 14.2 1.00 1.00
Black African 3410 12.7 0.97 (0.78-1.21) 0.765 0.98 (0.74-1.30) 0.882 1.11 (0.76-1.62) 0.590
Other 383 15.1 1.20 (0.86-1.68) 0.273 1.21 (0.79-1.86) 0.377 1.39 (0.83-2.32) 0.211
Maternal age at delivery   
<25 years 811 12.8 1.00 1.00
25-34 years 2842 12.9 0.97 (0.78-1.20) 0.794 0.96 (0.74-1.26) 0.792 0.94 (0.69-1.29) 0.715
≥35 years 791 14.0 1.10 (0.84-1.45) 0.468 1.13 (0.81-1.59) 0.470 1.03 (0.70-1.50) 0.896
Source of infection   
Other/no known risk 4296 12.8 1.00 1.00
Injecting drug use 149 22.1 1.64 (1.19-2.25) 0.002 1.88 (1.23-2.88) 0.004 2.78 (1.44-5.38) 0.002
Clinical status   
Asymptomatic 3881 12.4 1.00 1.00
HIV-related symptoms or AIDS 529 18.5 1.58 (1.26-1.98) <0.001 1.76 (1.31-2.36) <0.001 1.75 (1.26-2.43) 0.001
 
 
N.B. All rates and odds ratios are in ART-treated women only. Adjustment for repeat pregnancies was by inclusion of a random effect term. 
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CD4 count and viral load 
CD4 count was reported for 85.3% (3792/4445) of pregnancies, and was measured at 
a median of 29 days before delivery (IQR: 14-56 days). Median CD4 count was 400 
cells/µl (IQR: 270-560 cells/µl). Viral load was reported for 70.9% of pregnancies 
(3150/4445), and was measured at a median of 21 days before delivery (IQR: 8-36 
days). Median viral load was <50 copies/ml (IQR: <50-158 copies/ml) overall, and 
300 copies/ml (IQR 103-1600 copies/ml) among the 38.6% (1215/3150) of women 
with detectable viral load (≥50 copies/ml). 
CD4 count and viral load were significantly associated with prematurity rates, which 
tended to be increased in women with low CD4 counts or high viral loads (Table 
5.4). The prematurity rate in pregnancies with missing CD4 count was higher than in 
those with CD4 reported (17% versus 12% respectively, p<0.001), and similarly for 
viral load (16% versus 13% respectively, p=0.015), probably reflecting lack of 
opportunity for testing women in premature labour. 
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Table 5.4 CD4 count, viral load and prematurity: rates and unadjusted odds 
ratios 
 
  Total Premature Univariable  
  n n % OR (95% CI) p-value 
CD4 cell count (cells/µl)      
≥500 1282 130 10.1 1.00  
200-500 2000 267 13.4 1.53 (1.10-2.13) 0.012 
<200 503 80 15.9 2.14 (1.34-3.41) 0.001 
Missing 1295 220 17.0   
Viral load (copies/ml)      
<50 1935 199 10.3 1.00 
 
51-999 * 838 112 13.4 1.51 (1.04-2.17) 0.028 
1000-9999 266 41 15.4 1.91 (1.10-3.31) 0.022 
>10,000 111 11 9.9 0.98 (0.40-2.41) 0.965 
Missing 660 106 16.1     
 
* Includes 84 cases with viral load reported as ‘<200 copies/ml’ or ‘<400 copies/ml’. 
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Initially, separate models including either CD4 count or viral load were developed, to 
avoid over-adjusting for factors that were potentially on the same causal pathway. 
Although the suggested effect of HAART on prematurity is mediated through the 
cytokine environment (not through viral load and CD4 count), the possible 
confounding effects of viral load and CD4 cell count may be on the same causal 
pathway: HAART reduces viral load, leading to an increase in CD4 cell counts, 
which may reduce the risk of preterm delivery (see Figure 7.1, page 278). Restricting 
the logistic regression model to pregnancies where viral load was reported led to a 
reduction in the AOR for the association between HAART and prematurity, and loss 
of statistical significance (AOR=1.46, p=0.113), partly due to a reduction in the 
number of births (from 4407 to 3136). However, after adjusting for viral load, 
HAART was associated with a significantly increased risk of prematurity 
(AOR=1.92). Including CD4 count in the model reduced the AOR slightly (from 
1.64 to 1.54), but the association remained significant (p=0.027; Table 5.5). Both 
viral load and CD4 count were independently associated with prematurity in separate 
models (Table 5.5). However, when they were included in the same model (n=2994), 
CD4 count was no longer significant (likelihood ratio test [LRT], p=0.257). The 
association between HAART and prematurity remained significant in this model, 
which included ethnic group, maternal age, IDU-acquired infection, clinical status, 
CD4 count, viral load and repeat pregnancies (AOR=1.88, 95% CI: 1.10-3.22, 
p=0.021). 
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Table 5.5 Adjusted odds ratios for premature delivery, including viral load or CD4 count  
 
Subset with CD4 reported 
(n =3761)
Adjusting for CD4 count        
(n =3761)
Subset with viral load reported 
(n =3136)
Adjusting for viral load        
(n =3136)
AOR  ( 95% CI) p -value AOR  ( 95% CI) p -value AOR  ( 95% CI) p -value AOR  ( 95% CI) p -value
Antiretroviral therapy
Mono/dual therapy 1.00 1.00 1.00 1.00
HAART 1.64 (1.12-2.41) 0.011 1.54 (1.05-2.25) 0.027 1.46 (0.91-2.33) 0.113 1.92 (1.17-3.15) 0.010
Ethnic origin
White 1.00 1.00 1.00 1.00
Black African 1.11 (0.68-1.79) 0.677 1.02 (0.63-1.66) 0.929 0.94 (0.55-1.59) 0.814 0.92 (0.55-1.55) 0.760
Other 1.49 (0.78-2.83) 0.228 1.43 (0.75-2.71) 0.274 1.40 (0.68-2.86) 0.360 1.34 (0.67-2.69) 0.413
Maternal age at delivery (years)
<25 1.00 1.00 1.00 1.00
25-34 0.87 (0.59-1.28) 0.474 0.84 (0.57-1.24) 0.382 0.95 (0.61-1.48) 0.810 0.98 (0.64-1.53) 0.946
≥35 1.02 (0.63-1.64) 0.939 0.97 (0.60-1.56) 0.899 1.22 (0.71-2.09) 0.468 1.31 (0.77-2.23) 0.314
Source of infection
Other/no known risk 1.00 1.00 1.00 1.00
Injecting drug use 2.68 (1.12-6.44) 0.027 2.52 (1.05-6.01) 0.038 2.79 (0.96-8.11) 0.059 2.75 (0.97-7.82) 0.058
Clinical status    
Asymptomatic 1.00 1.00 1.00 1.00
HIV-related symptoms or AIDS 1.94 (1.28-2.93) 0.002 1.78 (1.18-2.70) 0.006 2.20 (1.36-3.54) 0.001 2.18 (1.36-3.51) 0.001
CD4 cell count (cells/µl)  
≥500 NA 1.00 NA NA
200-500 NA 1.45 (1.04-2.02) 0.028 NA NA
<200 NA 1.81 (1.13-2.89) 0.014 NA NA
Viral load (copies/ml)   
<50 NA NA NA 1.00
51-999 NA NA NA 1.71 (1.18-2.50) 0.005
1000-9999 NA NA NA 2.60 (1.44-4.71) 0.002
>10,000 NA NA NA 1.07 (0.44-2.62) 0.878
 
NA, not applicable. * Includes viral loads reported as <200 copies/ml or <400 copies/ml. All AORs adjusted for ART, ethnic group, maternal age, IDU-acquired infection, 
clinical status, and repeat pregnancies.
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Severe prematurity 
The association between HAART and prematurity was more pronounced for delivery 
at <35 weeks and <32 weeks (AOR=2.78 and 2.70, respectively), than at <37 weeks 
gestation (AOR=1.63) (Table 5.6). 
Type of HAART 
Among 3384 HAART-exposed pregnancies, premature delivery occurred in 8.7% of 
those with exposure to NRTIs only, 14.3% with NNRTI exposure, 13.5% with PI 
exposure, and 17.5% with both PI and NNRTI exposure (χ2=4.37, df=3, p=0.224) 
(Table 5.2). After adjusting for clinical status, IDU, ethnic group and maternal age, 
PI-based HAART was not associated with a significantly increased risk of 
prematurity compared with NNRTI-based HAART (AOR=0.85, 95% CI: 0.63-1.15, 
p=0.302), nor were regimens which included both PIs and NNRTIs (AOR=1.14, 
95% CI: 0.66-1.95, p=0.644) or those consisting only of NRTIs (AOR=0.41, 95% 
CI: 0.13-1.33, p=0.138). However, statistical power to detect a significant difference 
between these subgroups was limited.  
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Table 5.6 Odds ratios for delivery at <37 weeks, <35 weeks and <32 weeks 
gestation in women on HAART compared with mono/dual therapy   
 
      Univariable (n=4445)   Multivariable (n=4407) 
Timing of 
delivery n 
% pre-
mature OR (95% CI) 
p-
value   AOR (95% CI) 
p-
value 
<37 weeks 
       
Mono/dual 1061 10.1 1.00 
  
1.00 
 
HAART 3384 14.1 1.61 (1.21-2.15) 0.001  1.63 (1.22-2.19) 0.001 
<35 weeks        
Mono/dual 1061 3.6 1.00   1.00  
HAART 3384 7.8 2.70 (1.72-4.25) <0.001  2.78 (1.74-4.44) <0.001 
<32 weeks        
Mono/dual 1061 1.4 1.00   1.00  
HAART 3384 3.6 2.74 (1.51-4.95) 0.001   2.70 (1.48-4.92) 0.001 
 
N.B. Univariable analyses were adjusted for repeat pregnancies only; multivariable analysis was 
adjusted for IDU-acquired infection, ethnic group, maternal age, clinical status, and repeat 
pregnancies. 
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Timing of initation of ART 
Among women starting HAART in pregnancy, later initiation of therapy was 
associated with a 7% reduction in the risk of prematurity for each additional week of 
gestation without treatment, after adjusting for clinical status, IDU-acquired 
infection, ethnic group and maternal age (OR=0.93 per week of gestation, 95% CI: 
0.90-0.97, p<0.001, n=2426; AOR=0.94, 95% CI: 0.91-0.98, p=0.001, n=2412). 
However, lower prematurity rates would naturally be expected in women who started 
treatment in the later stages of pregnancy, because this group would exclude women 
who were due to start ART later, but delivered before initiating treatment. Because 
this effect could potentially lead to an over-estimate of the association between 
prematurity and duration of HAART, the analysis was limited to 1328 women who 
initiated treatment before the end of the second trimester (i.e. by 26 completed weeks 
gestation). Later exposure to HAART was associated with a 10% reduction in 
prematurity per gestation week without HAART (OR=0.89 per week gestation, 95% 
CI: 0.83-0.96, p=0.003; AOR=0.91, 95% CI: 0.84-0.97, p=0.007; n=1322). 
Prematurity rates by grouped gestation week at initiation are shown in Table 5.7; the 
prematurity rate in women who started HAART before pregnancy (16.2%, 148/913) 
was not significantly higher than the rate in those who started HAART in the first 19 
weeks of pregnancy (17.5%, 66/377, χ²=0.324, df=1, p=0.578), but numbers were 
small. 
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Table 5.7 Odds ratios and adjusted odds ratios for premature delivery by 
timing of initiation of HAART  
 
Gestation week 
at initiation of 
HAART n 
% pre-
mature OR (95% CI) 
p-
value AOR (95% CI) 
p-
value 
≥32 333 9.3 *    
27-31  765 12.8 *    
20-26  1011 13.8 1.00  1.00  
13-19  276 17.4 1.46 (0.86-2.50) 0.163 1.47 (0.82-2.64) 0.192 
0-12  41 22.0 2.38 (0.74-7.73) 0.148 2.38 (0.67-8.50) 0.180 
Before pregnancy 873 16.2 1.34 (0.92-1.97) 0.131 1.08 (0.60-1.94) 0.798 
 
* Excluded from univariable and multivariable analyses. 
N.B. ORs were adjusted for repeat pregnancies; AORs were adjusted for IDU-acquired infection, 
ethnic group, maternal age and clinical status. 
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Further analyses 
Subgroup analyses  
Information on some known risk factors for prematurity was not available in the 
NSHPC, including obstetric history (prior preterm delivery, history of miscarriage 
and stillbirth), socio-demographic factors and smoking in pregnancy (Slattery & 
Morrison, 2002). Demographic characteristics, including ethnic group and IDU, 
changed substantially over time (as shown in Chapter 3), and concurrent changes in 
the prevalence of other risk factors for prematurity are also likely to have occurred. 
Although it was not possible to control for these factors, the analyses were repeated 
for nulliparous and parous women, and for women who delivered in 1994-1999 and 
2000-2005. The magnitude of the association was similar in nulliparous and parous 
women, and both were statistically significant (AOR=1.62, p=0.014, and AOR=1.61, 
p=0.026, respectively) (Table 5.8). The association between HAART and 
prematurity was also of similar magnitude in 1994-1999 (AOR=1.40, p=0.254) and 
in 2000-2005 (AOR=1.67, p=0.008), although due to the small sample size in the 
earlier period (n=489), the former was not statistically significant.  
Sensitivity analyses 
The effect of the inclusion criteria for this analysis on the findings were also 
explored by: 
1.  Excluding pregnancies in women on dual therapy (n=155) 
2.  Excluding stillbirths (n=49) 
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3.  Excluding pregnancies in women who were on treatment at conception or in 
the first trimester of pregnancy (n=959), since early ART consisted mostly of 
HAART (94.4%, 914/968). 
The association between HAART and prematurity was not substantially altered by 
excluding dual therapy (AOR=1.48, p=0.011), stillbirths (AOR=1.59, p=0.002) or 
pregnancies with early treatment (AOR=1.59, p=0.005) (Table 5.8).  
 
Table 5.8 Subgroup and sensitivity analyses – adjusted odds ratios for the 
risk of premature delivery in women on HAART compared with mono/dual 
therapy 
 
  n AOR (95% CI) p-value 
Main adjusted model 4407 1.63 (1.22-2.19) 0.001 
Pregnancies in nulliparous women 1391 1.61 (1.06-2.44) 0.026 
Pregnancies in parous women 2614 1.62 (1.10-2.38) 0.014 
Pregnancies in 1994-1999 489 1.40 (0.79-2.48) 0.254 
Pregnancies in 2000-2005 3918 1.67 (1.14-2.44) 0.008 
HAART and monotherapy only 
(excluding dual therapy) 4252 1.48 (1.09-2.01) 0.011 
Live births only (excluding stillbirths) 4358 1.59 (1.18-2.14) 0.002 
Treatment during pregnancy only 
(excluding early treatment) 3448 1.59 (1.15-2.19) 0.005 
 
N.B. AORs are for HAART compared with mono/dual therapy (baseline omitted), and are adjusted 
for repeat pregnancies, IDU-acquired infection, ethnic group, maternal age and clinical status. 
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Birth weight 
Mean birth weight was slightly but significantly lower for infants exposed to 
HAART in utero than for infants exposed to mono/dual therapy (2978 g versus 3096 
g, respectively, p<0.001). To explore whether this difference was attributable to 
prematurity or whether infants were small for their gestational age, standard 
deviation scores (z-scores) for birth weight were derived. HAART-exposed infants 
were significantly lighter, after standardising for gestational age, than those exposed 
to mono/dual therapy (mean z-scores: HAART, -0.06; mono/dual therapy, 0.06, 
p=0.002). Results were similar for term (mean z-scores: HAART, -0.06; mono/dual 
therapy, 0.06, p=0.003, n=3116) and preterm infants (mean z-scores: HAART, -0.08; 
mono/dual therapy, 0.08, p=0.329, n=469), but not statistically significant for the 
premature group, probably due to sample size. 
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5.3 Comparative analysis of ART and prematurity in three studies 
Despite growing evidence linking HAART with an increased risk of premature 
delivery over the last decade, several large-scale studies have failed to detect an 
association (Tuomala et al., 2002; Tuomala et al., 2005; Watts et al., 2004a). There 
is ongoing debate about the reasons underlying these differences in findings, but no 
clear explanation has so far emerged (Thorne, Fiore, & Rudin, 2003; Tuomala & 
Yawetz, 2006). In response to this, a collaboration of three study groups (the PSD, 
ECS and NSHPC) was established, with the aim of exploring these differences. At 
the time this project was initiated, a recent ECS publication updating earlier findings 
from 2000 had indicated a two-fold increased risk of preterm delivery associated 
with HAART, compared with monotherapy or dual therapy (European Collaborative 
Study, 2004a). Preliminary analyses from the NSHPC suggested a similar risk for 
HIV-infected women in the UK and Ireland. Researchers from the PSD, a US 
monitoring study, were approached regarding a combined analysis. Preliminary 
findings from their study (published subsequently) suggested an increased risk of 
prematurity associated with PI-containing HAART, compared with dual therapy, the 
group with the lowest prematurity rate (Schulte et al., 2007). These findings 
supported an association between treatment and prematurity, but with some 
differences. A comparative analysis was therefore carried out using data from the 
three studies.  
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Methodological differences 
Study design  
The three studies included in this project were chosen in part for their different 
methodologies, which were described briefly in Chapter 2. All three studies were 
observational, but varied in their approach. The ECS was the only study requiring 
enrolment and consent. A small survey carried out in 11 ECS centres in 2005 
indicated that high enrolment rates were generally achieved: less than 5% (32/724) of 
eligible women in 2002-2004 were not enrolled, mostly because they moved away; 
none of the centres reported refusal as a reason for non-enrolment (Patel, 2007).  
In both the PSD and NSHPC, births were included regardless of the timing of a 
woman’s diagnosis or presentation for antenatal care. However, the PSD was 
restricted to US states with the highest prevalence of HIV. In some states the study 
only covered particular hospitals, and therefore did not necessarily include all births 
in a particular geographic area. For example, in Washington DC, Stanford 
(California) and North Carolina, the PSD covered only the large referral hospitals, 
where most women and children would have been seen. The other five sites – Puerto 
Rico, New York City, Massachusetts, Texas and California (Los Angeles County) – 
were more comprehensive, and included other hospitals and centres aside from the 
key referral centres; these sites were therefore considered ‘population-based’. There 
were also changes in the sites over time; for instance, in Texas the PSD initially 
covered only a few cities, but was later extended to include others, although at no 
time were all cities included. The NSHPC, on the other hand, is a population-based 
surveillance study, which aims to include all HIV-infected pregnant women seeking 
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antenatal care in the UK and Ireland. Because the study relies on complementary 
paediatric and obstetric reporting systems, case ascertainment of infants born to HIV-
infected women is high; over 90% of all HIV-infected women giving birth in 
England and Scotland are diagnosed by the time of delivery and reported to the 
NSHPC (Health Protection Agency, 2008).  
In all three studies, women may have been excluded from the study hospitals due to 
issues around access to healthcare, either through lack of health insurance in the US, 
or due to language or social barriers experienced by recent immigrants in Europe. A 
recent report from France suggested that HIV-infected African women were more 
likely to present late for antenatal care, and be diagnosed late in pregnancy, than 
HIV-infected French women (Jasseron et al., 2008), an issue that may also occur 
elsewhere in Europe.  
None of the studies were set up specifically to investigate ART and premature 
delivery, but data on ART and gestational age were collected along with other 
maternal and pregnancy characteristics. Data in the PSD came mainly from 
paediatric medical records, with some input from maternal records where available, 
and was collected by trained CDC staff. In the NSHPC and ECS, forms were 
completed prospectively by clinicians and other health professionals, often those 
responsible for the women and children. Maternal and pregnancy data were therefore 
more complete in the ECS and NSHPC.  
All three studies were observational, and decisions about type of treatment were 
based on a number of factors, including existing local or national guidelines, 
availability of antiretroviral drugs, and clinical indication. Different guidelines on the 
management of HIV infection in pregnancy are available in the US (Perinatal HIV 
Guidelines Working Group, 2008), Europe (Coll et al., 2002), and the UK 
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(BHIVA/CHIVA, 2008), and guidelines were also updated periodically both in the 
US (Perinatal HIV Guidelines Working Group, 2005; Perinatal HIV Guidelines 
Working Group, 2008; Public Health Service Task Force, 1998; Public Health 
Service Task Force, 2002) and in the UK (BHIVA, 1999; BHIVA, 2001; BHIVA, 
2005b; BHIVA/CHIVA, 2008). Differences in the way treatment was assigned are 
therefore likely, in terms of whether monotherapy, dual therapy or HAART was 
prescribed.  
Variables 
Similar information was collected in the three studies, but there were some 
differences in the range and definition of variables collected (Table 5.9). Variables 
that were consistent across the three studies included child’s year of birth, mother’s 
country of birth, gestational age and ART. ART was categorised as none, 
monotherapy, dual therapy, or HAART (three or more drugs), and HAART was 
classified as to whether PIs were included; combinations of three or more NRTIs 
were classified as non-PI HAART.  
The prematurity variables used in the analyses (delivery at <37 weeks or <32 weeks 
gestation) were derived from actual gestational age (in completed weeks, as reported 
by clinicians) in all three studies. In the ECS, gestational age was based on an 
ultrasound scan if available (for the majority), and otherwise (rarely) on date of last 
menstrual period. In some ECS centres, especially in Germany (Grosch-Woerner et 
al., 2008), planned caesarean sections are carried out at 36 weeks gestation; these 
cases were excluded from analyses where a 37 week cut-off was used, but included 
in the analyses involving a cut-off of 32 weeks gestation. In the PSD gestational age 
was as recorded in the paediatric notes, and in the NSHPC, as reported by 
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respondents. In the PSD, an additional binary (yes/no) variable for whether the child 
was preterm (defined as <37 weeks) was also available; in cases where gestational 
age was missing, this ‘preterm’ variable was used instead to classify infants with 
regard to prematurity. Where there were discrepancies between the two variables 
(n=177), actual gestational age was used; only nine cases were recorded as term but 
with a gestational age of <35 weeks.  
Maternal region of birth was classified as within or outside the study region; for 
example, in the PSD, this referred to whether a woman was born in the US or not. 
Maternal ethnic origin was classified as white, black, Hispanic or other, with 
Hispanic only specified in the PSD. Information on IDU was collected in all three 
studies, but there were differences in the meaning of the variable between studies: in 
the PSD, history of IDU was recorded; in the ECS history or current use of IDU was 
based on self-report, evidence of drug withdrawal in the infants, and clinical 
observation; in the NSHPC, information on IDU related to whether it was the likely 
mode of acquisition of HIV. In addition, in the PSD and NSHPC, IDU was one of a 
number of risk factors for acquisition of HIV. If neither IDU, nor any other factors 
were given, the mother’s risk factor was recorded as ‘Other’; there are therefore no 
missing values. The ECS included a specific question on history of intravenous drug 
abuse (yes/no), and missing values were recorded as such. In the PSD, although 
information on maternal clinical status (HIV-related symptoms) at delivery was 
collected, no details of CD4 count or viral load were available. Because information 
on clinical status in the PSD related to the time of delivery, HIV-related symptoms or 
AIDS at delivery was used in the NSHPC.
  
171
Table 5.9 Summary of main differences between studies 
 
  
Pediatric Spectrum of HIV Disease 
project (PSD) 
European Collaborative Study 
(ECS) 
National Study of HIV in Pregnancy 
and Childhood (NSHPC) 
Study Design Review of paediatric medical records Cohort study with enrolment  Confidential surveillance study 
Coverage Eight geographical sites; part 
population-based, part hospital-based 
Over 25 centres in nine European 
countries 
All maternity units in the UK and 
Ireland 
Years included 1990-2004 (study concluded in 2004) 1990-2006 1990-2006 
Maternal and pregnancy variables   
Ethnicity Dataset included only white non-
Hispanic, black non-Hispanic, 
Hispanic, and other (missing excluded) 
White, black, other White, black, other; child’s ethnicity 
used if mother’s not completed 
Region of birth Recorded as US, US Dependencies and 
Possessions, or other 
Maternal country of birth Maternal country of birth 
Age at delivery (years) Not available Available Available 
Injecting drug use (IDU) History of IDU, as reported in medical 
records 
Self-reported history or current use of 
IDU 
IDU as route of acquisition of HIV 
Parity Not available Previous live births or stillbirths Previous live births or stillbirths * 
HIV symptoms Available Not routinely recorded (only for ~40% 
of mothers) 
Available 
Viral load and CD4 count Not available In pregnancy, nearest to delivery, up 
to one week after delivery 
In pregnancy, nearest to delivery (viral 
load up to one week after delivery) 
ART  Monotherapy, dual therapy, HAART 
with/without protease inhibitor 
Monotherapy, dual therapy, HAART 
with/without protease inhibitor 
Monotherapy, dual therapy, HAART 
with/without protease inhibitor 
Mode of delivery Vaginal or caesarean section Vaginal, elective or emergency 
caesarean section 
Vaginal, elective or emergency 
caesarean section 
* For details, see page 58 (Chapter 2).
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Population differences 
Distribution of births over time 
Figure 5.1 shows the distribution of births over time in the three studies. The skewed 
pattern seen in NSHPC births (described in Chapter 3) was driven both by an 
increase in HIV prevalence over time (particularly since 2000) and by an increase in 
the uptake of routine antenatal HIV screening, and reflects the actual number of 
diagnosed HIV-infected women giving birth in the UK and Ireland each year. The 
number of births in the PSD was influenced by the number of sites involved and their 
coverage; for instance, both North Carolina and Stanford ceased reporting after 1997 
and 1998, respectively. Meanwhile, the number of cases from Texas increased from 
34 in 1990 to 244 in 2002, as the PSD was expanded to include additional hospitals 
within the state. The number of cases from all sites declined after 2003, and the study 
concluded in 2004. In the ECS, the decline in number of cases in recent years reflects 
delayed reporting, as well as reduced enrolment from some centres. Enrolment from 
centres in the Ukraine increased in recent years, but these centres were not included 
in this analysis.  
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Figure 5.1 Distribution of births by year and study 
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Demographic characteristics 
There was marked variation between studies in the baseline demographic 
characteristics of the mothers. The proportion of white mothers ranged from 9% in 
the PSD to 65% in the ECS, and the proportion of black mothers from 30% in the 
ECS to 81% in the NSHPC (Table 5.10). In the NSHPC, over 80% of mothers were 
born outside the study region, compared with about a third in the ECS and a fifth in 
the PSD (χ2, df=2, p<0.001). There were also differences in the associations between 
characteristics; for example, black women in the PSD were predominantly US-born 
(83.3%, 3307/3971), whereas over 95% of those in the ECS (1174/1189) and 
NSHPC (5086/5242) were born abroad, mainly in sub-Saharan Africa. 
Prevalence of maternal IDU was 13% in the PSD, 35% in the ECS, and 4% in the 
NSHPC (χ2, df=2, p<0.001) (Table 5.10); IDU prevalence in the NSHPC may have 
been an underestimate compared with the other studies, since IDU referred to the 
route of HIV acquisition. In all three studies, IDU was more common in white 
women (Table 5.11); very low rates of IDU (<1%) were reported for black women in 
the ECS and NSHPC, with rates of around 9% for black women in the PSD. 
In the PSD, maternal age was not available until after 2000 and was therefore not 
included in the analysis. However, age at delivery was available for the mothers of 
1450 infants born since 2000; median maternal age was 28 years (IQR: 23-32 years). 
In the ECS, median maternal age was 27 years (IQR: 23-31 years) and in the 
NSHPC, 29 years (IQR: 26-33 years). 
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Table 5.10 Maternal demographic characteristics by study 
 
    PSD   ECS   NSHPC   
Maternal characteristics n % n % n % 
Region of birth  Within study region 5722 79.8 2613 61.4 987 14.8 
 
Outside study region 1445 20.2 1380 32.4 5473 82.1 
 Total 7167  3993  6460  
  
Missing 1500 17.3 260 6.1 205 3.1 
Ethnic group White 810 9.3 2673 65.4 1009 15.3 
 
Black 4849 55.9 1232 30.1 5350 81.1 
 
Hispanic 2743 31.6 0 0.0 0 0.0 
 
Other 265 3.1 183 4.5 237 3.6 
 Total 8667  4088  6596  
  
Missing 0 0.0 165 3.9 69 1.0 
Injecting drug use Non-IDU 7541 87.0 2650 64.6 6370 95.6 
 
IDU 1126 13.0 1453 35.4 295 4.4 
 Total 8667  4103  6665  
  
Missing 0 0.0 150 3.5 0 0.0 
Age at delivery  14-19 0  113 2.9 230 3.5 
(years) 20-24 0  681 17.2 1024 15.5 
 
25-34 0  2485 62.9 4221 64.1 
 
35-39 0  554 14.0 961 14.6 
 
≥40 0  120 3.0 154 2.3 
 Total 0  3953  6590  
  
Missing 8667 100.0 300 7.1 75 1.1 
Parity  0 0  1931 48.2 1791 33.4 
(live births  1 0  1228 30.6 1935 36.0 
+ stillbirths) 2 0  538 13.4 974 18.1 
 
3 or more 0  313 7.8 670 12.5 
 Total 0  4010  5370  
  
Missing 8667 100.0 243 5.7 1295 19.4 
Total*   8667   4253   6665   
 
* The overall total was used as the denominator for calculating the proportion of births with missing 
data on each of the variables; all other totals and proportions are based only on births with data 
available. 
 
Table 5.11  Maternal injecting drug use by ethnic group and study 
 
PSD ECS NSHPC 
  IDU    IDU    IDU  Maternal 
ethnic group n n (%) n n (%) n n (%) 
White 810 249 (30.7) 2612 1399 (53.6) 1009 270 (26.8) 
Black 4849 419 (8.6) 1218 8 (0.7) 5350 15 (0.3) 
Other 265 23 (8.7) 174 17 (9.8) 237 9 (3.8) 
Hispanic 2743 435 (15.9) 0 - 0 - 
χ
2
 p-value  
 (df=4) <0.001 (df=2) <0.001  (df=2) <0.001 
 
df, degrees of freedom.
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Treatment and pregnancy characteristics  
Antiretroviral therapy 
Overall differences between studies in the use of ART in pregnancy were apparent 
(Table 5.13, page 179); however, because of the differences over time in the 
distribution of births (Figure 5.1) and in the availability of ART, use of ART was 
explored in more detail over different time periods. General patterns of ART use 
over time were broadly similar across studies (Figures 5.2-5.4), although significant 
differences were also apparent. For example, uptake of zidovudine monotherapy was 
more rapid in the PSD than in the two European studies; in 1995, 83.8% (685/817) of 
mothers in the PSD were on monotherapy, compared with only 56.6% (145/256) in 
the ECS, and 58.0% (29/50) in the NSHPC (χ2, df=2, p<0.001). Once dual therapy 
became available, it was also taken up faster in the PSD, with over a quarter of 
women (26.2%, 518/1975) on dual therapy between 1997 and 1999, compared with 
less than 20% in the ECS (18.0%, 124/688) and NSHPC (13.4%, 56/417; χ2, df=2, 
p<0.001). Dual therapy remained more common in the PSD throughout the study 
period, and was used in around 15% of women between 2001 and 2004, compared 
with 10% in the ECS and 3% in the NSHPC (Table 5.12). Between 1998 and 2000, 
the proportion of women on HAART was similar in the three studies, increasing 
from around a third in 1998, to half in 1999, and 60% in 2000. Between 2001 and 
2004, the proportion of mothers on HAART or monotherapy was higher in the 
NSHPC than in the ECS or PSD, and the proportion of women remaining untreated 
in pregnancy was lower (Table 5.12). 
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Table 5.12  Use of ART by study in 2001-2004 
 
 PSD ECS NSHPC 
Type of ART n % n % n % 
χ
2
 (df=2)        
p-value* 
Untreated 161 8.0 126 9.3 113 3.6 <0.001 
Monotherapy 112 5.6 95 7.0 490 15.8 <0.001 
Dual therapy 264 13.1 123 9.1 79 2.5 <0.001 
HAART 1480 73.4 1009 74.6 2420 78.0 <0.001 
Non-PI 479 23.8 450 33.3 1505 48.5 <0.001 
PI 1000 49.6 559 41.3 913 29.5 <0.001 
Total 2017 100.0 1353 100.0 3102 100.0  
 
* p-values are for each ART level compared with all others combined 
N.B. Comparing PSD with ECS, differences in proportions of women who were untreated or on dual 
therapy were not statistically significant, nor was the difference in the overall proportion on HAART; 
other comparisons were statistically significant (p<0.001). 
 
 
Of all pregnancies in women on monotherapy, 87.8% (2291/2608) occurred between 
1990 and 1998 in the PSD, 72.4% (540/746) in the ECS, and 21.6% (209/969) in the 
NSHPC. Few pregnancies in women on HAART occurred before 1999: 11.3% 
(294/2605) in the PSD, 4.5% (73/1624) in the ECS, and 1.1% (53/4776) in the 
NSHPC. Comparisons between HAART and monotherapy in the PSD and ECS were 
therefore more historical than in the NSHPC, in which the majority of both HAART 
and monotherapy exposures occurred since 1999.  
In all three studies, the majority of dual therapy regimens consisted of zidovudine 
and lamivudine: 81.1% (792/976) in the PSD, 74.7% (236/316) in the ECS, and 
72.6% (130/179) in the NSHPC (χ2=10.48, df=2, p=0.005). There were significant 
differences between studies in the use of HAART regimens, with PI-based regimens 
favoured in the PSD (67.6% of HAART regimens, 1000/1480) and ECS (55.4%, 
559/1009), and non-PI regimens favoured in the NSHPC (62.2%, 1505/2418) (Table 
5.13, page 179). It is also likely that the use of specific antiretroviral drugs differed 
between studies, partly due to differences in the distribution of cases over time; 
however, details of specific regimens were not available for comparison. 
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Figure 5.2 Use of ART over time in the PSD 
n=
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
90 
(228)
91 
(362)
92 
(458)
93 
(568)
94 
(672)
95 
(817)
96
(774)
97 
(632)
98
(645)
99
(698)
00
(796)
01
(741)
02
(606)
03
(528)
04
(141)
Year of delivery
Pe
rc
en
t
Untreated
Monotherapy
Dual therapy
HAART no PI
HAART + PI
 
 
Figure 5.3  Use of ART over time in the ECS 
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Figure 5.4  Use of ART over time in the NSHPC 
n=
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
90 
(26)
91 
(47)
92 
(48)
93 
(48)
94 
(66)
95 
(50)
96 
(85)
97 
(85)
98
(130)
99
(202)
00
(343)
01
(516)
02
(652)
03
(922)
04
(1010)
05
(1117)
06
(1068)
Year of delivery
Pe
rc
e
n
t
Untreated
Monotherapy
Dual therapy
HAART no PI
HAART + PI
 
 179 
Table 5.13 Maternal pregnancy, clinical and treatment characteristics by study 
 
    PSD   ECS   NSHPC   
  n % n % n % 
ART Untreated 2478 28.6 1567 36.8 492 7.7 
 
Monotherapy 2608 30.1 746 17.5 969 15.1 
 
Dual therapy 976 11.3 316 7.4 189 2.9 
 
HAART 2605 30.1 1624 38.2 4776 74.3 
 Total 8667  4253  6426  
  
Missing 0 0.0 0 0.0 239 3.6 
Clinical status in  No symptoms 4566 86.8 0  4942 92.0 
pregnancy Symptoms 694 13.2 0  427 8.0 
 Total 5260  0  5369  
  
Missing 3407 39.3 4253 100.0 1296 19.4 
CD4 cell count ≥500 0  1190 39.7 1658 34.3 
(cells/µl) 350-499 0  762 25.4 1225 25.4 
 
200-349 0  683 22.8 1321 27.4 
 
<200 0  362 12.1 625 12.9 
 Total 0  2997  4829  
  
Missing 8667 100.0 1256 29.5 1836 27.5 
Viral load <50 0  761 36.0 2660 55.2 
(copies/ml) 50-999 * 0  753 35.6 1166 24.2 
 
1000-9999 0  357 16.9 567 11.8 
 
≥10,000 0  243 11.5 430 8.9 
 Total 0  2114  4823  
  
Missing 8667 100.0 2139 50.3 1842 27.6 
Mode of delivery Caesarean section 3017 36.2 2486 59.8 4878 76.6 
 
Vaginal  5320 63.8 1673 40.2 1491 23.4 
 Total 8337  4159  6369  
  
Missing 330 3.8 94 2.2 296 4.4 
Premature delivery ≥37 7014 82.6 3385 85.1 5677 87.5 
(completed weeks) <37 1482 17.4 592 14.9 808 12.5 
 Total 8496  3977  6485  
  
Missing 171 2.0 276† 6.5 180 2.7 
Gestational age ≥37 7014 83.2 3385 85.1 5677 87.5 
(completed weeks) 35-36 739 8.8 297 7.5 400 6.2 
 
32-34 434 5.1 192 4.8 238 3.7 
 
<32 247 2.9 103 2.6 170 2.6 
 Total 8434  3977  6485  
  
Missing 233‡ 2.7 276† 6.5 180 2.7 
  
Total § 8667   4253   6665   
 
* Includes viral loads reported as ‘<200 copies/ml’ or ‘<400 copies/ml.’  
† Missing category (ECS) includes 175 elective caesarean section deliveries at 36 weeks gestation (see 
explanation on page 169). 
‡ Missing category (PSD) includes 62 infants reported as ‘preterm’ but for whom actual gestational 
age was not provided; these 62 infants were included in the ‘Premature delivery’ variable (see 
explanation on page 182).  
§ The overall total was used as the denominator for calculating the proportion of births with missing 
data on each of the variables; all other totals and proportions are based only on births with data 
available.
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Mode of delivery  
There were significant overall differences between studies in mode of delivery 
(Table 5.13, page 179). Overall caesarean section rates increased substantially 
between 1997 and 1999 in all three studies, but rates were lower throughout the study 
period in the PSD (Figure 5.5). In the ECS and NSHPC, rates increased from around 
45% in 1995-1997 (ECS: 287/651; NSHPC: 97/217) to 81% from 1999 to 2004 
(ECS: 1565/359; NSHPC: 3012/3719), while in the PSD, caesarean section rates 
were just over 20% (950/4283) up to 1997 and then rose to around 50% (333/679) in 
1999, with a slight increase thereafter to about 58% (77/137) in 2004 (Figure 5.5). 
 
Figure 5.5 Caesarean section rates over time by study 
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N.B Information on mode of delivery in the NSHPC was only available from 1995 onwards; the PSD 
concluded in 2004. 
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Maternal clinical and immunological characteristics 
The proportion of women with HIV-related symptoms at delivery was higher in the 
PSD than in the NSHPC (13% versus 8%, p<0.001), but this was partly associated 
with the higher proportion of untreated women in the PSD; among women on 
HAART, the proportion of mothers with symptoms was similar: 7.7% (121/1564) in 
the PSD and 8.5% (333/3911) in the NSHPC (p=0.346). In the PSD, information on 
clinical status was only available for 40% of mothers, and there was wide variation 
between study sites in the proportion with missing information, from 10% (100/952) 
in Puerto Rico to 57% in New York (813/1419) and Texas (1347/2382).  
Mothers in the ECS were less likely to have viral load <50 copies/ml than those in 
the NSHPC (Table 5.13), but this was mainly due to the higher proportion of recent 
births in the NSHPC, when uptake of treatment was high and the detection limit of 
most assays was <50 copies/ml. In 2005-2006, there was no significant difference 
between the two studies in the proportion of women with viral load <50 copies/ml: 
70.6% (108/153) in the ECS, and 66.5% (1216/1828) in the NSHPC (p=0.305). 
Mothers in the ECS had higher CD4 cell counts (40% ≥500 cells/µl) than those in the 
NSHPC (34%, p<0.001).
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Prematurity rates and risk factors 
Baseline prematurity rates and changes over time 
Overall prematurity rates were 17.4% in the PSD, 14.9% in the ECS (after excluding 
175 elective caesarean section deliveries at 36 weeks), and 12.5% in the NSHPC 
(Table 5.13, page 179) (p<0.001). There was no statistically significant change in 
prematurity rates over time in the PSD or NSHPC, but unadjusted rates in the ECS 
increased by an average of 3% per year (OR=1.03, 95% CI: 1.01-1.05, p=0.002) 
(Figure 5.6).  
In the PSD, actual gestational age was missing for 20% of infants (1748/8667) but of 
these, 90% (1577/1748) had information on whether or not they were premature. 
Overall, term infants were less likely to have actual gestational age reported (78.4%, 
5499/7014) than premature infants (95.8%, 1420/1482), so for the grouped 
gestational age variable (≥37, 35-36, 32-34, <32 weeks), the 1515 infants reported as 
‘term’ were classified as ≥37 weeks. The 62 infants reported as ‘preterm’ were 
excluded from this variable: this led to a slight overestimate of the proportion of term 
infants (83.2%), compared with the prematurity variable (<37 weeks), in which they 
were included (82.6% were categorised as ≥37 weeks). The proportion of infants 
born at <32 weeks was 2.9% in the PSD, 2.5% in the ECS and 2.6% in the NSHPC 
(p=0.284).
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Figure 5.6  Prematurity rates over time by study 
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* Excludes elective caesarean section deliveries carried out at 36 weeks (n=175). 
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Crude prematurity rates by ART 
Prematurity rates by treatment in each of the three studies are shown in Table 5.14 
and Figure 5.7. In unadjusted analyses, untreated women were 1.2, 1.3 and 1.5 times 
more likely to deliver prematurely in the PSD, ECS and NSHPC respectively, 
compared with those on monotherapy. Untreated women were not considered a 
suitable comparison group for two reasons: 
1. As shown earlier (Chapter 5, page 148), premature delivery is likely to have 
prevented some women from initiating treatment, particularly in recent years, 
when uptake of ART was high; this is most likely to affect the NSHPC, in 
which over 85% of cases were reported since 2000. 
2. Since a higher proportion of untreated women than treated women were 
reported in the pre-ART era, they were less likely to have information on 
CD4 count and symptoms reported. CD4 count was missing for 43.7% 
(684/1567) of untreated women, and 21.3% (572/2686) of treated women in 
the ECS (p<0.001), and for 59.3% (292/492) of untreated and 22.0% 
(1307/5934) of treated women in the NSHPC (p<0.001). Untreated women in 
the ECS were also more likely to have CD4 <200 cells/µl than treated women 
(14.8%, 131/883, versus 10.9%, 231/2114, p=0.001). In the PSD, untreated 
women were more likely to have missing information on symptoms (45.5%, 
1127/2478, versus 36.8%, 2280/6189, p<0.001), and more likely to be 
symptomatic (21.5%, 290/1351, versus 10.3%, 404/3909, p<0.001) compared 
with treated women.  
Compared with women on monotherapy, premature delivery was significantly less 
likely in women on dual therapy in the PSD (OR=0.79), and more likely in women 
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on HAART in the ECS (OR=1.60) and NSHPC (OR=1.28), but not in the PSD 
(OR=0.99) (Table 5.14).  
Because of the significant differences in prematurity between the monotherapy and 
dual therapy groups in the PSD, these two groups were not combined in these 
analyses, although they were in the NSHPC analysis described in the previous 
section (5.2). Using dual therapy as a baseline, ORs for prematurity in women on 
HAART were 1.25 (95% CI: 1.01-1.54, p=0.039) in the PSD, 1.80 (95% CI: 1.21-
2.67, p=0.004) in the ECS, and 1.51 (95% CI: 0.90-2.54, p=0.122) in the NSHPC. 
Although prematurity was lowest among women on dual therapy in all three studies, 
and the ORs were more homogeneous across studies than with monotherapy as the 
baseline, dual therapy was not selected as the reference group for the main analysis, 
because (1) only a small proportion of women were included in this group 
(particularly in the ECS and NSHPC); and (2) dual therapy is not a standard line of 
treatment and was mainly used during the transition from monotherapy to HAART in 
the mid- to late 1990s.  
In the following analyses, monotherapy is used as the baseline and untreated women 
are excluded (n=2395 in the PSD, 1481 in the ECS and 482 in the NSHPC). A series 
of logistic regression models was developed; these models are summarised in Figure 
5.8.  
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Table 5.14 Prematurity rates by ART  
 
  ART n 
Prematurity 
rate OR (95% CI) p-value 
PSD No ART 2395 20.2 1.24 (1.07-1.43) 0.003 
(n=8496) Monotherapy* 2552 16.9 1.00   
 
Dual therapy  958 13.9 0.79 (0.64-0.98) 0.029 
 
HAART 2591 16.8 0.99 (0.85-1.14) 0.865 
ECS No ART 1481 14.7 1.30 (0.99-1.71) 0.058 
(n=3977) Monotherapy* 703 11.7 1.00   
 
Dual therapy  294 10.5 0.89 (0.58-1.38) 0.611 
 
HAART 1499 17.5 1.60 (1.23-2.09) 0.001 
NSHPC No ART 482 14.3 1.46 (1.05-2.04) 0.023 
(n=6291) Monotherapy* 957 10.2 1.00   
 Dual therapy  181 8.8 0.85 (0.49-1.48) 0.565 
  
HAART 4671 12.8 1.28 (1.02-1.61) 0.031 
 
* Baseline. 
 
Figure 5.7 Prematurity rates by ART 
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Figure 5.8 Flowchart showing logistic regression models for ART and 
prematurity in the PSD, ECS and NSHPC  
 
 
 
 
 Model denominators (n) 
Models  PSD ECS NSHPC 
Unadjusted/univariable 6101 2496 5809 
Basic multivariable 5056 2318 5722 
Basic multivariable + study site 5056 2318 5722 
Basic multivariable + mother NA 2318 5424 
Refined multivariable 3404 2367 4923 
Refined multivariable <32 weeks 2783 2512 4785 
Refined multivariable with/without PIs 3404 2367 4923 
Basic multivariable models 
 
Table 5.18 
Unadjusted univariable 
models 
 
Tables 5.15-5.17 
Refined multivariable models  
 
Table 5.21 
 
Refined multivariable models 
- HAART with/without PI(s) 
 
Table 5.23 
Basic multivariable models 
+ study site or mother (RE) 
 
Table 5.20 
Refined multivariable models 
- delivery at <32 weeks 
 
Table 5.22 
Adjusted for: 
 
 
 
 - Ethnic group 
 - Region of birth 
 - IDU 
 - Year 
 
 
 
 PSD 
 - Ethnic group 
 - IDU 
 - Symptoms 
 - Year 
 
 ECS 
 - IDU 
 - Parity 
 - CD4 count 
 - Site (RE) 
- Mother (RE) 
 
 NSHPC 
 - IDU 
- Symptoms 
 - CD4 count 
- Mother (RE) 
 
RE, random effect 
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Heterogeneity in the association between ART and prematurity 
Heterogeneity between studies in the association between ART and prematurity was 
assessed using a weighted Mantel-Haenszel estimate for HAART compared with 
monotherapy, stratified by study. There was evidence of significant heterogeneity 
between studies (test of homogeneity of ORs: χ2=11.63, df=2, p=0.009), suggesting 
that a summary estimate would not be appropriate. Separate logistic regression 
models were therefore developed for each individual study. 
If, instead of monotherapy, dual therapy was used as a baseline, there was no 
significant heterogeneity between studies (test of homogeneity of ORs: χ2=2.70, 
df=2, p=0.259), but if monotherapy and dual therapy were combined as a baseline, 
the association remained heterogeneous (test of homogeneity of ORs: χ2=11.56, 
df=2, p=0.003).  
Univariable risk factors for prematurity 
Associations between prematurity and maternal characteristics are shown in Tables 
5.15 (main variables) and 5.17 (variables only available in the ECS and NSHPC). In 
univariable analyses, ART was significantly associated with prematurity in all three 
studies (Table 5.15); however, in the PSD, the rate was lower in women on dual 
therapy than in those on monotherapy or HAART. In the ECS and NSHPC, rates 
were similar in women on monotherapy and dual therapy and higher in those on 
HAART (see also Figure 5.7, page 186). In the ECS and NSHPC, black women had 
lower rates of prematurity than white women (although the association was only 
borderline significant), and in the PSD there was no significant association with 
ethnic group. 
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Table 5.15 Rates and unadjusted odds ratios for prematurity in ART-treated 
women 
 
      n 
% 
pre-
term OR  ( 95% CI) 
p-
value 
PSD ART Monotherapy 2552 16.9 1.00  
  Dual therapy 958 13.9 0.79 (0.64-0.98) 0.029 
  HAART 2591 16.8 0.99 (0.85-1.14) 0.865 
 Ethnic origin White 564 15.8 1.00  
  Black 3358 17.9 1.16 (0.91-1.48) 0.222 
  Other 215 12.1 0.73 (0.46-1.17) 0.196 
  Hispanic 1964 14.4 0.90 (0.69-1.16) 0.418 
 Birth region In study region 4063 17.0 1.00  
  Abroad 993 12.6 0.70 (0.57-0.86) 0.001 
 IDU Non-IDU 5520 15.5 1.00  
  IDU 581 24.3 1.74 (1.42-2.13) <0.001 
 Clinical status No symptoms 3480 14.8 1.00  
  Symptoms 397 25.7 1.99 (1.56-2.53) <0.001 
  Year   6101   1.01 (0.99-1.03) 0.466 
ECS ART Monotherapy 703 11.7 1.00  
 
 Dual therapy 294 10.5 0.89 (0.58-1.38) 0.611 
  HAART 1499 17.5 1.60 (1.23-2.09) 0.001 
 Ethnic origin White 1354 16.2 1.00  
  Black 940 13.3 0.79 (0.63-1.01) 0.058 
  Other 115 19.1 1.23 (0.75-1.99) 0.412 
  Hispanic 0    
 Birth region In study region 1310 16.5 1.00  
  Abroad 1047 13.8 0.81 (0.65-1.02) 0.077 
 IDU Non-IDU 1859 13.3 1.00  
  IDU 601 20.5 1.68 (1.32-2.13) <0.001 
 Clinical status No symptoms NA    
  Symptoms NA    
  Year   2496   1.03 (1.00-1.07) 0.074 
NSHPC ART Monotherapy 957 10.2 1.00  
  Dual therapy 181 8.8 0.85 (0.49-1.48) 0.565 
  HAART 4671 12.8 1.28 (1.02-1.61) 0.031 
 Ethnic origin White 798 14.4 1.00  
  Black 4754 11.9 0.80 (0.64-0.99) 0.042 
  Other 223 13.0 0.89 (0.57-1.37) 0.594 
  Hispanic 0    
 Birth region In study region 833 14.8 1.00  
  Abroad 4919 11.8 0.77 (0.62-0.95) 0.014 
 IDU Non-IDU 5620 11.9 1.00  
  IDU 189 22.2 2.12 (1.49-3.01) <0.001 
 Clinical status No symptoms 4533 11.8 1.00  
  Symptoms 390 19.0 1.74 (1.33-2.28) <0.001 
  Year   5809   1.00 (0.96-1.03) 0.772 
 
NA, not applicable.
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IDU was strongly associated with prematurity in all three studies, with unadjusted 
ORs ranging from 1.7 to 2.1. Maternal age at delivery was available in the ECS and 
NSHPC; there was no evidence of a U-shaped association between maternal age and 
prematurity (Table 5.16), as reported for the general population (Slattery & 
Morrison, 2002), although this may have been due to small numbers. In the ECS, 
older mothers were marginally more likely to deliver prematurely than younger 
mothers (Table 5.17). Parity was not associated with prematurity in the NSHPC, but 
in the ECS, prematurity rates were higher among parous than nulliparous women 
(Table 5.17).  
 
Table 5.16 Maternal age and prematurity in ART-treated women 
 
Maternal age (years) n 
Prematurity 
rate OR (95% CI) p-value 
ECS      
14-19 56 10.7 0.73 (0.30-1.74) 0.473 
20-24 321 13.4 0.94 (0.64-1.38) 0.737 
25-29* 684 14.2 1.00   
30-34 765 15.7 1.13 (0.84-1.50) 0.423 
35-39 424 18.4 1.36 (0.98-1.89) 0.062 
≥40 101 13.9 0.97 (0.53-1.78) 0.931 
NSHPC      
14-19 200 11.5 1.03 (0.65-1.62) 0.904 
20-24 859 11.6 1.04 (0.81-1.34) 0.744 
25-29* 1908 11.2 1.00   
30-34 1776 12.8 1.17 (0.96-1.42) 0.130 
35-39 896 13.8 1.27 (1.00-1.61) 0.047 
≥40 141 11.4 1.01 (0.59-1.74) 0.962 
 
* Baseline. 
 191 
Table 5.17 Rates and unadjusted odds ratios for prematurity in ART-treated 
women in the ECS and NSHPC 
 
n
% pre-
term OR  ( 95% CI)
p -
value n
% pre-
term OR  ( 95% CI)
p -
value
Maternal age 
(years)
<25 377 13.0 1.00 1059 11.6 1.00
25-34 1449 15.0 1.18 (0.85-1.65) 0.332 3684 12.0 1.04 (0.84-1.28) 0.734
≥35 525 17.5 1.42 (0.98-2.07) 0.066 1037 13.5 1.19 (0.92-1.54) 0.193
Parity (live births 
+ stillbirths)
0 1106 12.7 1.00 1705 12.8 1.00
1 748 15.9 1.31 (1.00-1.70) 0.048 1772 11.7 0.90 (0.74-1.11) 0.321
2 343 19.0 1.61 (1.17-2.23) 0.004 895 12.3 0.95 (0.74-1.21) 0.686
3 or more 198 17.7 1.48 (0.99-2.22) 0.058 584 13.0 1.02 (0.77-1.34) 0.916
CD4 count 
(cells/µl)
≥500 762 11.0 1.00 1593 10.5 1.00
350-499 527 13.5 1.26 (0.90-1.76) 0.185 1163 11.4 1.10 (0.87-1.40) 0.428
200-349 464 18.5 1.84 (1.33-2.54) <0.001 1275 12.5 1.23 (0.97-1.54) 0.084
<200 207 21.3 2.18 (1.46-3.26) <0.001 596 14.8 1.48 (1.12-1.95) 0.006
Missing 536 16.8 1.63 (1.18-2.24) 0.003 1182 13.7 1.36 (1.08-1.71) 0.010
Viral load 
(copies/ml)
<50 692 13.2 1.00 2646 10.1 1.00
50-999 524 16.8 1.33 (0.97-1.83) 0.076 1139 12.6 1.28 (1.03-1.59) 0.023
1000-9999 252 17.5 1.40 (0.94-2.07) 0.095 537 16.4 1.75 (1.35-2.28) <0.001
≥10,000 153 20.3 1.68 (1.07-2.64) 0.025 384 16.1 1.72 (1.28-2.33) <0.001
Missing 875 13.8 1.06 (0.79-1.42) 0.697 1103 13.7 1.42 (1.15-1.76) 0.001
ECS NSHPC
 
* Includes viral loads reported as ‘<200 copies/ml’ or ‘<400 copies/ml’ (n=336 in the ECS; n=162 in 
the NSHPC)
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Maternal clinical status at delivery was strongly associated with prematurity in both 
the PSD and NSHPC with ORs of 2.0 and 1.7 respectively, for symptomatic 
compared with asymptomatic women (Table 5.15, page 189). A comparable variable 
was only available for about 40% of ECS mothers, but CD4 cell count, a related 
variable, was available for about 78% of mothers in both the ECS (2114/2686) and 
NSHPC (4627/5934). In the NSHPC, although mothers with low CD4 count (<200 
cells/µl) were over 3.5 times more likely to have HIV-related symptoms reported 
than those with high CD4 count (≥500 cells/µl) (16.8%, 93/555, versus 5.1%, 
76/1490), over 80% of all those with low CD4 count were asymptomatic. Compared 
with a CD4 count of ≥500 cells/µl, CD4 <200 cells/µl was associated with a two-fold 
increased risk of prematurity in the ECS, and a 1.5-fold increased risk in the NSHPC 
(Table 5.17). Prematurity rates among those with missing CD4 count were not 
significantly different from those with CD4 reported: 16.8% (90/536) versus 14.5% 
(285/1960) in the ECS (p=0.196), and 13.7% (162/1182) versus 11.8% (548/4627) in 
the NSHPC (p=0.081). High viral load was also associated with a significantly 
increased risk of prematurity (Table 5.17). 
Multivariable risk factors for prematurity 
Basic multivariable logistic regression models were developed (Figure 5.8, page 
187), initially including only covariates common to all three studies (ART, ethnic 
group, region of birth, IDU and year) (Table 5.18). Year of delivery was considered a 
possible confounder because underlying trends in the baseline prematurity rate could 
result from changes over time in unmeasured risk factors for prematurity, such as the 
prevalence of other sexually transmitted infections.  
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ART was independently associated with prematurity in all three studies after 
adjusting for ethnicity, region of birth, IDU and year of delivery; however, in the 
PSD dual therapy was associated with a significantly reduced risk of prematurity 
compared with monotherapy (AOR=0.76), while in the ECS and NSHPC, HAART 
was associated with a significantly increased risk of prematurity (AOR=1.79 and 
1.38, respectively) (Table 5.18). The increased risk of prematurity (AOR=1.35) 
among black women in the PSD became significant only after adjusting for other risk 
factors, whereas in the ECS and NSHPC, the borderline association with ethnicity 
disappeared in the adjusted models, probably because it was driven by high rates of 
IDU in white women (shown in Table 5.11, page 175). Being born outside the study 
region was associated with a reduced risk of prematurity in all three studies; 
however, because of the substantial overlap between maternal ethnic origin and 
region of birth in the ECS and NSHPC (as described earlier, page 174), this 
association lost significance in the adjusted models. In all three studies, IDU was 
strongly associated with prematurity, with AORs ranging from 1.8-2.2; adjusting for 
ART, ethnicity, region of birth and year led to an increase in the ORs for IDU (Table 
5.18), due to the association between IDU and ethnic group in the PSD (Table 5.11, 
page 175), and IDU and ART in the NSHPC (Table 5.1, page 149) and ECS. In the 
PSD, year of delivery was not associated with prematurity in univariable analysis, 
but in the adjusted model was associated with a borderline significant 4% increase in 
prematurity per year (p=0.055). In the ECS, the borderline association between year 
of delivery and prematurity in univariable analysis was removed by adjusting for 
other risk factors. 
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Table 5.18 Unadjusted and adjusted odds ratios for prematurity in ART-
treated women (basic models) 
 
    Univariable Multivariable 
    OR ( 95% CI) p-
value AOR ( 95% CI) 
p-
value 
PSD ART (n=6101)  (n=5056)  
 Monotherapy 1.00 
 
1.00 
 
 Dual therapy 0.79 (0.64-0.98) 0.029 0.76 (0.59-0.98) 0.037 
 HAART 0.99 (0.85-1.14) 0.865 0.88 (0.69-1.13) 0.326 
 Ethnic origin     
 White 1.00 
 
1.00 
 
 Black 1.16 (0.91-1.48) 0.222 1.35 (1.03-1.77) 0.027 
 Other 0.73 (0.46-1.17) 0.196 1.00 (0.59-1.70) 0.993 
 Hispanic 0.90 (0.69-1.16) 0.418 1.02 (0.76-1.35) 0.918 
 Region of birth     
 In study region 1.00 
 
1.00 
 
 Abroad 0.70 (0.57-0.86) 0.001 0.77 (0.62-0.96) 0.018 
 IDU     
 Non-IDU 1.00 
 
1.00 
 
 IDU 1.74 (1.42-2.13) <0.001 1.88 (1.49-2.37) <0.001 
  Year 1.01 (0.99-1.03) 0.466 1.04 (1.00-1.08) 0.055 
ECS ART (n=2496)   (n=2318)  
 Monotherapy 1.00 
 
1.00 
 
 Dual therapy 0.89 (0.58-1.38) 0.611 0.93 (0.57-1.50) 0.754 
 HAART 1.60 (1.23-2.09) 0.001 1.79 (1.24-2.60) 0.002 
 Ethnic origin     
 White 1.00 
 
1.00 
 
 Black 0.79 (0.63-1.01) 0.058 1.27 (0.61-2.65) 0.516 
 Other 1.23 (0.75-1.99) 0.412 1.91 (0.87-4.20) 0.107 
 Hispanic NA   NA   
 Region of birth     
 In study region 1.00 
 
1.00 
 
 Abroad 0.81 (0.65-1.02) 0.077 0.74 (0.36-1.52) 0.411 
 IDU     
 Non-IDU 1.00 
 
1.00 
 
 IDU 1.68 (1.32-2.13) <0.001 1.83 (1.36-2.46) <0.001 
  Year 1.03 (1.00-1.07) 0.074 1.00 (0.95-1.05) 0.958 
NSHPC ART (n=5808)  (n=5722)  
 Monotherapy 1.00 
 
1.00 
 
 Dual therapy 0.85 (0.49-1.48) 0.565 0.78 (0.45-1.37) 0.386 
 HAART 1.28 (1.02-1.61) 0.031 1.38 (1.08-1.77) 0.011 
 Ethnic origin     
 White 1.00 
 
1.00 
 
 Black 0.80 (0.64-0.99) 0.042 1.19 (0.82-1.73) 0.355 
 Other 0.89 (0.57-1.37) 0.594 1.27 (0.76-2.11) 0.360 
 Hispanic NA   NA   
 Region of birth     
 In study region 1.00 
 
1.00 
 
 Abroad 0.77 (0.62-0.95) 0.014 0.76 (0.54-1.07) 0.111 
 IDU     
 Non-IDU 1.00 
 
1.00 
 
 IDU 2.12 (1.49-3.01) <0.001 2.16 (1.43-3.26) <0.001 
  Year 1.00 (0.96-1.03) 0.772 0.98 (0.95-1.02) 0.314 
 
Multivariable AORs adjusted for ART, maternal ethnic origin, region of birth, IDU and year.
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Interactions between ART and other risk factors 
Interactions between ART and other variables were assessed first using stratified 
Mantel-Haenszel ORs, and then through the addition of interaction terms to the 
multivariable logistic regression models presented in Table 5.18. There was no 
evidence of any significant interactions in the ECS or NSHPC. In the PSD, there was 
some evidence of an interaction between ART and maternal ethnicity (test of 
homogeneity of ORs: p=0.0217): in univariable analysis, white and Hispanic women 
tended to be more likely to deliver prematurely if they were on HAART than if they 
were on monotherapy, while black women and those of other ethnic groups tended to 
be less likely to deliver prematurely (Table 5.19). Stratified odds ratios were 
calculated for each ethnic group separately. After adjusting for IDU and year, the 
differences in the association between ART and prematurity across ethnic groups 
were less clear (Table 5.19). The increased unadjusted OR for the association 
between ART and prematurity among white women in the PSD was explained by 
differences in prematurity rates over time in this group, possibly relating to changes 
in the risk profile of these women. Rates were 13.0% (78/601) before 2000, when 
monotherapy was more common, and 23.6% (46/195) in 2000-2004 (p<0.001), when 
HAART was more common; however, within each time period there was no 
association between HAART and prematurity. 
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Table 5.19 ART and prematurity stratified by ethnic group in the PSD  
 
    
 HAART versus monotherapy 
  n  OR (95% CI) 
p-
value AOR (95% CI) 
p-
value 
Ethnic group      
White  470 1.55 (0.94-2.57) 0.087 0.74 (0.35-1.56) 0.427 
Black 2829 0.86 (0.71-1.04) 0.122 0.81 (0.61-1.08) 0.148 
Hispanic 1668 0.46 (0.18-1.20) 0.111 0.44 (0.13-1.45) 0.177 
Other 176 1.20 (0.92-1.56) 0.186 1.17 (0.77-1.77) 0.460 
 
* Adjusted for injecting drug use and year 
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Effect of study site and repeat pregnancies 
All three studies were set across wide geographical areas, covering different 
countries, states and regions, and data were collected from different sites. The PSD 
included eight sites, distributed across seven US states, the ECS included 30 centres 
distributed across nine countries, and NSHPC data came from 205 hospitals 
distributed across 14 countries or regions (Ireland, Northern Ireland, Scotland, 
Wales, and 10 English regions). Differences in the HIV epidemiology, baseline 
population characteristics and clinical practice between areas included within a study 
may also be associated with variation in unmeasured baseline risk factors for 
prematurity. For example, in the PSD there were substantial differences in maternal 
ethnicity between the eight study sites: almost all mothers in Puerto Rico (99.8%) 
were Hispanic, as were half of mothers in California, whereas in New York and 
North Carolina, 80-85% of women were black. Although it was possible to control 
for ethnicity in the analysis, these disparities suggest that there may be differences in 
other, unmeasured risk factors for prematurity between sites (e.g. socio-demographic 
factors, smoking, parity, etc). In order to address this potential variation, models 
were fitted including a random effect term for study site, which adjusts for 
differences between sites attributable to unobserved variables (Rabe-Hesketh, 
Skrondal, & Pickles, 2002). Study site referred to PSD site, ECS study centre and 
NSHPC hospital. In addition, NSHPC and ECS models were adjusted for repeat 
pregnancies, using a random effect term for maternal identity.  
In the PSD, the random effect term for study site was significant only in the 
unadjusted model, suggesting that although there were baseline differences in 
prematurity between sites, they were explained by the variables included in the 
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multivariable model (Table 5.20); ORs for the association between ART and 
prematurity were not altered by the inclusion of random effect terms in either the 
univariable or the multivariable model. In the ECS, including a term for study centre 
significantly improved both the univariable and multivariable models (Table 5.20), 
as assessed by LRTs, and caused the OR and AOR for the association between ART 
and prematurity to increase by 10-15%. Including a random effect term on NSHPC 
hospital had very little effect on the overall estimates and did not improve the models 
(Table 5.20), nor did fitting a term on UK region/country (n=14; LRT, p=1.000).  
In the ECS and NSHPC, it was also possible to adjust for effects associated with 
repeat pregnancies, using a random effect term on maternal identity. This 
significantly improved the models in both the ECS and NSHPC (Table 5.20). In the 
ECS, adjusting for unmeasured effects attributable to the mother led to over a 30% 
increase in the ORs (OR: 1.60 to 2.13; AOR: 1.79 to 2.36) for the association 
between ART and prematurity, whereas in the NSHPC, there was only a moderate 
(<10%) increase in the ORs.
 199 
Table 5.20 Logistic regression models for ART and prematurity including 
random effects on study site and mother  
 
Univariable Multivariable*
OR                    AOR
( 95% CI) ( 95% CI)
PSD
Basic model 0.99  (0.85-1.14) 0.865 0.88  (0.69-1.13) 0.326
+ site (RE) 0.99  (0.85-1.15) 0.895 0.008 0.89  (0.69-1.13) 0.335 0.372
ECS
Basic model 1.60  (1.23-2.09) 0.001 1.79  (1.24-2.60) 0.002
+ site (RE) 1.78  (1.33-2.37) <0.001 <0.001 2.17  (1.46-3.22) <0.001 <0.001
+ mother (RE) 2.13  (1.35-3.36) 0.001 <0.001 2.36  (1.30-4.29) 0.005 <0.001
NSHPC
Basic model 1.28  (1.02-1.61) 0.031 1.38  (1.08-1.77) 0.011
+ site (RE) 1.28  (1.02-1.61) 0.031 0.490 1.38  (1.08-1.77) 0.011 0.491
+ mother (RE) 1.34  (1.00-1.78) 0.048 <0.001 1.48  (1.08-2.02) 0.015 <0.001
p -value 
(LRT)**
HAART vs. 
monotherapy p -value
p -value 
(LRT)** p -value
 
 
LRT, likelihood ratio test; RE, random effects. 
All models included three levels of ART (monotherapy, dual therapy and HAART), but only odds 
ratios for HAART compared with monotherapy are shown.  
* Adjusting for maternal ethnic origin, region of birth, IDU, and year of delivery.  
** p-value relates to LRT for inclusion of random effect term.  
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Risk factors for prematurity adjusting for clinical and immunological factors  
Logistic regression models were then expanded to include the additional covariates 
that were not available for all of the studies – maternal age, parity, clinical status and 
CD4 count – as well as the random effect terms, where appropriate. The optimal 
model was then selected for each study, based on inclusion of each covariate and 
assessment with LRTs (Table 5.21).  
Factors significantly and consistently associated with prematurity in all the models 
(where available) included ART, IDU, clinical status and CD4 count. Compared with 
monotherapy, HAART was associated with a two-fold and 1.5-fold increased risk of 
prematurity in the ECS and NSHPC respectively, and dual therapy with 25% 
reduction in risk in the PSD; HAART was not associated with prematurity in the 
PSD when monotherapy was used as the baseline group. Despite differences between 
studies in the way IDU was measured and in the proportion of women with IDU 
reported, there was a consistent two-fold increased risk of prematurity associated 
with this group in all three studies. Maternal HIV symptoms were associated with a 
1.9-fold increased risk of prematurity in both the PSD and NSHPC. Because the 
inclusion of symptoms in the PSD model reduced the sample by about a third (from 
6101 to 3877), an alternative model was fitted with three levels for clinical status: 
asymptomatic, symptomatic and missing. Results were very similar (AOR for 
HAART versus monotherapy = 0.88, 95% CI: 0.70-1.09, p=0.243), and having 
missing information on symptoms was not associated with an increased risk of 
prematurity (AOR=1.12, 95% CI: 0.96-1.31, p=0.141). Low CD4 cell count was also 
consistently associated with prematurity, but the AOR was greater and more highly 
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significant in the ECS (AOR=2.47 for CD4 <200 cells/µl compared with ≥500 
cells/µl, p<0.001) than in the NSHPC (AOR=1.54, p=0.028).  
Maternal age was not significantly associated with prematurity in either the ECS or 
the NSHPC and was therefore excluded from the models. Maternal ethnic group, 
region of birth and year of delivery were not significant risk factors in the ECS or 
NSHPC, after adjusting for other factors, but black ethnicity remained significantly 
associated with prematurity in the PSD model (AOR=1.55, compared with white 
ethnicity), and baseline prematurity rates increased by an average of 5% per year 
(AOR=1.05), irrespective of other measured risk factors (Table 5.21). Parity was 
significantly associated with prematurity in the ECS but not the NSHPC; because 
prematurity rates were similar in women with one, two, or at least three previous live 
births or stillbirths, parity was recoded as a binary variable. The ECS model was 
adjusted for random effects attributable to the study site and to the mother, and the 
NSHPC model for random effects attributable to the mother. 
Although in the ECS and NSHPC viral load was also significantly associated with 
prematurity in univariable analyses, models were not adjusted for both viral load and 
CD4 count, due to collinearity. However, adjusting for viral load instead of CD4 
count (in addition to the covariates shown in Table 5.21) yielded similar results in the 
ECS, with an AOR of 2.90 (95% CI: 1.68-4.99, p<0.001, n=2460) for the association 
between HAART and prematurity, compared with monotherapy; in the NSHPC, the 
AOR increased from 1.47 in the model with CD4 count (Table 5.21) to 2.14 (95% 
CI: 1.51-3.03, p<0.001, n=4923) in the model with viral load. 
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Table 5.21 Significant risk factors for prematurity; results of logistic 
regression models developed separately for each study  
 
n AOR 95% CI p -value
PSD (n =3404)
ART Monotherapy 1659 1.00
Dual therapy 661 0.74 (0.54-1.02) 0.067
HAART 1557 0.92 (0.67-1.26) 0.598
Ethnic origin White 439 1.00
Black 1758 1.55 (1.13-2.12) 0.006
Other 103 1.19 (0.59-2.36) 0.629
Hispanic 1577 1.08 (0.78-1.49) 0.655
Region of birth United States 3418 1.00
Elsewhere 459 0.77 (0.59-1.00) 0.053
IDU Non-IDU 3418 1.00
IDU 459 1.97 (1.51-2.57) <0.001
Maternal symptoms Asymptomatic 3480 1.00
Symptomatic/AIDS 397 1.99 (1.53-2.59) <0.001
Year of delivery Per year 3877 1.05 (1.00-1.11) 0.053
ECS (n =2367)
ART Monotherapy 662 1.00
Dual therapy 277 0.80 (0.36-1.75) 0.571
HAART 1428 2.92 (1.53-5.56) 0.001
IDU Non-IDU 1795 1.00
IDU 572 3.78 (1.84-7.78) <0.001
Parity Nulliparous 1832 1.00
Parous 535 2.27 (1.27-4.02) 0.005
CD4 count (cells/µl) ≥500 723 1.00
350-499 497 1.45 (0.79-2.64) 0.232
200-349 438 2.53 (1.23-5.19) 0.012
<200 200 4.46 (1.69-11.72) 0.002
missing 509 2.34 (1.13-4.88) 0.023
Centre (random effect) constant 31 groups 1.00 (0.59-1.73) <0.001*
Mother (random effect) constant 2180 groups 4.46 (1.25-4.65) <0.001*
NSHPC (n =4923)
ART Monotherapy 874 1.00
Dual therapy 138 0.55 (0.24-1.29) 0.169
HAART 3911 1.47 (1.07-2.02) 0.017
IDU Non-IDU 4794
IDU 129 2.13 (1.13-3.99) 0.019
Maternal symptoms Asymptomatic 4533
Symptomatic/AIDS 390 1.87 (1.28-2.73) 0.001
CD4 count (cells/µl) ≥500 1490
350-499 1108 1.09 (0.79-1.49) 0.604
200-349 1184 1.24 (0.91-1.70) 0.168
<200 555 1.54 (1.05-2.26) 0.028
missing 586 1.84 (1.26-2.70) 0.002
Mother (random effect) constant 4333 groups 0.44 (0.27-0.61) <0.001*
 
 
 
* p-value for likelihood ratio test for inclusion of random effect terms. 
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ART and severe prematurity (<32 weeks) 
The association between ART and severe prematurity (<32 weeks) was also 
investigated. Similar models to those in Table 5.21 were fitted, but due to the fact 
that very few women had more than one delivery at <32 weeks (three in the ECS, 
four in the NSHPC), the ECS and NSHPC models were not adjusted for repeat 
pregnancies. As shown previously in the NSHPC (page 160), the association between 
HAART and prematurity was stronger when 32 weeks was used as a cut-off, with 
about a two-fold increase in severe prematurity both in univariable and multivariable 
analysis, adjusting for IDU, clinical status and CD4 count (Table 5.22). Due to small 
numbers, the dual therapy group in the NSHPC was omitted from the model. In the 
ECS, HAART was associated with over a 3.5-fold increase in severe prematurity, 
after adjusting for IDU, parity, CD4 count and centre. In the PSD, however, severe 
premature delivery was reduced in women on dual therapy or HAART compared 
with monotherapy, although this was only of borderline significance (Table 5.22).
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Table 5.22 ART and severe prematurity (<32 weeks gestation)  
 
% <32 
weeks
n   
(OR) OR (95% CI) p -value
n 
(AOR) AOR (95% CI) p -value
PSD
Monotherapy 2.8 2537 1.00 1427 1.00
Dual therapy 2.3 957 0.82 (0.50-1.33) 0.414 605 0.50 (0.24-1.05) 0.065
HAART 2.5 2570 0.89 (0.63-1.25) 0.493 1356 0.51 (0.25-1.04) 0.065
ECS  
Monotherapy 1.0 733 1.00 690 1.00
Dual therapy 1.6 308 1.71 (0.54-5.43) 0.362 291 1.00 (0.26-3.92) 0.996
HAART 3.5 1604 3.75 (1.70-8.27) 0.001 1531 3.73 (1.67-8.32) 0.001
NSHPC  
Monotherapy 1.4 957 1.00 874 1.00
Dual therapy 1.1 181 0.81 (0.18-3.63) 0.784 - -
HAART 2.6 4671 1.93 (1.09-3.44) 0.025 3911 2.06 (1.09-3.88) 0.026
Multivariable*Univariable
 
 
* AORs in the PSD adjusted for maternal ethnicity, region of birth, IDU, symptoms and year of 
delivery; in the ECS for IDU, CD4 count, and site; and in the NSHPC for IDU, symptoms and CD4 
count. 
N.B. Dual therapy was dropped from the NSHPC multivariable model due to small numbers.
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Protease inhibitors 
Both PI- and non-PI-based HAART were associated with an increased risk of 
prematurity in the ECS and NSHPC, compared with monotherapy (Table 5.23). 
Prematurity rates in the PSD were slightly higher with PI-based HAART (17.3%) 
than with non-PI-based HAART (15.5%), but the difference was not statistically 
significant (p=0.251). 
 
 
Table 5.23 ART and prematurity: HAART with and without protease 
inhibitors  
 
      Univariable Multivariable* 
  n  
% pre-
mature OR (95% CI) 
p-
value AOR (95% CI) 
p-
value 
PSD       
Monotherapy 2552 16.9 1.00  1.00  
Dual therapy 958 13.9 0.79 (0.64-0.98) 0.029 0.74 (0.54-1.02) 0.067 
HAART, non-PI 788 15.5 0.90 (0.72-1.12) 0.340 0.89 (0.61-1.31) 0.566 
HAART, PI 1802 17.3 1.03 (0.88-1.21) 0.739 0.93 (0.67-1.29) 0.665 
ECS         
Monotherapy 703 11.7 1.00  1.00  
Dual therapy 294 10.5 0.89 (0.58-1.38) 0.611 0.80 (0.36-1.76) 0.573 
HAART, non-PI 591 18.1 1.67 (1.23-2.29) 0.001 2.77 (1.38-5.56) 0.004 
HAART, PI 908 17.1 1.56 (1.17-2.08) 0.003 3.04 (1.51-6.13) 0.002 
NSHPC         
Monotherapy 957 10.2 1.00  1.00  
Dual therapy 181 8.8 0.85 (0.49-1.48) 0.565 0.55 (0.24-1.29) 0.168 
HAART, non-PI 2244 12.8 1.29 (1.01-1.64) 0.043 1.43 (1.02-2.02) 0.039 
HAART, PI 2418 12.8 1.28 (1.01-1.63) 0.042 1.51 (1.08-2.11) 0.017 
 
*AORs in the PSD adjusted for maternal ethnicity, region of birth, IDU, symptoms and year of 
delivery; in the ECS for IDU, CD4 count, site and mother; and in the NSHPC for IDU, symptoms, 
CD4 count, and mother. 
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Summary estimates 
ECS and NSHPC 
Due to heterogeneity between the studies, it was not appropriate to calculate an 
overall summary estimate for the association between HAART and prematurity in 
relation to monotherapy. However, as there was no evidence of heterogeneity 
between the ECS and the NSHPC (χ2=1.58, df=1, p=0.209), these two studies were 
combined. Only statistically significant variables that were available in both studies 
were included. The overall OR for HAART-associated prematurity compared with a 
baseline of monotherapy was 1.41 (95% CI: 1.19-1.68, p<0.001, n=8305) adjusting 
only for study, 1.47 (95% CI: 1.23-1.76, p<0.001, n=8269) adjusting for IDU and 
CD4 cell count as well as study, and 1.36 (95% CI: 1.07-1.72, p=0.011, n=6305) 
adjusting also for log10 viral load.  
Dual therapy baseline 
Since there was no significant evidence of heterogeneity between the studies when 
dual therapy was selected as a reference group (see page 188), a pooled estimate for 
the association between HAART and prematurity was obtained by combining the 
three studies. For this analysis, variables had to be consistent across the studies; 
maternal ethnic group was therefore classified as white, black or other (including 
Hispanic); and in order to adjust for maternal clinical status, CD4 cell count was used 
as a proxy for symptoms in the ECS (women with CD4 <200 cells/µl were classified 
as symptomatic). Three models were developed (Table 5.24): the first was adjusted 
only for study (model 1); the second also for ethnic group, region of birth, IDU, and 
year of delivery, but not clinical status due to the high proportion of women with 
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missing information on this variable (model 2); the third also for clinical status 
(model 3).  
HAART was strongly associated with premature delivery in all three models (Table 
5.24); in the final model (model 3), HAART was associated with a 1.5-fold increased 
risk of prematurity compared with dual therapy, after adjusting for study, ethnic 
group, region of birth, IDU, clinical status and year. Monotherapy was associated 
with a small but significant increase in prematurity (OR=1.22, p=0.026) compared 
with dual therapy in the first model (adjusted only for study), but the effect was 
reduced and non-significant in the adjusted models. 
Study was significantly associated with prematurity in the first model, reflecting the 
lower baseline prematurity rates in the ECS and NSHPC, compared with the PSD; 
after adjusting for the other variables, this association was reduced, suggesting that 
baseline differences in prematurity between the studies were partly explained by 
these other factors. Although only borderline significant, prematurity remained 
slightly lower in the NSHPC compared with the PSD, but the differences between 
the ECS and PSD disappeared.  
IDU and clinical status were both strongly associated with prematurity, with AORs 
around 1.8-1.9. Being born abroad was associated with a significantly lower risk of 
prematurity (final model, AOR=0.71). Although region of birth was not significant in 
the ECS or NSHPC models presented earlier (Table 5.18), the AORs were consistent 
with those for the PSD, and there was no evidence of interaction between study and 
region of birth (Mantel-Haenszel test for homogeneity of ORs, p=0.579).  
Homogeneity tests on unadjusted stratified ORs indicated no evidence of interaction 
between study and region of birth, IDU or symptoms; there was, however interaction 
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between study and both ethnic group and year, consistent with earlier results. 
Excluding these two variables from the final model did not substantially alter the 
results (data not shown).
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Table 5.24 Summary adjusted odds ratios for the association between HAART and prematurity compared with dual therapy 
 
  Model 1  (n=14,406) Model 2  (n=13,096) Model 3  (n=10,110) 
  AOR ( 95% CI) p-value AOR ( 95% CI) p-value AOR ( 95% CI) p-value 
ART          
Monotherapy 1.22 (1.02-1.46) 0.026 1.17 (0.96-1.42) 0.129 1.13 (0.89-1.43) 0.319 
Dual therapy 1.00   1.00   1.00   
HAART 1.41 (1.19-1.68) <0.001 1.44 (1.19-1.73) <0.001 1.50 (1.20-1.88) <0.001 
Study          
PSD 1.00 
 
 1.00 
 
 1.00 
 
 
ECS 0.87 (0.77-1.00) 0.042 0.94 (0.78-1.13) 0.508 0.93 (0.75-1.16) 0.529 
NSHPC 0.66 (0.59-0.74) <0.001 0.79 (0.66-0.95) 0.012 0.81 (0.66-1.01) 0.057 
Ethnic origin          
White  
 
 1.00 
 
 1.00 
 
 
Black    1.32 (1.10-1.58) 0.002 1.48 (1.20-1.82) <0.001 
Other/Hispanic    1.10 (0.88-1.37) 0.397 1.17 (0.92-1.50) 0.205 
Region of birth          
In study region  
 
 1.00 
 
 1.00 
 
 
Abroad    0.73 (0.62-0.86) <0.001 0.71 (0.59-0.86) <0.001 
IDU          
Non-IDU  
 
 1.00 
 
 1.00 
 
 
IDU    1.85 (1.57-2.18) <0.001 1.93 (1.59-2.33) <0.001 
Year 
         
Per year  
 
 1.00 (0.98-1.03) 0.686 1.01 (0.98-1.04) 0.476 
Clinical status          
Asymptomatic/CD4≥200       1.00 
 
 
Symptomatic/CD4<200             1.82 (1.54-2.16) <0.001 
 
Model 1 adjusted only for study, model 2 for all other variables except symptoms/CD4, and model 3 adjusted also for symptoms/CD4.
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Conclusions 
There were significant differences between the PSD, ECS and NSHPC in the 
association between ART and prematurity; in the ECS and NSHPC, HAART was 
associated with a significantly increased risk of prematurity compared with 
monotherapy, whereas no such association was observed in the PSD. These 
differences remained when controlling for other prematurity risk factors, some of 
which were consistently associated with prematurity (IDU, symptoms, CD4 count), 
and were also apparent when a lower gestational age (32 weeks) was used as a cut-
off. Both PI- and non-PI-based HAART were significantly associated with 
prematurity in the ECS and NSHPC. The heterogeneity between studies was also not 
explained by adjusting for random effects attributable to study sites. However, it was 
not possible to control for some factors in the PSD, including maternal CD4 cell 
count and repeat pregnancies, both of which had significant effects on the HAART-
prematurity association in the other two studies; it is possible that the difference in 
prematurity between HAART and monotherapy could be due to the inability to 
adjust for these factors in the PSD.   
In all three studies, the risk of prematurity was higher in women on HAART than in 
those on dual therapy. In a pooled analysis, HAART was associated with a 1.5-fold 
increased risk of prematurity compared with dual therapy, after adjusting for study, 
ethnic group, region of birth, IDU, year and clinical status or CD4 count.  
In conclusion, pooling data from these three studies revealed a statistically 
significant association between HAART and prematurity compared with dual 
therapy, but there was heterogeneity between studies when monotherapy was chosen 
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as a baseline, which could not clearly be explained by methodology or study-specific 
factors on which information was available. 
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5.4 Key Points 
Prematurity in the NSHPC 
• In the NSHPC, HAART was associated with a 1.6-fold increased risk of 
premature delivery, compared with mono/dual therapy, which remained after 
adjusting for clinical status, injecting drug use, ethnic origin and maternal age.  
• Low CD4 cell count and high viral load were also independently associated with 
an increase in prematurity, and adjusting for these factors did not explain the 
differences observed by type of ART. 
• The association between HAART and prematurity was stronger for earlier 
gestational ages, with over a 2.5-fold increased risk of delivery at <35 or <32 
weeks gestation.  
• Among women on HAART, prematurity rates did not differ by class of drugs 
(PIs and/or NNRTIs). 
• Later initiation of HAART was associated with significantly reduced prematurity 
rates. After excluding women who started HAART after 26 weeks to avoid 
possible selection bias, later initiation was associated with a 10% reduction in 
prematurity per week of gestation without HAART. 
• Findings were robust across different subgroups, including pregnancies in parous 
and nulliparous women, those before and after 2000, and after excluding 
stillbirths, dual therapy exposures and ART early in pregnancy. 
• Infants exposed to HAART were slightly but significantly lighter for their 
gestational age, compared with those exposed to monotherapy. 
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Comparative analysis 
• There were substantial differences between the PSD, ECS and NSHPC in the 
distribution of births over time, maternal characteristics, uptake of interventions, 
and baseline prematurity rates. 
• There were differences in use of ART between studies, overall and within 
different time periods.  
• IDU and maternal clinical and immunological factors (symptoms, CD4 cell count 
and viral load) were consistently associated with prematurity in the three studies, 
but maternal ethnic origin and year of delivery were only independently 
associated with prematurity in the PSD. 
• ART was significantly associated with prematurity in all three studies; compared 
with monotherapy, dual therapy was associated with lower prematurity rates in 
the PSD, whereas HAART was associated with increased prematurity rates in the 
ECS and NSHPC. 
• With monotherapy as a baseline, there was significant heterogeneity between the 
studies in the association between HAART and prematurity, and it was therefore 
not appropriate to pool the studies for this comparison.  
• Population characteristics did not explain the differences in the HAART-
prematurity relationship; adjusting for IDU, ethnic group, year of delivery, and 
clinical and immunological factors did not substantially alter the association 
between treatment and prematurity, and did not remove the differences between 
studies.  
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• Heterogeneity between studies remained in analyses involving type of HAART 
(PI or other) and a prematurity cut-off of <32 weeks, and after adjusting for study 
site and repeat pregnancies. 
• There was no significant heterogeneity between studies with dual therapy as a 
baseline, and pooling the data from the three studies revealed an overall 1.5-fold 
increased risk of prematurity associated with HAART, after adjusting for other 
risk factors. 
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Chapter 6 Modelling the risks and benefits of 
antiretroviral therapy in terms of pregnancy 
outcomes and mother-to-child transmission  
There are clear benefits of antiretroviral therapy (ART) in terms of preventing 
mother-to-child transmission (MTCT), with transmission rates in 2000-2006 around 
1% in women on highly active antiretroviral therapy (HAART) (Chapter 3). 
Nevertheless, there is increasing evidence linking HAART to adverse pregnancy 
outcomes. In this thesis, significant associations have been shown between HAART 
and both stillbirth (Chapter 4) and prematurity (Chapter 5). Early HAART was also 
associated with an increased risk of pre-eclampsia compared with HAART later in 
pregnancy, although this was only borderline significant (Chapter 4). The aim of this 
chapter is to model these risks in relation to the reduction in MTCT rates using 
Monte Carlo simulation methods.  
6.1 Methods 
Risk and benefit estimates 
Since pre-eclampsia in the mother affects the infant mainly by increasing the risk of 
prematurity and low birth weight (Sibai, Dekker, & Kupferminc, 2005), it was not 
addressed as a separate outcome in the analyses; risks and benefits were constrained 
to those directly affecting paediatric outcome. Risk estimates for stillbirth were 
obtained from the models presented in Chapter 4 (page 116), and estimates for 
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prematurity were obtained from Chapter 5 (Tables 5.14, page 186; Table 5.21, page 
202; and Table 5.22, page 204), and are summarised in Table 6.1 in this Chapter. 
MTCT rates were derived specifically for these analyses, as appropriate comparisons 
were not previously shown. In recent years, monotherapy has been recommended 
only for women not needing HAART for their own health, and the transmission rate 
in this group is low. In order to obtain an estimate corresponding to a situation where 
monotherapy is used exclusively, HAART at any time (1990-2006) was compared 
with monotherapy up to 1997 (by 1998 over a third of women were on HAART; 
Figure 3.3, page 83).  
For the baseline scenario, observed prematurity and MTCT rates in women on 
monotherapy were used. To estimate adjusted rates in the HAART group, the 
definition of an odds ratio (OR) was used: ( )( )00
11
1/
1/
pp
ppOR
−
−
=  , where p0 is the rate in 
the unexposed or baseline group (i.e. monotherapy), and p1 is the rate in the exposed 
group (i.e. HAART) (Kirkwood & Sterne, 2003). Since p0 and OR were known, the 
equation could be solved for p1 to give prematurity and transmission rates for the 
HAART group: 
)(1 00
0
1 pORp
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×+−
×
=   Equation 1 
In order to account for confounding, rates for women on HAART were calculated 
using adjusted odds ratios (AORs) estimated in logistic regression models. 
Incremental risk-benefit ratio 
Incremental risks and benefits were calculated as p1 – p0 (rate in HAART-exposed 
women minus rate in monotherapy-exposed women);  R1 – R0 was denoted as 
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incremental risks and B1 – B0 as incremental benefits. The incremental risk-benefit 
ratio (IRBR) is defined as: 
01
01
BB
RR
B
RIRBR
−
−
=
∆
∆
=  Equation 2 
Monte Carlo simulation 
In order to incorporate simultaneously the uncertainty from the risk and benefit 
estimates, Monte Carlo methods suggested by Lynd and O’Brien (Lynd & O'Brien, 
2004) were used to simulate the joint probability densities of incremental benefit 
(MTCT) and incremental risk (prematurity <37 or <32 weeks, or stillbirth). Values 
for proportions were generated from beta probability density functions (Gupta & 
Nadarajah, 2004), in order to account for the fact that normality cannot always be 
assumed when calculating confidence intervals around proportions, which are 
bounded by the interval [0,1] (Lynd & O'Brien, 2004). A brief explanation of beta 
distributions is provided in Appendix 5, and the beta distributions modelling the 
probabilities of prematurity (<37 weeks) and MTCT are shown in Figure 6.1. To 
model the uncertainty relating to the AOR, the estimate of the natural logarithm of 
the AOR (ln(AOR)) was used, since it has better statistical properties than the AOR 
(Kirkwood & Sterne, 2003).  
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Figure 6.1 Beta distributions describing the probability of prematurity and 
mother-to-child transmission (MTCT) in women on monotherapy 
 
0.00 0.05 0.10 0.15 0.20 0.25 0.30
0
10
20
30
40
 
 
 
Beta distribution for prematurity <37 weeks
Pr
ob
ab
ilit
y 
de
ns
ity
Probability of prematurity (<37 weeks)
mean = 0.102
sd = 0.010
0.00 0.05 0.10 0.15 0.20 0.25 0.30
0
5
10
15
20
 
 
Beta distribution for MTCT
Pr
ob
ab
ilit
y 
de
ns
ity
Probability of MTCT
mean = 0.070
sd = 0.019
 
 
 
MTCT, mother-to-child transmission; sd, standard deviation.
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The simulations consisted of repeatedly sampling from the assumed parameters’ 
distributions by randomly selecting values from the beta distributions for the baseline 
proportions and from the normal distributions for ln(AOR), using the following 
algorithm:  
1. A value for the baseline risk ( 0ˆR , denoting sampled 0R ) was sampled from 
the distribution (prematurity or stillbirth) for monotherapy-exposed women, 
and a value for the baseline MTCT rate ( 0ˆB ) was sampled from the MTCT 
distribution for monotherapy-exposed women (Figure 6.2). This was 
replicated 1000 times in order to simulate the joint uncertainty around the 
estimates. 
2. ln(AOR)s for the risks and benefits were also randomly sampled 1000 times 
from the normal distribution, and rates for the HAART group ( 1ˆR  and 1ˆB ) 
were calculated from Equation 1 using the point estimates for risk and benefit 
rates in the baseline group (R0 and B0), and the sampled ln(AOR).  
3. For each of the 1000 realisations, the incremental risk ( 01 ˆˆ RR − ) and 
incremental benefit ( 01 ˆˆ BB − ) were calculated by subtracting the baseline rate 
from the adjusted rate.  
4. The incremental risk-benefit ratio was then calculated for each risk-benefit 
pair. 
So that simulations could be replicated, the same random number seed was fixed at 
the start of each simulation using the function ‘set.seed’ in R version 2.8.0. The 
functions ‘rbeta’ and ‘rnorm’ in R were used to generate values from the beta and 
normal distributions (R Development Core Team, 2006). 
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Confidence intervals  
Calculating confidence intervals for the IRBR is problematic, since ratios can be 
negative and tend not to be normally distributed (Briggs, O'Brien, & Blackhouse, 
2002). For comparison, four different methods were used to calculate confidence 
intervals:  
(1) Crude extrapolation from the point estimates for the baseline rates and the 
confidence intervals around the AORs. 
(2) Calculation of the best and worst case scenarios using the confidence intervals 
around both the baseline and the comparison rates. The lower confidence limit 
corresponds to the ratio of lowest risk to highest benefit, and the upper interval to 
the ratio of highest risk to lowest benefit.  
(3) The confidence box approach (Briggs, Mooney, & Wonderling, 1999), which 
involves plotting the confidence intervals for the risk and benefit differences 
around the point estimate on the risk-benefit plane. These intervals define a box, 
and the slopes of the two rays which bound the box can be taken as confidence 
limits for the ratio.  
(4) Taking the 2.5% and 97.5% quantiles of the data generated by Monte Carlo 
simulation. 
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Figure 6.2 Flowchart showing the simulation algorithm for the Monte Carlo 
risk-benefit model of ART in pregnancy 
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Selective monotherapy scenario 
In the basic model, two scenarios were compared: exclusive HAART and exclusive 
monotherapy. In the UK, zidovudine monotherapy is one of the treatment options for 
women who do not need HAART for their own health and have a baseline viral load 
<6000-10,000 copies/ml, if they are willing to deliver by elective caesarean section 
(BHIVA/CHIVA, 2008). The MTCT rate among the 12% of women on monotherapy 
between 2000 and 2006 was 0.5% (3/638, 95% CI: 0.1-1.4%), and 73% delivered by 
elective caesarean section (Chapter 3). This scenario was modelled by sampling 12% 
of the simulated values (the same proportion as were on monotherapy in 2000-2006) 
from the monotherapy distributions and the remainder from the HAART 
distributions; this scenario was compared with the exclusive HAART scenario. 
Assumptions and sensitivity analysis 
Assumptions 
The only risks included in the analysis were ones that were explored in this thesis 
and directly affected outcomes in the child. Maternal toxicities and adverse events 
were excluded, as were other paediatric outcomes such as mitochondrial toxicity or 
anaemia, which could not be assessed through the National Study of HIV in 
Pregnancy and Childhood (NSHPC). Other benefits of treatment, for instance 
slowing maternal disease progression, were omitted for the same reasons.  
Differences in risks and benefits between the HAART and early (pre-HAART) 
monotherapy groups were considered to be attributable to the treatment only. No 
allowance was made for ART duration or indication for treatment (whether HAART 
was taken for maternal treatment or primarily to prevent MTCT). Although AORs 
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were used to control for other potential risk factors, baseline rates assumed a 
prevalence of other risk factors equivalent to the prevalence in this population 
(described in Chapters 3 and 5). 
Association between MTCT and prematurity 
Although some studies have shown an increased risk of transmission in infants born 
prematurely, preterm delivery appears to have reduced importance as a risk factor for 
MTCT in treated women. This could be a consequence of a differential effect of 
prematurity by viral load or mode of delivery, or because of reduced statistical 
power, given the small number of transmissions in treated women. Prematurity was 
not an independent risk factor for MTCT in this population (as reported in Chapter 
3), and the association observed in the unadjusted analysis was mainly a result of 
reduced maternal exposure to ART and unplanned vaginal delivery, both commonly 
associated with premature delivery. Furthermore, prematurity was not a significant 
risk factor for MTCT in women on HAART.  
However, the effect of an association between prematurity and MTCT was 
investigated in a sensitivity analysis. Models were adapted by incorporating a 
relative risk for the increase in MTCT resulting from premature delivery. For each 
simulation, a transmission rate ( 0ˆB ) was generated from a beta distribution; the 
corresponding transmission rates for premature and term infants were then derived 
using the equations shown in Appendix 6. A sampled prematurity rate was then 
realised ( 0ˆR ), and the sampled transmission rate was adjusted by taking the weighted 
average of the transmission rates in the term and premature groups (Equation 5, 
Appendix 6).  
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6.2 Prematurity and mother-to-child transmission 
Risk and benefit estimates  
The estimates used in the risk-benefit models are shown in Table 6.1. For 
prematurity, estimates were obtained from Chapter 5. For MTCT, rates in women on 
HAART were compared with those in women on monotherapy before HAART 
became available in 1998. Results of this comparison are shown in Table 6.2. 
HAART was associated with an 87% reduction in MTCT compared with pre-1998 
monotherapy (AOR=0.13). Although the transmission rate in this analysis was higher 
in very premature infants than in term infants (6.7% versus 2.7%), there was no 
significant association after adjusting for ART, mode of delivery and sex 
(AOR=1.14, p=0.86).  
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Table 6.1 Prematurity and mother-to-child transmission estimates 
 
  Estimate n SE (95% CI) From 
Prematurity <37 weeks      
Baseline rate, mono (R0) 10.2% 98/957 0.010 (8.4-12.3) Table 5.14, p. 186 
AOR (HAART vs. mono) 1.47  0.237 (1.07-2.02) Table 5.21, p. 202* 
Prematurity <32 weeks      
Baseline rate, mono (R0) 1.4% 13/957 0.004 (0.7-2.3) Table 5.22, p. 204 
AOR (HAART vs. mono) 2.06  0.666 (1.09-3.88) Table 5.22, p. 204 
Stillbirth      
Baseline rate, mono (R0) 0.3% 3/1061 0.002 (0.06-0.82) Table 4.2, p. 117 
AOR (HAART vs. mono) 3.10  1.854 (0.98-10.0) Chapter 4, p. 116 
Mother-to-child transmission      
Baseline rate, mono (B0) 7.0% 12/172 0.019 (3.7-11.9) Table 6.2 
AOR (HAART vs. mono) 0.13   0.048 (0.06-0.27) Table 6.2 
 
SE, standard error. 
* Estimates were taken from Section 5.2, rather than Section 5.1, because stillbirth and prematurity 
are analysed as a separate outcomes in this chapter, and prematurity estimates in Section 5.2 excluded 
stillbirths. Furthermore, the analysis in Section 5.2 was based on a later (and larger) dataset.  
 
Table 6.2 Rates and adjusted odds ratios for mother-to-child transmission, 
comparing HAART (anytime) with monotherapy in the pre-HAART era (before 
1998) 
 
n % n AOR 95% CI p-value
Antiretroviral therapy
Monotherapy (pre-1998) 172 12 7.0 148 1.00
HAART 4282 42 1.0 4171 0.13 (0.06-0.27) <0.001
Mode of delivery
Elective caesarean section 3263 31 1.0 2398 1.00
Emergency caesarean section 1126 21 1.9 902 2.34 (1.12-4.88) 0.024
Vaginal delivery 1310 49 3.7 1019 1.51 (0.76-2.98) 0.238
Gestational age
≥37 weeks 5230 140 2.7 3772 1.00
35-36 weeks 373 10 2.7 271 0.69 (0.21-2.35) 0.557
32-34 weeks 220 7 3.2 171 1.50 (0.49-4.55) 0.478
<32 weeks 135 9 6.7 105 1.14 (0.26-5.08) 0.860
Sex of infant
Male 3091 69 2.2 2155 1.00
Female 3019 99 3.3 2164 2.31 (1.27-4.18) 0.006
Infected Multivariable model (n =4319)n 
(total)
 
 
* Estimates were obtained from a similar dataset used in the MTCT analyses in Chapter 3, but with 
the exclusion of births to women on monotherapy since 2000 (n=638), and the addition of births to 
women on monotherapy before 1998 (n=172) or HAART before 2000 (n=162). 
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Point estimates for the incremental risk-benefit ratio 
The incremental benefit associated with exclusive HAART (versus exclusive 
monotherapy) was a reduction in MTCT of 6.0%, and the incremental risk was an 
increase in prematurity of 4.1% for <37 weeks and 1.4% for <32 weeks. The 
incremental risk-benefit ratio (from Equation 2) was 0.68 premature infants and 0.23 
very premature infants for each infection averted.  
One way of crudely displaying confidence limits for the incremental risks and 
benefits is shown in Figure 6.3, with the horizontal bar corresponding to the 
confidence interval for the incremental MTCT benefits (0.10%, 2.2%), and the 
vertical bar to the confidence interval for the incremental prematurity risk (-0.01%, 
9.3%). The two bars intersect at the point (∆B, ∆R) and the slope of the line passing 
through that point is therefore equal to ∆B/∆R or the incremental risk-benefit ratio. 
The ‘confidence box’ resulting from the two bars can be drawn, and corresponds to 
the combined area of confidence (Briggs, Mooney, & Wonderling, 1999). The slopes 
of the lines that intersect with the corners of the box can be taken as an 
approximation to the 95% confidence limits (-0.46, 4.25). However, this interval is 
wider than the true 95% confidence interval for the ratio, because it does not consider 
the elliptical nature of the joint distribution, which arises from the fact that the 
chance of falling simultaneously at the edge of the risk and benefit distributions (i.e. 
in one of the corners of the box) is lower than 5% (Polsky et al., 1997). The 
confidence box approach also assumes that the incremental risks and benefits are 
normally distributed, which may not be the case.  
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Figure 6.3 Risk-benefit plane showing the incremental risks of prematurity 
and benefits in terms of MTCT, for exclusive HAART compared with exclusive 
monotherapy, with 95% confidence intervals and resulting confidence box.  
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Simulation  
To avoid the limitations of the confidence box method for obtaining confidence 
limits, the joint probability densities of prematurity and MTCT were modelled using 
a two-stage Monte Carlo algorithm (Lynd & O'Brien, 2004) (as shown in Figure 6.2), 
which does not require any particular distributional assumptions about the 
incremental risk-benefit ratio. This method simulates the probabilities of prematurity 
and transmission for women assumed to be treated with either monotherapy or 
HAART. One thousand simulated risks and benefits for monotherapy (red triangles) 
and HAART (black circles) are plotted in Figure 6.4. A clear difference between the 
two treatment groups was apparent; the limited overlap on the horizontal axis reflects 
the strong and highly significant association between treatment and MTCT, while the 
overlap between points on the vertical axis reflects the fact that the confidence 
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interval for the prematurity AOR approaches one. The simulation was repeated for 
prematurity at <32 weeks, and a similar pattern was observed (Figure 6.5). Note the 
difference in the y-axis’ scales for the two Figures. 
The incremental risk-benefit pairs were then computed using the simulated rates. The 
frequency distributions of the simulated ratio estimates for prematurity <37 weeks 
and <32 weeks are shown in Figures 6.6 and 6.7. The skewed nature of the 
distributions is one of the reasons for not computing confidence intervals using 
methods based on the normal distribution. The median value was taken as the 
estimate for the incremental risk-benefit ratio: 0.69 premature infants and 0.24 very 
premature infants for each infection averted. While the median values were very 
close to the point estimates (0.68 and 0.23, respectively), the means tended to be 
higher (0.81 and 0.30, respectively) due to the right-skewed distribution of the ratios.
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Figure 6.4 Joint densities of prematurity and mother-to-child transmission, 
resulting from 1000 simulations 
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Figure 6.5 Joint densities of severe prematurity (<32 weeks) and mother-to-
child transmission, resulting from 1000 simulations 
 
0.00 0.05 0.10 0.15
0.
00
0.
02
0.
04
0.
06
0.
08
  
 
 
MTCT rate
Pr
e
m
a
tu
rit
y 
ra
te
 
(<3
2 
w
e
e
ks
)
HAART
Monotherapy
 
 
Note: y-axis scale differs from Figure 6.4 
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Figure 6.6 Distribution of 1000 simulations of the incremental risk-benefit 
ratio estimate for prematurity 
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Figure 6.7 Distribution of 1000 simulations of the incremental risk-benefit 
ratio estimate for severe prematurity (<32 weeks) 
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Risk-benefit plane 
The incremental risk-benefit pairs for the simulations were then plotted on a risk-
benefit plane (Figures 6.8 and 6.9), with the x-axis representing the difference in the 
probability of a benefit (a reduction in MTCT) )( B∆ occurring with HAART relative 
to monotherapy; and the y-axis representing the difference in the probability of an 
adverse event )( R∆  (premature delivery at <37 weeks or <32 weeks).  
Risk-benefit acceptability thresholds 
The red lines in Figures 6.8 and 6.9 correspond to acceptability thresholds (µ), or the 
number of adverse events we would be willing to accept for one additional beneficial 
event. The line µ=1 (shown in blue) means that for one additional transmission 
averted, we would be willing to accept one additional premature delivery. If we take 
this to be true, this condition is satisfied for all the points lying below this line, but 
not for those lying above it. The proportion of points below the line therefore 
corresponds to the probability that the condition (each beneficial event corresponding 
to one adverse event) is satisfied. These lines can also be used to indicate confidence 
limits: the upper and lower red lines indicate the limits between which fall 95% of 
the points, and correspond to µ=0.01 and µ=2.22 in the first model (prematurity <37 
weeks), and µ= -0.01 and µ=0.94 in the second model (prematurity <32 weeks). 
In the model for prematurity <37 weeks, 95% of the points fell below the line with 
slope µ=1.75; the corresponding line for the <32 weeks model had a slope of µ=0.77. 
There is therefore a 95% chance that for each transmission avoided, the maximum 
number of premature infants (<37 weeks) would be 1.75 and the maximum number 
of very premature infants (<32 weeks) would be 0.77. This approach can be used 
instead of a confidence interval. 
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Figure 6.8 Risk-benefit plane showing the incremental risk of prematurity 
relative to the incremental MTCT benefit, for exclusive HAART compared with 
exclusive monotherapy 
0.00 0.05 0.10 0.15
0.
00
0.
05
0.
10
  
 
 
Incremental benefit (MTCT)
In
cr
e
m
e
n
ta
l r
is
k 
(P
re
m
a
tu
rit
y 
<
37
 
w
e
e
ks
)
µ = 1
2.22
0.68
0.01
 
 
Figure 6.9 Risk-benefit plane showing the incremental risk of severe 
prematurity (<32 weeks) relative to the incremental MTCT benefit, for 
exclusive HAART compared with exclusive monotherapy 
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Points correspond to results of 1000 Monte Carlo simulations; lines represent acceptability thresholds 
(µ), with slope values provided. MTCT, mother-to-child transmission.  
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Risk-benefit acceptability curve 
The risk-benefit acceptability threshold (µ) is not usually a known value; indeed, the 
number of adverse events one would be willing to accept for a given benefit may 
vary according to a number of factors, such as the population and the resources 
available to manage the adverse events in question. In general, a treatment can be 
considered beneficial if the incremental risk-benefit ratio lies below the chosen value 
of µ (Lynd & O'Brien, 2004). If µ is not known, its value can be varied, and the 
proportion of points falling below the line with slope equal to µ can be plotted 
against the range of possible values of µ (Figure 6.10); this proportion corresponds to 
an estimate of the probability of the treatment providing a net benefit for a given 
risk-benefit acceptability threshold. The vertical dotted lines in Figure 6.10 indicate 
the acceptability thresholds (values of µ) described on page 231, corresponding to the 
median (point estimate) and the 95% probability level for each of the two models 
(prematurity <37 weeks and <32 weeks). For example, the risk-benefit acceptability 
curve for the prematurity <37 model (shown in black) intersects the point (1.75, 
0.95), indicating that 95% of the simulated points on the risk-benefit plane fell below 
the line with slope equal to µ=1.75. 
Acceptability thresholds can be decided on the basis of relative morbidity, mortality, 
cost, or quality of life data; the probability of an overall benefit based on a particular 
acceptability threshold can then be determined from the risk-benefit acceptability 
curve. For example, if it were decided that one premature delivery would be 
considered acceptable in order to avert one transmission (i.e. µ=1), the curve would 
indicate that (1) this threshold lay above the point estimate for the IRBR (along the x-
axis), and the treatment should therefore be accepted, and (2) the probability of there 
being a net benefit at this threshold would be ~70%.
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Figure 6.10 Risk-benefit acceptability curve for the probability that HAART 
provides a net benefit relative to monotherapy at a given risk-benefit 
acceptability threshold (µ)  
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Confidence intervals 
Confidence limits calculated from the confidence box method and from the simulated 
data were shown above, and are summarised (for prematurity <37 weeks) in Table 
6.3. Confidence intervals can also be calculated crudely by computing upper and 
lower limits from the baseline estimates and the limits of the confidence intervals for 
the AOR; this method yields a much narrower interval as it only takes into account 
the uncertainty in the AOR and not the uncertainty around the estimates of baseline 
(monotherapy) and comparison (HAART) rates. Alternatively, confidence intervals 
can be calculated by computing the worst and best case scenarios and calculating a 
ratio for each (Table 6.3). This method yields a much wider interval than the 
simulation method, because like the confidence box method it ignores the fact that 
the probability of falling simultaneously in the tails of the two distributions being 
compared is less than 5%. The quantile method based on the simulated data provided 
the best estimate of the confidence interval for the incremental risk-benefit ratio, 
since it allows for non-normality in the distribution of the ratio, and avoids the 
obvious limitations of the other three approaches.
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Table 6.3 Comparison of alternative methods for estimation of the 95% 
confidence interval of the incremental risk-benefit ratio for prematurity <37 
weeks 
 
Method for calculating 
confidence interval
Point 
estimate 95% CI Range Limitation
Crude, based on AOR limits 0.68 0.10,  1.69 1.59 Ignores uncertainty around 
baseline estimates
Confidence box * 0.68 -0.46,  4.25 4.71
Best/worst case scenarios ** 0.68 -0.13,  6.00 6.13
Quantiles of simulated data 0.69  0.01,  2.22 2.21
Ignores reduced probability of 
falling simultaneously in tails 
of two distributions
 
 
* Based on a normal approximation for confidence intervals 
** Based on exact confidence intervals 
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Association between prematurity and MTCT 
The model was then adapted to incorporate a measure of association between risks 
and benefits, to allow for the possibility of an increased risk of transmission in 
infants born prematurely. Because no such association was detected in this 
population of women reported to the NSHPC, the relative risk of MTCT in the 
premature group compared with the term group was varied in a sensitivity analysis. 
The adjustment was fixed so that for a sampled prematurity rate falling on or near the 
point estimate, the ‘adjusted’ MTCT rate would remain close to the sampled rate. 
However, if a higher prematurity rate was sampled, the sampled MTCT rate would 
be raised due to the increased risk of transmission in the premature proportion, and 
vice versa. The point estimates therefore remained unchanged whatever the 
association between prematurity and MTCT. Modelling up to a four-fold increased 
risk of transmission associated with prematurity produced only a small shift in the 
joint densities. The confidence intervals remained similar to those in the unadjusted 
model (see summary findings, Table 6.4, page 244).  
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6.3 Stillbirth  
To model the increased risk of stillbirth associated with HAART (shown in Chapter 
4) in relation to the reduction in MTCT, the simulation was repeated with stillbirth as 
the adverse outcome. Results of the simulations are shown in Figures 6.11 and 6.12. 
Rates and AORs used in the model are shown in Table 6.1. The incremental risk-
benefit ratio was 0.10 additional stillbirths for each infection averted, with 95% of 
the simulations lying between -0.02 and 0.54. In other words one additional stillbirth 
would be expected for every 10 averted transmissions. The negative lower quartile (-
0.02) reflects the fact that the AOR for the association between HAART and 
stillbirth (relative to monotherapy) was only borderline significant (p=0.055). 
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Figure 6.11 Joint densities of stillbirth and mother-to-child transmission, 
resulting from 1000 simulations 
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Figure 6.12 Risk-benefit plane showing the incremental risk of stillbirth relative 
to the incremental MTCT benefit, for exclusive HAART compared with 
exclusive monotherapy 
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Points correspond to results of 1000 Monte Carlo simulations; lines represent acceptability thresholds 
(µ)
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6.4 Selective monotherapy scenario 
A scenario representative of recent years, with selective use of monotherapy for 
healthier women with a low transmission risk (Table 6.1), was then modelled, and 
the exclusive HAART scenario was compared with the combined scenario. Figure 
6.13 shows the joint densities of prematurity (<37 weeks) and MTCT for the 
HAART scenario (black circles) and the selective monotherapy scenario (red 
triangles). Although the joint distributions of two scenarios overlap substantially, the 
lower prematurity rate among women on monotherapy is reflected in the cluster of 
red triangles around the 10% prematurity level. Incremental risk-benefit pairs are 
plotted in Figure 6.14. The points cluster around the origin, indicating that there is 
little difference between the two scenarios. The median point is located at (0, 0.007), 
indicating no difference in transmission rates, but a small increase in risk associated 
with the exclusive HAART scenario. This example demonstrates one of the problems 
of ratio estimation: as the difference in benefit (denominator) approaches zero, the 
ratio approaches infinity. Indeed, in Figure 6.14, the line intersecting the median 
point would be vertical and has been omitted. Point estimates and confidence 
intervals are shown in the summary table (Table 6.4), but do not provide useful 
information.  
At a population level, the combined scenario provides only a small reduction in risk 
compared with exclusive HAART (since only 12% of the women are subject to 
different treatments), with no discernable difference in transmission rates. However, 
this should not be interpreted as evidence against the use of selective monotherapy, 
because for women who do not require HAART for their own health, HAART is 
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associated with a significantly increased prematurity risk, while not providing any 
additional benefits in terms of transmission risk, according to the estimates obtained 
using NSHPC data.  
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Figure 6.13  Joint densities of prematurity and mother-to-child transmission, 
resulting from 1000 simulations – exclusive HAART versus combined 
HAART/selective monotherapy scenario  
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Figure 6.14 Risk-benefit plane showing incremental risks of prematurity and 
MTCT benefits, for exclusive HAART versus combined HAART/selective 
monotherapy scenario 
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6.5 Summary of scenarios 
Table 6.4 shows the incremental risk-benefit ratios for prematurity <37 weeks 
(scenario 1), prematurity <32 weeks (scenario 2) and stillbirth (scenario 3) with 
exclusive HAART compared with exclusive monotherapy. These findings suggest 
that avoiding 100 transmissions through exclusive use of HAART would result in an 
additional 68 infants born at <37 weeks, of whom 23 would be born at <32 weeks, as 
well as 10 additional stillbirths. The minimal effects of incorporating a two-fold and 
four-fold increased risk of MTCT associated with prematurity are also shown 
(scenarios 4 and 5). 
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Table 6.4 Results of six Monte Carlo simulations of risk and benefits 
associated with different treatment scenarios 
 
   Rates 
Incremental rate 
difference  
Scenario and 
parameters Result 
Baseline 
group 
Exclusive 
HAART 
Point 
estimate 
Simulation 
median 
95% 
confidence 
limits 
(simulation) 
        
1 Risk 10.24 14.37 4.13 4.01 (0.04, 8.9) 
 Benefit 6.98 0.94 6.04 5.79 (2.62, 10.59) 
 
Risk=prem <37 wks, 
baseline=selective 
mono, RR=1 
IRBR   0.68 0.69 (0.01, 2.22) 
2 Risk 1.36 2.75 1.40 1.38 (-0.1, 3.98) 
 Benefit 6.98 0.94 6.04 5.77 (2.56, 10.25) 
 
Risk=prem <32 wks, 
baseline=selective 
mono, RR=1 
IRBR   0.23 0.24 (-0.01, 0.94) 
3 Risk 0.28 0.86 0.58 0.59 (-0.14, 2.55) 
 Benefit 6.98 0.94 6.04 5.79 (2.61, 10.11) 
 
Risk=stillbirth, 
baseline=selective 
mono, RR=1 
IRBR   0.10 0.10 (-0.02, 0.54) 
4 Risk 10.24 14.37 4.13 4.01 (0.04, 8.9) 
 Benefit 6.98 0.94 6.04 5.80 (2.64, 10.42) 
 
Risk=prem <37 wks, 
baseline=selective 
mono, RR=2 
IRBR   0.68 0.68 (0.01, 2.22) 
5 Risk 10.24 14.37 4.13 4.01 (0.04, 8.9) 
 Benefit 6.98 0.94 6.04 5.79 (2.61, 10.5) 
 
Risk=prem <37 wks, 
baseline=selective 
mono, RR=4 
IRBR   0.68 0.68 (0.01, 2.24) 
6 Risk 13.88 14.37 0.50 0.66 (-5.19, 7.46) 
 Benefit 0.81 0.94 -0.13 -0.09 (-1.81, 1.81) 
  
Risk=prem <37 wks, 
exclusive HAART 
vs. 12% selective 
mono, RR=1 IRBR     -3.80 -0.33 (-68.47, 52.4) 
 
Prem, prematurity; mono, monotherapy; RR, relative risk of transmission in premature infants 
compared with term infants
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6.6 Key Points 
• Monte Carlo simulation was used to model the joint uncertainty around risks and 
benefits associated with ART, and estimates of the ratio of risks to benefits were 
calculated. Confidence intervals for the estimates were obtained by taking 
quantiles of the simulated data.  
• The incremental risk-benefit ratios for prematurity (<37 weeks), severe 
prematurity (<32 weeks) and stillbirth were 0.68 (95% CI: 0.01, 2.22), 0.23        
(-0.01, 0.94), and 0.10 (-0.02, 0.54) adverse events, respectively, for each 
additional transmission event averted by exclusive use of HAART compared 
with exclusive monotherapy.  
• In a sensitivity analysis enabling an increase in transmission among premature 
infants compared with term infants to be incorporated into the model, even a 
four-fold increase in MTCT associated with prematurity was shown not to 
substantially alter the incremental risk-benefit ratio or the confidence intervals.  
• In a scenario comparing HAART and selective use of monotherapy with 
exclusive HAART, little difference was observed at a population level. However, 
for women who do not require HAART for their own health, monotherapy is 
associated with a significantly lower risk of prematurity than HAART, with no 
additional benefits in terms of MTCT.
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Chapter 7 Discussion  
7.1 HIV in pregnant women in the UK and Ireland  
The prevalence of HIV in pregnant women in the UK has increased substantially 
since the mid-1990s, reaching 0.21% in 2007 in areas of England and Scotland 
covered by the unlinked anonymous seroprevalence survey (Health Protection 
Agency, 2008). Since the introduction of effective antiretroviral therapy (ART), an 
increasing number of diagnosed HIV-infected women have become pregnant, as 
evidenced by increasing birth rates in infected women (European Collaborative 
Study, 2005b; Massad et al., 2004). Universal antenatal HIV screening, introduced 
from 2000 onwards in the UK and Ireland, now ensures that the majority of infected 
women (over 95%) are diagnosed before they deliver, in time to be offered 
interventions to reduce the risk of mother-to-child transmission (MTCT) (Health 
Protection Agency, 2008). The result of these parallel trends has been a dramatic 
increase in the number of pregnancies in diagnosed HIV-infected women reported to 
the UK and Ireland national surveillance scheme, the National Study of HIV in 
Pregnancy and Childhood (NSHPC) (Chapter 3). The annual number of reported 
pregnancies increased from around 100 in the early 1990s to over 1200 in 2006, the 
sharpest rise occurring between 1999 and 2003, when uptake of universal screening 
also rose substantially (Townsend, Cliffe, & Tookey, 2006).  
Changes in antenatal screening policies also affected the proportion of women 
diagnosed before or during pregnancy. Immediately after routine screening was 
introduced, pregnancies in women diagnosed antenatally surpassed those in women 
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who were already diagnosed when they became pregnant. This pattern was reversed 
within five years, as women who were previously diagnosed in an antenatal setting 
were reported with subsequent pregnancies; over 1200 women included in the 
surveillance between 1990 and 2006 had more than one pregnancy notified during 
this period. Although the number of reports continued to rise each year, the rate of 
increase declined in recent years, possibly because the proportion of HIV-infected 
women diagnosed by delivery has stabilised at around 95% since 2004 (Figure 1.5, 
page 31) (The UK Collaborative Group for HIV and STI Surveillance, 2007). 
However, since the majority of pregnancies in HIV-infected women in the UK and 
Ireland are in women from sub-Saharan Africa, the number of reports is also likely to 
be influenced by patterns of migration from Africa. Noticeable trends in country of 
origin have been reported among HIV-infected Africans seeking HIV care in 
London, with possible links to periods of conflict within Africa (Forsyth, Burns, & 
French, 2005; Sinka et al., 2003). 
Pregnancy terminations and miscarriages occurring after booking for antenatal care 
were also reported to the surveillance study, although very early miscarriages and 
terminations carried out in specialist clinics were likely not reported. Nevertheless, 
because the overall design of the surveillance study remained constant, as did the 
inclusion criteria (all pregnancies in diagnosed HIV-infected women seen in 
antenatal clinics, regardless of timing of diagnosis or pregnancy outcome), these data 
can provide an indication of trends in these pregnancy outcomes. There was no 
change over time in the proportion of miscarriages or late miscarriages (after 19 
weeks gestation). An overall decline in the proportion of pregnancy terminations was 
observed in this population, and was probably related to reductions in HIV-
associated morbidity and mortality and in mother-to-child transmission rates 
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following the introduction of ART (Duong et al., 1999; European Collaborative 
Study, 2005d; Mocroft et al., 2003). The lower termination rate in women diagnosed 
during pregnancy compared with those diagnosed previously could be due to 
differential reporting of terminations between the two groups, but could also reflect a 
lack of opportunity for termination among women diagnosed later in pregnancy, as 
suggested by the later median gestational age at termination in this group (15 weeks 
versus 10 weeks). It was not possible to explore the association between ART and 
miscarriage in this population, due to the likely differential ascertainment of 
pregnancy losses in the NSHPC, according to a woman’s contact with antenatal 
services, knowledge of her HIV status and timing of the miscarriage.  
Changes in the demographic profile of the women were also apparent. In the early 
1990s, almost half of all pregnancies reported to the NSHPC were in women who 
acquired HIV through injecting drug use (IDU) or whose partner was a drug user, 
declining to only 3% in recent years. Similar patterns were observed elsewhere in 
Europe and in the United States (US) (European Collaborative Study, 1996a; 
European Collaborative Study, 2001; Martinelli et al., 2008; Peters et al., 2008). In 
later years the majority of pregnancies were in women originating from areas with 
generalised HIV epidemics, particularly sub-Saharan Africa (accounting for over 
75% of pregnancies). This is consistent with the much higher prevalence of HIV, 
within the UK, in women born in sub-Saharan Africa (2.5% in 2007) than in those 
born in the UK (0.05% in 2007) (Health Protection Agency, 2008). This pattern also 
reflects the overall increase, within the adult population, in the number of newly 
diagnosed infections acquired heterosexually in Africa, which rose from around 500 
in 1995 to over 3000 in 2004 (63% of which were in women) (The UK Collaborative 
Group for HIV and STI Surveillance, 2005). There was also a small but significant 
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increase over time in the proportion of pregnancies in women born in Asia (0% in 
1990-1993 to 2.2% in 2004-2006), and in those of Caribbean origin (1.4% to 3.7%). 
Although there was evidence of an increase in new diagnoses in Caribbean 
populations between 1997 and 2001 (Dougan et al., 2004), no such trend has been 
observed among Asian populations in the UK (Ades et al., 1999; Cliffe et al., 1999; 
The UK Collaborative Group for HIV and STI Surveillance, 2006), despite 
increasing prevalence rates in some parts of Asia (UNAIDS/WHO, 2007). In recent 
years, several pregnancies in young women who acquired HIV vertically from their 
own mothers were notified to the NSHPC. Similar cases have been reported in other 
countries (Brogly et al., 2007; Ezeanolue et al., 2006; Thorne et al., 2007; Zorrilla et 
al., 2003), and are likely to increase in number in the future, as girls infected 
perinatally in the early years of the HIV epidemic reach childbearing age.  
There were also changes in the geographic origin of pregnancy reports across the 
British Isles. Although reporting rates (number of reports per million women of 
childbearing age) remained highest in London throughout the study period, the 
proportion of pregnancies reported from elsewhere in England increased markedly, 
from 13% in 1997-1999 to 43% in 2004-2006. This trend was likely due to several 
factors; firstly it probably reflected differences in the prevalence of HIV among 
women giving birth, which rose from an estimated 0.19% to 0.42% in London, and 
0.02% to 0.14% in the rest of England between 1997 and 2007 (Health Protection 
Agency, 2008; The UK Collaborative Group for HIV and STI Surveillance, 2007). 
Secondly, there were regional differences in antenatal detection rates over time, due 
to earlier introduction of routine antenatal screening in London than elsewhere, and 
initially higher uptake (Townsend, Cliffe, & Tookey, 2006). Finally, the UK 
government policy of dispersing asylum seekers from the South East of England to 
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other parts of the country is also likely to have contributed to the increase in reports 
from areas outside of London (Immigration and Asylum Act, 1999; National AIDS 
Trust, 2006; The UK Collaborative Group for HIV and STI Surveillance, 2007).  
7.2 Trends in uptake of interventions – antiretroviral therapy and 
mode of delivery  
The combination of ART, elective caesarean section and avoidance of breastfeeding 
has been highly successful in reducing the risk of mother-to-child HIV transmission 
(Thorne & Newell, 2003), as was shown in Chapter 3 of this thesis. Following the 
licensing of zidovudine for use in pregnancy in 1994, uptake increased rapidly, 
reaching over 50% in 1997. Zidovudine monotherapy was gradually replaced with 
more effective dual therapy regimens and then with highly active antiretroviral 
therapy (HAART) from around 1998 onwards. Currently, almost all diagnosed HIV-
infected women (98%) take ART when pregnant. Although most receive HAART, a 
small proportion take zidovudine monotherapy, generally in accordance with the 
BHIVA Guidelines. Among women on HAART, the use of regimens containing 
protease inhibitors (PI) increased dramatically, from about a third in 1999 to over 
two thirds in 2006. Women diagnosed antenatally and those with higher CD4 counts 
were more likely to be on PIs than those diagnosed before pregnancy, or those with 
lower CD4 counts, respectively. This suggests that the increase in PI-based HAART 
was probably associated with concerns about nevirapine hepatotoxicity in women 
with CD4 counts >250 cells/µl (Lyons et al., 2003; Mazhude et al., 2002).  
The increasing use of ART over time is likely to have contributed to the observed 
patterns in clinical and immunological factors, with a rise in median CD4 counts and 
decline in plasma RNA viral loads, and in the proportion of women reported to have 
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HIV-related symptoms (Chapter 3). Improvements in maternal immunological 
factors may also reflect earlier diagnosis of HIV infection associated with the 
introduction of the universal antenatal screening policy. In the UK in recent years 
(2000-2004), women who were newly diagnosed antenatally were less likely to have 
been diagnosed late (i.e. with a CD4 count below 200 cells/µl) than those diagnosed 
in other settings (20% versus 38%) (Chadborn et al., 2006). Among pregnant women 
reported to the NSHPC, HIV-related symptoms declined sharply from over 20% in 
the 1990s to 11% between 2000 and 2006, suggesting a possible link with the 
introduction of the screening policy. However, trends in CD4 count and viral load 
were more gradual. Although the decrease in viral load over time was undoubtedly 
associated with a rise in uptake of effective ART, the trend in undetectable viral load 
(<50 copies/ml) may have been slightly overestimated, since more sensitive assays 
tended to be available in later years (Mulder et al., 1994; Mulder et al., 1997). 
Following evidence linking elective caesarean section with a reduction in the risk of 
MTCT in the mid-1990s (European Collaborative Study, 1994; European Mode of 
Delivery Collaboration, 1999), the proportion of women delivering by planned pre-
labour caesarean section increased from around 40% before 1998 to 66% in 1999. 
The success of HAART, however, has led to uncertainty about the additional benefit 
of elective caesarean section for women achieving undetectable HIV RNA plasma 
viral load by the time of delivery. Guidelines now suggest that such women may opt 
for a vaginal delivery (BHIVA/CHIVA, 2008); planned vaginal deliveries rose from 
17% to 28% between 1999 and 2006, with a corresponding decline in elective 
caesarean sections from 66% to 50%. This recommendation may also have 
contributed to the observed increase in emergency caesarean sections, which could 
result from unexpected complications arising during planned vaginal deliveries; the 
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increase in proportion of emergency procedures being carried out at term (49% in 
1999 to 61% in 2006) supports this interpretation (Chapter 3). Uncertainty around the 
risk of transmission in cases where duration of ruptured membranes is prolonged 
may also lead to additional emergency caesarean sections. The impact of policies and 
recommendations around management of delivery needs to be monitored closely, as 
unintended effects may occur. For instance, while elective caesarean section 
deliveries are likely to be scheduled at times when HIV specialist midwives and 
obstetricians are available, vaginal deliveries and emergency caesarean sections may 
occur unexpectedly, when specialist staff are less likely to be on duty. 
7.3 Mother-to-child transmission 
Overall mother-to-child transmission rates among diagnosed HIV-infected women in 
the UK and Ireland declined from 24% in 1993 to 2% in 1998 (Chapter 3); these 
rates were slightly different from previously published estimates for 1990-1998 
(Duong et al., 1999), due to the inclusion of late reports and fluctuation caused by 
the relatively small number of births during this period. The analysis described in 
Chapter 3 indicated sustained low transmission rates from 1998 onwards. Between 
2000 and 2006, the overall transmission rate was 1.2%, with a non-significant 
decline from 1.6% in 2000-2002 to 1.0% in 2003-2006. These low rates are 
consistent with reports from elsewhere in Europe and the United States (US) 
(Centers for Disease Control and Prevention, 2006; European Collaborative Study, 
2005d; Peters et al., 2008; Warszawski et al., 2008). Similar transmission rates were 
observed among women on HAART who had either elective caesarean section or 
planned vaginal deliveries (0.7% in both groups). The transmission rate was 
particularly low (0.1%) in the 2117 women on HAART who achieved viral 
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suppression near delivery, with only three transmissions reported, two of which 
probably occurred in utero, based on the timing of their first positive test result.  
In cases where transmission occurred despite HAART and planned vaginal or 
elective caesarean section delivery, most infections could be explained by failure to 
reduce viral load, mainly due to short duration of treatment or adherence problems, 
or to in utero transmission. Of the nine infected children born to women with low or 
undetectable viral loads, four had detectable virus at birth and were probably infected 
in utero. In the absence of prophylactic interventions, most transmission takes place 
around the time of delivery or postnatally (through breastfeeding) (Newell, 1998). 
However, available interventions have had a greater impact on reducing intrapartum 
and postpartum transmission, and cases of in utero transmission have been 
highlighted in recent years (AIAU, NSHPC, & CHIVA, 2007; Warszawski et al., 
2008). In non-breastfeeding populations in the pre-HAART era, intrauterine 
transmission accounted for around a quarter of transmissions (Thorne & Newell, 
2003), whereas in a French study of ART-treated women delivering between 1997 
and 2004, over 40% of infants born to women with viral loads <400 copies/ml were 
presumed to have been infected in utero (Warszawski et al., 2008). Information on 
HIV RNA PCR tests at birth were not explicitly collected for infants in this study, so 
it was not possible to explore timing of infection overall.  
There were no transmissions reported in over 450 infants born to women who 
received zidovudine monotherapy in the HAART era (2000-2006) and delivered by 
elective caesarean section. This finding suggests that selective monotherapy is also a 
reasonable strategy for preventing MTCT, particularly as low rates of drug resistance 
have been reported among women opting for this approach (Larbalestier et al., 2003; 
Read, Costelloe, & Mullen, 2006). There may also be additional benefits of 
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monotherapy, including a reduced risk of toxicity to the mother and infant 
(BHIVA/CHIVA, 2008), as well as potential benefit in relation to future treatment 
options. It should be noted, however, that these findings are based on a population in 
which zidovudine monotherapy was generally used selectively, in accordance with 
the BHIVA Guidelines (BHIVA/CHIVA, 2008). Furthermore, the fact that the 
majority of women on monotherapy had detectable viral loads near the time of 
delivery underlines the need for careful management of delivery, probably by 
caesarean section. This approach, as an alternative to HAART, is therefore only 
appropriate in settings with access to safe surgical delivery and appropriate post-
operative care. 
In multivariable analysis, both lack of ART and vaginal delivery, particularly if 
unplanned, were independently associated with transmission, and remained so after 
further controlling for plasma viral load near delivery. The lack of a statistically 
significant association between maternal CD4 cell count and MTCT was likely due 
to small numbers, since low CD4 has been shown to be associated with an increased 
risk of transmission (European Collaborative Study, 2001), and MTCT rates tended 
to be higher in women with low CD4 (1.5% in women with CD4 <200 cells/µl, 
compared with 0.8% in those with CD4 ≥500 cells/µl).  
Before the widespread use of HAART, prematurity was identified as a risk factor for 
transmission (European Collaborative Study, 1999). However, in this analysis, the 
increased risk of transmission associated with very premature delivery in the main 
multivariable analysis was not observed in a similar analysis restricted to women on 
HAART, although it is possible that this was due to lack of statistical power, as only 
four very premature infants were infected. Girls were at increased risk of infection 
compared with boys, although the association was no longer significant when the 
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analysis was restricted to cases where maternal viral load was recorded, possibly due 
to the reduced number of cases in the analysis. A sex difference in mother-to-child 
transmission rates has been reported in other studies, both for HIV and for hepatitis C 
virus (Biggar et al., 2006; European Paediatric Hepatitis C Virus Network., 2005; 
Piwoz et al., 2006; The Breastfeeding and HIV International Transmission Study 
(BHITS) Group, 2004; Thorne & Newell, 2004a). In some studies, the association 
between sex and transmission was restricted to infants infected in utero, suggesting a 
higher risk of intrauterine infection in girls, or of fetal death following intrauterine 
infection in boys (Piwoz et al., 2006; Thorne & Newell, 2004a). There was no 
evidence of the latter in this study, with twice as many stillborn girls reported as 
boys. Although the reasons underlying this finding remain unclear, there is now a 
consistent body of evidence supporting an association between risk of MTCT and 
sex.  
Viral load was associated with 2.4-fold increase in transmission for each log10 
increase in viral load copies, which was consistent with the literature (Cooper et al., 
2002; European Collaborative Study, 2005d; Warszawski et al., 2008). In 
multivariable analysis, adjusting for viral load led to an increase in the adjusted odds 
ratio (AOR) for the association between vaginal delivery and MTCT; this can be 
explained by the observation that most vaginal deliveries in recent years were 
planned, and therefore tended to be in women with low or undetectable plasma viral 
load. In other words, the association between vaginal delivery and transmission was 
negatively confounded by viral load. Adjusting for viral load also reduced the AOR 
for the association between lack of ART and transmission from 9.1 to 3.2; this is 
because viral load is on the causal pathway, with ART affecting the risk of 
transmission by reducing viral load. Because viral load was less likely to be reported 
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for untreated women, restricting the analysis to women with viral loads reported led 
to some selection bias. 
Among women on HAART, there was no significant difference in transmission rates 
by type of regimen (0.9% for regimens containing non-nucleoside reverse 
transcriptase inhibitors [NNRTIs] and 1.1% for PI-containing regimens), even 
though NNRTI-based HAART, when initiated in pregnancy, has been shown to be 
associated with a more rapid decline in plasma viral load than PI-based regimens 
(European Collaborative Study, 2007). However, although there were around 1800 
women in each of the two groups, the ability to detect a difference was limited by the 
low overall transmission rates. There was evidence that women on PI-based HAART 
were diagnosed more recently than those on NNRTI-based HAART and were less 
immunocompromised; this pattern was probably due to avoidance of nevirapine-
based regimens in women with CD4 counts above 250 cells/µl in recent years, owing 
to toxicity concerns (BHIVA, 2005b; Lyons et al., 2003). Although a difference in 
the risk of transmission by type of regimen cannot be ruled out, it is reassuring that 
rates were around 1% in both groups.  
There was evidence that being on HAART at conception was associated with a lower 
risk of transmission than starting HAART in pregnancy. Longer duration of HAART 
was also associated with a reduced risk of transmission, even after adjusting for viral 
load. Both of these observations could be due in part to a lower risk of intrauterine 
transmission when HAART is started earlier. In these analyses, plasma viral loads 
closest to delivery were used, which might explain why timing of initiation of 
HAART remained associated with transmission after adjusting for viral load, since 
viral loads later in pregnancy would not necessarily reflect the infant’s exposure to 
high maternal viral loads at earlier stages of pregnancy.  
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Children whose infection status had not yet been reported were more likely than 
those with known infection status to have recognised risk factors for transmission. 
Among those with unreported infection status, the excess of children born to black 
African mothers occurred because infection status was more likely to be missing for 
recent cases (due to reporting delay), when the proportion of African women was 
higher (80% in 2006, versus 71% in 2000). However, although this bias could 
potentially lead to an underestimate of the overall transmission rate, any effect is 
likely to be small. Imputing infection status on the basis of other available risk 
factors did not alter the overall transmission rate. 
These findings, showing low rates of MTCT in appropriately managed pregnancies, 
are reassuring. However, because of the small number of transmissions occurring in 
recent years, statistical power was limited in these analyses, particularly when 
comparing subgroups of women with very low transmission rates.  
7.4 Adverse effects of antiretroviral therapy 
The association between ART and a number of adverse pregnancy outcomes was 
explored in this thesis: stillbirth, neonatal death, and pregnancy complications such 
as pre-eclampsia were explored in Chapter 4, and prematurity and birth weight were 
covered in Chapter 5.  
Stillbirth, neonatal mortality and other pregnancy complications 
The neonatal mortality rate among infants born to HIV-infected women in the UK 
and Ireland was 3.6 (95% CI: 2.4-5.1) per 1000 live births (Chapter 4); this was 
lower than rates of 6-7 per 1000 live births reported for HIV-infected women 
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enrolled in the ECS (1985-2003) (European Collaborative Study, 2004a), but was in 
line with population rates for England, Wales and Northern Ireland, which declined 
from 3.9 (95% CI: 3.7-4.0) to 3.4 (95% CI: 3.3-3.6) per 1000 between 2000 and 2006 
(Confidential Enquiry into Maternal and Child Health, 2008). In the NSHPC, the 
stillbirth rate of 10.9 (95% CI: 8.8-13.4) per 1000 births was substantially and 
significantly higher than the population rate of 5.3 (95% CI: 5.1-5.5) per 1000 births 
in 2006 (Confidential Enquiry into Maternal and Child Health, 2008). In an analysis 
by Suy and colleagues, in which fetal death was defined as intrauterine death after 22 
weeks (a slightly lower cut-off than the one used here), rates were significantly 
higher in HIV-infected (61 per 1000 deliveries) than uninfected women (5 per 1000 
deliveries), although the analysis included only 82 HIV-infected women (all 
delivering between 2001 and 2003) (Suy et al., 2006). Although the reasons for these 
differences are unclear, possible explanatory factors include differences in the risk 
profile of HIV-infected women compared with the wider population, factors related 
to HIV infection or disease, and adverse effects associated with ART.  
There was some evidence in support of an association between ART and stillbirth: 
the rate in women on HAART in pregnancy (11 per 1000 births) was significantly 
higher than the rate in those on monotherapy (3 per 1000 births), which was more in 
line with the population rate. However, the association was reduced and only 
borderline significant after adjusting for CD4 count and multiple pregnancy, partly 
due to a reduction in the odds ratio from 4.0 (OR) to 3.1 (AOR), and partly due to 
small numbers (only three stillbirths in women on monotherapy). Furthermore, 
because women who take monotherapy in pregnancy tend to start treatment slightly 
later than those who start HAART (Chapter 5), and stillbirths tend to occur earlier 
than live births (Chapter 4), some bias may occur, with women intending to start 
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monotherapy being less likely to initiate treatment prior to a stillbirth than those 
planning to start HAART. Although this finding is consistent with the evidence on 
HAART and prematurity, it should therefore be interpreted with caution. Information 
on stillbirths has been reported in a number of studies, but most have not had the 
power to detect an association with ART, with only a few stillbirths reported (Cotter 
et al., 2006; Ekouevi et al., 2008; Tuomala et al., 2002; Tuomala et al., 2005; Watts 
et al., 2004a). In a cohort of HIV-infected women delivering between 1985 and 2003 
(n=472) reported in the publication by Suy and colleagues, mentioned above, the 
incidence of fetal death was 17.0 per 1000 deliveries (95% CI: 7.3-33.4), and was 
significantly higher in women on HAART prior to pregnancy (OR=7.9, p=0.005), 
although the authors were not able to adjust for other variables.  
Information on pregnancy complications other than stillbirth was collected through 
the obstetric scheme of the NSHPC from mid-2004 onwards. Complications were 
reported in 7.7% of pregnancies, and included a wide range of obstetric problems and 
conditions, including pre-eclampsia and gestational diabetes (Chapter 4). Overall, 
complications were associated with older maternal age and multiple pregnancy, 
consistent with patterns in the general population (Luke & Brown, 2007; Rao, 
Sairam, & Shehata, 2004). Complications were also more likely in women with HIV-
related symptoms or low CD4 count, which is consistent with the generally higher 
rates of postpartum complications in these women (Duarte et al., 2006). The 
prevalence of complications was slightly higher in women on non-PI-based HAART 
than in those on monotherapy, but the association was mostly explained by clinical 
status and CD4 count and disappeared in adjusted analyses. Pregnancy complications 
were significantly more likely in women on HAART at conception than in those 
starting in pregnancy (11% versus 7%), even after adjusting for other factors. Upon 
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further investigation, the association was found to be driven by one particular 
adverse outcome, pre-eclampsia, which has been linked with early HAART (Suy et 
al., 2006) and was explored separately. Even though the definition of pregnancy 
complications used in this analysis was broad (no reported complications were 
excluded), associations with known risk factors for pregnancy complications were 
detected in this population of HIV-infected women. However, rates of specific 
complications, such as pre-eclampsia and gestational diabetes, were somewhat lower 
than expected, compared with population rates (National Institute for Clinical 
Excellence, 2008; Sibai, Dekker, & Kupferminc, 2005), possibly due to under-
reporting.  
In light of concerns raised in a Spanish study (Suy et al., 2006) about a possible 
association between HAART at conception and pre-eclampsia, this outcome was 
explored in more detail in the NSHPC (Chapter 4). While the interactions between 
HIV, ART and pre-eclampsia are not fully understood, there is some evidence to 
suggest that HIV reduces the risk of pre-eclampsia in untreated women (Hall, 2007; 
Stratton et al., 1999). Because information on pre-eclampsia was only collected from 
2004 onwards in the NSHPC, few untreated women were reported (n=53), with one 
case of pre-eclampsia. It was therefore not possible to comment on differences 
between treated and untreated women, or between HIV-infected and uninfected 
women, due to the lack uninfected controls. The overall rate of reported pre-
eclampsia was 2.1%, which is consistent with rates of 2-5% observed in large 
population-based studies in Europe and North America (Catov et al., 2007; 
Dahlstrom et al., 2006; Wallis et al., 2008; Xiong, Fraser, & Demianczuk, 2002). 
The causes of pre-eclampsia are unknown, although a number of risk factors have 
been identified, including extremes of maternal age, nulliparity, multiple pregnancy, 
chronic hypertension, and maternal infections (Conde-Agudelo & Belizan, 2000; 
  261 
Conde-Agudelo, Villar, & Lindheimer, 2008; Sibai, Dekker, & Kupferminc, 2005). 
The main clinical manifestations of pre-eclampsia are hypertension and proteinuria 
(abnormal protein levels in the urine), but can also include pulmonary oedema, 
thrombocytopenia or neurological symptoms, as well as reduced amniotic fluid and 
fetal growth restriction, and in severe cases can lead to eclampsia or haemolysis, 
elevated liver enzymes or low platelet counts (HELLP) syndrome (Sibai, Dekker, & 
Kupferminc, 2005). Pre-eclampsia is an important cause of maternal morbidity, 
particularly in developing countries, and eclampsia accounts for 12% of maternal 
deaths worldwide (World Health Organization, 2005).  
Pre-eclampsia was reported in 11% of all pregnancies delivered prematurely 
(Chapter 4); rates of preterm delivery in affected women were high, at 70%, 
compared with a reported range of 15-67% (Sibai, Dekker, & Kupferminc, 2005). 
The association between pre-eclampsia and parity was consistent with other studies 
(Conde-Agudelo & Belizan, 2000; Dekker & Sibai, 2001): in multivariable analysis, 
parous women were about half as likely as nulliparous women to develop pre-
eclampsia. HIV-related symptoms and low CD4 count were associated with 
significantly increased rates of pre-eclampsia; this was not consistent with the 
suggestion that immune suppression could explain the low rates of pre-eclampsia 
reported in one cohort of untreated HIV-infected women (Wimalasundera et al., 
2002). There is ongoing debate about the relationship between untreated HIV and 
pre-eclampsia (Hall, 2007), with at least one study having found no reduction in pre-
eclampsia rates in untreated HIV-infected women (Frank, Buchmann, & Schackis, 
2004). 
Among women on HAART, non-PI-containing regimens and initiation of HAART 
before pregnancy were associated with an increased risk of pre-eclampsia 
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(AOR=1.75 and 1.62, respectively), which in both cases was statistically significant 
only in women with CD4 counts ≥200 cells/µl (AOR=1.94 and 1.89, respectively). 
These findings are consistent with those reported by Suy and colleagues, and support 
the premise that earlier initiation of HAART is associated with an increased risk of 
pre-eclampsia (Suy et al., 2006). However, it should be noted that overall pre-
eclampsia rates among these HIV-infected women were on the low end of the range 
for HIV-uninfected populations, even among those who started HAART before 
pregnancy. Furthermore, given the likely under-ascertainment of pregnancy 
complications, and lack of specific case definitions, these findings should be 
interpreted with caution.  
There is some evidence of a link between PIs and gestational diabetes (Watts et al., 
2004a). In the NSHPC, gestational diabetes was reported in only 0.8% of 
pregnancies (Chapter 4), which is notably lower than the average for England and 
Wales of 3.5% (National Institute for Clinical Excellence, 2008). There was no 
significant difference by type of HAART, although the rate tended to be lower with 
PI-based HAART than with non-PI-based HAART (0.7% versus 1.4%), which 
contradicts findings of increased rates of gestational diabetes associated with PI use 
in other studies (Gonzalez-Tome et al., 2008; Watts et al., 2004a).  
Despite the high response rates to the question on pregnancy complications (93%), 
there is likely to have been some under-reporting. In particular, ascertainment of 
specific problems was probably incomplete due to the open nature of the question 
and lack of precise case definitions for individual problems. Pre-eclampsia was 
mentioned as an example in the question and reporting may therefore be more 
complete for this problem than for others. However, the spectrum of pre-eclampsia-
related conditions means that misclassification is also likely to have occurred. 
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Diagnosis of some complications including pre-eclampsia relies on a series of 
measurements taken at specific intervals, but details of how diagnosis was 
established were not collected in this study. Nevertheless, known risk factors were 
significantly associated with both overall pregnancy complications and pre-
eclampsia, and the observed pre-eclampsia rate was comparable to population rates 
(albeit on the low end of the range).  
Congenital abnormalities 
The overall congenital abnormality rate among live and stillborn infants in this 
population was 2.8% (2.1% excluding minor defects) (Chapter 4), which is 
consistent with national population estimates of 2-3% for major abnormalities in 
England and 2.2% for Europe as a whole (calculated from EUROCAT data tables, 
1980-2006) (EUROCAT, 2004; EUROCAT, 2008).  
Abnormality rates did not differ significantly by timing of ART in pregnancy, or by 
type of first trimester ART (PIs and/or NNRTIs). These findings support those of 
other European and American studies (Bucceri et al., 2002; European Collaborative 
Study, 2005a; Mandelbrot et al., 2001; Watts et al., 2007) and of the Antiretroviral 
Pregnancy Registry (APR) (Covington et al., 2004; Watts et al., 2004b). Because of 
concerns raised about two specific antiretroviral drugs, efavirenz and didanosine 
(Antiretroviral Pregnancy Registry Steering Committee, 2008; De Santis et al., 2002; 
Fundaro et al., 2002), abnormality rates in these groups were investigated separately. 
No significant increase in abnormalities was detected following early exposure to 
efavirenz (2.4% of 205 infants) or didanosine (3.4 % of 174 infants). In 2007, the 
Women and Infants Transmission Study (WITS) in the US reported an increase in 
the rate of hypospadias (AOR=10.7, 95% CI: 2.1-54.1, p=0.004) associated with 
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early zidovudine exposure (Watts et al., 2007). There were 12 reported cases of 
hypospadias among infants notified to the NSHPC, and rates were similar following 
early or late ART exposure and according to whether or not early treatment included 
zidovudine.  
Congenital abnormality rates were higher in boys than in girls, and in infants born to 
white, symptomatic women. The excess of abnormalities in boys was mainly 
accounted for by genital abnormalities (mostly undescended testes and hypospadias), 
all of which were in boys. When excluding genital abnormalities, the difference was 
no longer significant (2.8% in boys versus 2.2% in girls, p=0.098). There was also an 
excess of polydactyly in boys, which has been observed in a few studies, for example 
in Chile and Hungary (Bellovits, 2003; Cifuentes et al., 1996). The increased rate in 
symptomatic women was also observed in an earlier analysis of NSHPC data, which 
included 3100 infants (Townsend et al., 2006), as was the finding of an increased 
risk for infants born to white women compared with those born to black African 
women. The association with ethnic group was likely due to variation in other 
maternal characteristics or exposures, which are not routinely collected through the 
surveillance system. The rate among infants exposed only to NRTIs in the first 
trimester was also higher, although not significantly, than in infants exposed to other 
drug classes; this could be a chance finding (based on only eight abnormalities in 148 
infants) or could reflect the different risk profile of their mothers, who were more 
likely to be women who were young, white and/or had acquired HIV through IDU 
and were reported in the mid-1990s. The excess of infants with renal dilatation 
among those with early ART exposure could also be a chance finding, but rates of 
this abnormality within the NSHPC and in other studies should continue to be 
monitored. 
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Reports of congenital abnormalities in this population are likely to be relatively 
complete, at least for those detected in the first few weeks of life, due to the 
complementary obstetric and paediatric reporting systems. Nevertheless, a small 
number of abnormalities not apparent at birth might have remained unreported, either 
because the birth was only notified through the obstetric scheme, or because the 
abnormality was detected only after the last paediatric report to the NSHPC. It was 
also not possible to routinely check the details of reported abnormalities, for example 
if a defect was specified by one respondent but not the other. However, discrepancies 
in terms of the nature of reported abnormalities were rare. Although there is 
incomplete ascertainment of pregnancy terminations through the NSHPC, those 
carried out after a congenital anomaly scan are likely to be well reported, since 
contact with antenatal services will already have occurred.  
Infants missing information on presence of congenital abnormalities were more 
likely to be premature, a factor which was associated with having an abnormality; 
however, these infants were no more likely to have had early ART exposure that 
those with information provided, and it is therefore unlikely that this will have 
substantially affected the findings regarding the association with ART. Although 
information on maternal ethnicity, age, injecting drug use and clinical status was 
available, data on other potential confounders such as maternal smoking and diet 
during pregnancy, concurrent infections and non-HIV medication were not.   
This analysis included over 8200 infants (1700 with early ART exposure), with 
sufficient power (~80%) to detect a 1.5-fold increase in abnormalities associated 
with first trimester exposure. However, at least 370 exposures to any specific drug 
are required to detect a two-fold increase in overall risk of congenital abnormalities 
(from 3% to 6%) with 80% power, and even larger numbers would be required to 
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detect an association with a particular type of abnormality. Nevertheless, these 
results provide some reassurance that exposure to ART in utero does not pose a 
major risk of fetal anomaly, particularly given the consistent findings across many 
large-scale observational studies including the European Collaborative Study, the 
WITS study and the APR (Antiretroviral Pregnancy Registry Steering Committee, 
2008; European Collaborative Study, 2005a; Watts et al., 2007). Continued 
monitoring of congenital abnormalities in infants born to women on ART in early 
pregnancy is essential, particularly as new drugs and new combinations of drugs are 
introduced. Difficulties around statistical power in analyses involving individual 
drugs or types of abnormalities could potentially be overcome in the future by 
pooling data from several of these studies.  
Prematurity 
In developed countries, prematurity is the leading cause of perinatal mortality, 
accounting for up to 75% of perinatal deaths (Ananth & Vintzileos, 2006). Although 
the majority of premature infants do survive, they are at increased risk of serious 
morbidity, including respiratory distress and gastrointestinal complications, as well 
as neurodevelopmental impairment. Preterm birth can occur following spontaneous 
preterm labour (40-45% of preterm births in non-HIV populations), preterm 
premature rupture of membranes (25-30% of cases) or for medical indication with 
induction of labour or delivery by caesarean section (30-35% of cases) (Goldenberg 
et al., 2008). Risk factors for preterm birth include socio-demographic 
characteristics, nutritional status, obstetric history and infection (Table 7.1), many of 
which are associated with activation of inflammatory pathways (Goldenberg et al., 
2008). Differences in prematurity by ethnicity have been reported in Europe, 
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including in the UK, with black African women having higher prematurity rates than 
white women (Aveyard et al., 2002; Gardosi & Francis, 2000; Patel et al., 2004; 
Slattery & Morrison, 2002). There are clear ethnic differences in prematurity rates in 
the US, but it is unclear whether socio-demographic factors, including inequalities in 
access to health insurance and healthcare, are responsible. In many immigrant groups 
in the US, prematurity risk increases with longer duration spent living in the US, 
suggesting a role for cultural or social factors (Goldenberg et al., 2008). Use of illicit 
drugs in pregnancy is also associated with an increased risk of prematurity, as are 
extremes of maternal age.  
In this thesis, the association between ART and prematurity was first explored in the 
NSHPC, and subsequently in a combined analysis with two other studies.  
 
Table 7.1 Risk factors for preterm birth 
 
Socio-demographic factors 
Black, African-American or Afro-Caribbean ethnicity 
Low socio-economic/educational status 
Low and high maternal age (<20 or >35 years of age) 
Single marital status 
Long working hours / hard physical labour 
Obstetric factors 
Short interpregnancy interval 
Prior preterm birth 
Multiple pregnancy 
Obstetric complications (poly/oligohydramnios, placental abruption/praevia) 
Congenital abnormality 
Maternal health factors 
Low body-mass index / poor nutritional status 
Maternal medical problems (thyroid disease, asthma, diabetes, hypertension) 
Depression 
Smoking, drug or alcohol abuse 
Intrauterine infection 
Genital tract infection / bacterial vaginosis 
 
Derived from: (Goldenberg et al., 2008; Slattery & Morrison, 2002) 
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NSHPC analysis 
Overall prematurity rates and risk factors 
The overall prematurity rate in this population was 13.3%, more than twice the rate 
in the general population. In 2005, 6.2% of live singleton births in England occurred 
before 37 weeks, according to recent data from the Office for National Statistics, 
with substantial variation between ethnic groups; rates were 6.1% in infants 
classified as ‘white British’, 7.0% in black African infants and 9.7% in black 
Caribbean infants (Moser, Stanfield, & Leon, 2008). Although there were no national 
data on trends in gestational age in the UK until 2005 (Moser, Stanfield, & Leon, 
2008), the rate of low birth weight (<2500 g) in singleton infants in England and 
Wales remained relatively constant between 1983 (5.8%) and 2000 (6.1%) (Maher & 
Macfarlane, 2004). In this population of HIV-infected women, IDU and maternal 
HIV-related symptoms were significantly and positively associated with prematurity, 
but ethnic group and maternal age were not. The fact that black women were not at 
increased risk of premature delivery could be due to a high baseline prematurity rate 
in white HIV-infected women; higher rates of IDU were reported in this group, and it 
is likely that rates of other high risk behaviours (smoking, alcohol abuse) were also 
increased in these women. IDU was significantly associated with prematurity in this 
population, even though information was on IDU as the route of HIV acquisition, 
rather than drug use during pregnancy. Consistent with population trends in birth 
weight (Maher & Macfarlane, 2004), there was no detectable change in the overall 
prematurity rate over time. Low CD4 count and maternal HIV-related symptoms 
were also associated with prematurity. The association between maternal clinical 
factors and prematurity in HIV-infected women has been reported elsewhere 
(European Collaborative Study, 2004a; European Collaborative Study and the Swiss 
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Mother + Child HIV Cohort Study, 2000; Schulte et al., 2007), and in the general 
population, markers of poor maternal health, including low body mass index and 
chronic medical conditions, tend to be associated with an increased risk of preterm 
delivery (Haas et al., 2005). 
ART and prematurity 
The prematurity rate among women on HAART was 1.6 times higher than in those 
on monotherapy or dual therapy, and there was some evidence that the association 
was stronger at earlier gestational ages, with adjusted odds ratios of 2.7-2.8 for 
delivery at <35 weeks or <32 weeks. There was no difference in prematurity rates 
between PI-containing (14.3%) and NNRTI-containing (13.5%) HAART, despite 
substantial numbers of exposures to both types of HAART; these findings differ 
from some other studies, in which an increased risk of prematurity was detected only 
with PI-containing HAART (Cotter et al., 2006; Schulte et al., 2007). The 
association between HAART and prematurity remained after adjusting for known 
risk factors for prematurity, including maternal ethnic group, age, IDU and clinical 
status, as well as in separate analyses controlling for HIV RNA viral load and/or 
CD4 cell count.  
The lack of change in prematurity rates over time, despite increasing use of HAART, 
was probably due to a concurrent decrease in other risk factors for prematurity 
including HIV-related symptoms and IDU (shown in Chapter 3). Although 
acquisition of HIV through IDU was associated with an increased risk of 
prematurity, IDU did not substantially confound the association between treatment 
and prematurity: excluding IDU from the multivariable analysis yielded an AOR of 
1.46 (versus 1.51, a difference of 3%). The proportion of women who acquired HIV 
through IDU may not have reflected the true prevalence of IDU in pregnancy, 
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although in a recent London-based study of HIV-infected individuals, only 7.2% had 
a history of current or previous IDU (Mohsen, Murad, & Easterbrook, 2005). Failing 
to fully adjust for the effect of drug-use in pregnancy would tend to attenuate the 
relationship between treatment and prematurity, since IDU was associated with both 
prematurity and monotherapy.  
There was some evidence that earlier initiation of HAART was associated with an 
increased risk of prematurity. When pregnancies in which treatment was initiated 
after 26 weeks were excluded, to avoid bias introduced by differences in opportunity 
for starting treatment according to timing of delivery, later initiation of HAART was 
associated with a significantly reduced risk of prematurity. This finding suggests a 
dose-response effect of HAART on duration of pregnancy. Few studies have 
explored the effect of duration of HAART exposure (Cotter et al., 2006; European 
Collaborative Study, 2004a), probably because dates of treatment initiation are not 
always available, and because analysis is complicated by the fact that premature 
delivery naturally shortens the duration of antenatal treatment.  
Compared with prematurity rates in ART-treated women, those in untreated women 
in the NSHPC were higher overall (17% versus 13%) and increased over time (from 
11% in the early 1990s to 20% in 2000-2005). With the benefits of antenatal ART 
now widely accepted, the small proportion of women who are ART-naïve at delivery 
are usually untreated either because they decline treatment or because they deliver 
before treatment can be initiated (due to late booking for antenatal care and/or to 
premature labour or rupture of membranes). The prematurity rate among pregnancies 
in this group is therefore inherently higher than in treated women, and comparison of 
these two groups was therefore not appropriate. In addition, almost 40% of untreated 
women were reported before ART was widely used, at a time when many women 
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had acquired infection through drug use, and had a different risk profile to women 
reported later on (as shown in Chapter 3). For these reasons, pregnancies in untreated 
women were not considered an appropriate control group. 
Mechanisms 
Following initial concerns about HAART and prematurity, it was postulated that the 
balance of Th1 and Th2 inflammatory cytokines could play a role (see Box 1). This 
was investigated in a small study of 26 HIV-infected pregnant women, who were all 
on HAART throughout pregnancy (Fiore et al., 2006). Interleukin (IL)-10, an anti-
inflammatory cytokine, was shown to decline throughout pregnancy, while IL-2, a 
pro-inflammatory cytokine, increased (although not significantly), a pattern that is 
consistent with a reversal of the Th1 to Th2 shift. Furthermore, a more rapid increase 
in IL-2 was associated with an increased risk of prematurity.  
 
This mechanism suggests that ART-associated preterm delivery would result from 
spontaneous induction of labour or membrane rupture, rather than other pathological 
processes. In the ECS, uninfected children born prematurely following exposure to 
Box 1: Summary of Th1  Th2 pathway 
 
There are two major subsets of CD4+ T helper cells, Th1 and Th2, which play 
complementary roles within the immune system by producing different types of 
cytokines. The two subsets mediate each other, Th1 producing a pro-inflammatory 
immune response, and Th2 an anti-inflammatory response (Male et al., 2006). 
During pregnancy, an increase in Th2-type cytokines and suppression of Th1-type 
cytokines is required to avoid rejection of the fetus through an immune response to 
feto-paternal antigens. HIV infection is also characterised by a Th1 to Th2 shift. 
However, treatment with antiretroviral drugs seeks to reverse this process, and 
could therefore be detrimental to the maintenance of pregnancy (Fiore et al., 2006; 
Male et al., 2006). 
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combination therapy tended to fare better in terms of growth indicators than did 
unexposed premature infants, suggesting an absence of underlying morbidity in these 
children (European Collaborative Study, 2004c). It was not possible, in the NSHPC, 
to definitively classify preterm deliveries as spontaneous or induced. Further research 
into the reasons for premature delivery in HIV-infected women on HAART is 
needed.  
Findings in relation to existing literature 
These results concur with those from other European studies showing an increased 
risk of prematurity associated with HAART (Boer et al., 2007; European 
Collaborative Study, 2004a; European Collaborative Study and the Swiss Mother + 
Child HIV Cohort Study, 2000; Grosch-Woerner et al., 2008; Martin & Taylor, 
2007). Yet several large-scale US studies have failed to detect an association 
between HAART and prematurity (Tuomala et al., 2002; Tuomala et al., 2005; Watts 
et al., 2004a). In addition, a number of smaller studies have shown no association 
between ART and prematurity, but in many cases there are clear methodological 
reasons why findings differed. For example, some early studies looked at 
combination therapy rather than HAART, and combined dual and triple therapy in 
the analyses. In a French intervention study in which no association between ART 
and prematurity was detected, dual therapy (n=445) was compared with a historical 
cohort of women on monotherapy (n=899) (Mandelbrot et al., 2001). In a 
retrospective Italian study, a low rate of prematurity (10%) was reported in women 
on combination therapy, but the study included only 100 women and there were no 
controls (Bucceri et al., 2002). More recently, a study from Brazil reported no 
association between ART and preterm delivery in multivariable analysis (Szyld et 
al., 2006). However, the model was adjusted for mode of delivery, which although 
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associated with both treatment and prematurity, is not a confounder, since it does not 
in itself influence either factor. Mode of delivery is associated with type of treatment 
because of concurrent changes over time in use of ART and elective caesarean 
section (and in recent years because choice of ART influences delivery options). It is 
also affected by preterm delivery, since premature labour or rupture of membranes 
precludes delivery by elective caesarean section. In the Brazilian study, HAART was 
associated with a non-significant 1.6-fold increased risk of prematurity in univariable 
analysis, which is consistent with NSHPC findings (Szyld et al., 2006). In one of the 
early US studies, combination therapy was not explicitly defined but probably 
included a substantial proportion of dual therapy regimens, since all deliveries 
occurred between 1990 and 1998 (Tuomala et al., 2002).  
In a published report from Africa, infants exposed to HAART as part of a prevention 
study carried out between 2003 and 2007 were compared with infants exposed to 
zidovudine and single-dose nevirapine in 2001 to 2003. Although there may have 
been other limitations in this historical comparison, issues around indication for 
treatment would have been avoided since only one treatment approach was used in 
each period. Gestational age was not available in the study, but low birth weight was 
found to be more prevalent in infants born to women on HAART than in those 
exposed to zidovudine (22% versus 12%) (Ekouevi et al., 2008). 
Despite the growing evidence supporting a link between HAART and prematurity, a 
meta-analysis published in 2007 concluded that there was no association between the 
two (Kourtis et al., 2007). However, the analysis failed to address a number of 
methodological issues, including the possibility of bias in the comparison of treated 
and untreated women and combination of dual therapy and HAART, which could 
attenuate the association with exposure to more potent combinations of drugs. 
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Furthermore, in several of the studies included in the meta-analysis (Bellon Cano et 
al., 2004; Cooper et al., 2002; Lorenzi et al., 1998; Mandelbrot et al., 2001), only 
crude prematurity rates were available, and estimates were therefore not adjusted for 
any potential confounders. Finally, the conclusions put forward in the meta-analysis 
are in themselves contradictory, since it is suggested that although ART is not 
associated with preterm delivery, duration and type of ART may be.  
Strengths and weaknesses of NSHPC analysis 
Evidence to date linking ART and prematurity has arisen mainly from cohort studies; 
in contrast to other studies, which recruit selectively and require consent, the NSHPC 
provides comprehensive population-based data, thereby reducing the chance of 
selection or ascertainment bias. However, due to resource limitations and in order to 
maintain high response rates, the range of information collected on other prematurity 
risk factors was limited. Prior preterm delivery is an important risk factor on which 
information was not available through the study, and which has been postulated as a 
potential confounder in the association between ART and prematurity (Tuomala et 
al., 2005; Tuomala & Yawetz, 2006); in one study of ART-exposed pregnant 
women, those on monotherapy were less likely than those on combination therapy to 
have had a prior preterm delivery (Tuomala et al., 2005). Although it was not 
possible to adjust for history of preterm delivery in NSHPC analyses, stratifying by 
parity did not affect the findings, suggesting that any potential confounding by prior 
preterm delivery would be minimal. Information on other potential risk factors for 
prematurity, such as socio-economic status, smoking, and drug or alcohol abuse, was 
also not available through the surveillance system. However, despite substantial 
changes over time in the demographic characteristics of HIV-infected pregnant 
women, including risk factors for prematurity, the magnitude of the association with 
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HAART was similar in different time periods (1994-1999 and 2000-2005), 
suggesting that other factors were unlikely to have substantially confounded the 
association between ART and prematurity.  
An important source of bias in observational studies exploring ART and premature 
delivery is indication for treatment (Tuomala & Yawetz, 2006). According to the 
BHIVA Pregnancy Guidelines, monotherapy should only be offered to women who 
have low viral loads (<6000-10,000 copies/ml) and do not require treatment for their 
own health (BHIVA, 2001; BHIVA/CHIVA, 2008); those on monotherapy may 
therefore be at lower risk of premature delivery than those who require more 
aggressive HIV treatment, due to differences in disease stage or other immunological 
factors. Specific details about indication for treatment were not available in this 
analysis, but information on HIV-related symptoms, CD4 cell count and viral load 
was. Adjusting for these factors, which contribute to the decision about type and 
timing of initiation of treatment, tended to increase the association between HAART 
and prematurity. There is also some recent evidence in the literature that the 
association may be independent of treatment indication: in an Italian study, 
combination therapy with PIs was associated with an increased risk of prematurity 
(32% versus 18% in those not exposed to PIs) after adjusting for treatment indication 
and other variables (Ravizza et al., 2007). Information on reason for treatment is now 
being collected through the NSHPC. 
Classification of antiretroviral therapy was according to the total number of drugs 
received in pregnancy. Although switches in regimens do occur, most are from one 
HAART regimen to another, rather than from monotherapy to HAART or vice versa. 
Treatment misclassification was therefore likely to be minimal. Only 70 pregnancies 
were excluded from the analysis due to insufficient treatment information, some of 
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which were undoubtedly in untreated women since a third occurred in the 1990s, and 
treatment was only available from 1994 onwards. The prematurity rate in these few 
pregnancies was similar to the overall rate, and excluding them is unlikely to have 
introduced significant bias. 
Duration of pregnancy was explored as a categorical variable in these analyses, to 
avoid complications introduced by the censoring of pregnancies delivered by elective 
caesarean section at around 38 weeks gestation. Rates of caesarean section changed 
alongside uptake of ART, and it was therefore not possible to explore duration of 
pregnancy as a continuous variable without introducing bias. Nevertheless, the fact 
that the association between HAART and preterm delivery was observed for <37 
weeks, <35 weeks and <32 weeks gestation suggests that pregnancy duration is 
affected across the spectrum of gestational ages, possibly slightly more so at earlier 
gestational ages. It was also not possible to explore the type of preterm deliveries 
associated with ART, as details regarding preterm labour or premature rupture of 
membranes were not systematically collected. 
Birth weight  
Compared with infants exposed to mono/dual therapy, HAART-exposed infants had 
lower birth weight after adjusting for gestational age (and controlling for maternal 
clinical status, IDU-acquired infection, ethnic origin and maternal age at delivery). In 
clinical terms the difference in mean birth weight and in z-scores was small, but may 
have implications for very premature infants who are also of low birth weight for 
gestational age. In the ECS, differences in birth weight z-score by type of maternal 
ART were detected; however, these varied by gestational age, with infants born at 34 
to 36 weeks being heavier if exposed to combination therapy than if not exposed. 
There was no difference in z-scores for infants born before 34 weeks or at term 
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(European Collaborative Study, 2005). Few other studies have looked at birth weight 
standardised for gestational age, but very low birth weight (<1500 g) was associated 
with combination therapy in one US study (Tuomala et al., 2002), and an increase in 
low birth weight over time has been reported in the ECS (European Collaborative 
Study, 2004a).  
Conclusion 
In conclusion, the association between ART and prematurity was consistent across 
unadjusted and adjusted analyses, and across a number of sub-analyses, and supports 
the findings from several other studies. The link between ART and premature 
delivery or low birth weight has now been reported in both cohort and non-consented 
surveillance or monitoring studies, and in different populations in Europe, the US 
and Africa, lending support to these findings. Nevertheless, it remains unclear why 
some studies have failed to detect an association between treatment and prematurity.  
Comparative analysis 
In order to investigate possible reasons underlying the conflicting findings with 
respect to ART and prematurity, NSHPC data were compared with data from the 
European Collaborative Study (ECS) and from the Pediatric Spectrum of HIV 
Disease (PSD) project in the US. Preliminary findings from the three studies 
included in the comparative analysis had suggested some differences between studies 
with respect to prematurity (European Collaborative Study, 2004a; Schulte et al., 
2007; Townsend et al., 2007). This project set out to estimate the magnitude of the 
association between ART and prematurity using standard methods across the three 
studies, and to compare populations and methodologies in order to explain any 
differences between studies.  
  278 
Figure 7.1 illustrates the associations between ART, prematurity and other potential 
risk factors, along with areas which could lead to differences in study findings.  
 
Figure 7.1 Association between antiretroviral therapy, prematurity and other 
risk factors  
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In basic analyses comparing HAART with monotherapy, heterogeneity between 
studies in the association between ART and premature delivery was confirmed, 
implying that there were significant differences between studies in the association 
between ART and prematurity. Findings were consistent between the two European 
studies (ECS and NSHPC), with women on HAART in pregnancy at significantly 
increased risk of premature delivery compared with those on monotherapy; however 
in the US study (PSD), no such association was noted. Women on dual therapy in the 
PSD were at a lower risk of prematurity compared with those on monotherapy. These 
differences persisted in univariable and multivariable analyses, in basic and more 
refined multivariable models, at different gestational age cut-offs (<37 weeks and 
<32 weeks), and with PI and non-PI-based HAART. This heterogeneity precluded a 
combined analysis comparing HAART with monotherapy, although further 
investigation with dual therapy as the reference group, showing no significant 
heterogeneity, enabled a pooled analysis to be carried out subsequently.  
There were consistent associations between other risk factors and prematurity across 
the three studies; for example, in the final multivariable models, which included all 
significant variables, maternal IDU was associated with a two-fold (or more) 
increased risk of prematurity in all three studies, as was the presence of HIV-related 
symptoms in the PSD and NSHPC. These observations suggest some level of 
comparability between studies, despite differences in the prevalence of these risk 
factors and in the way they were measured.  
There were also some differences in the relationships between other risk factors and 
prematurity: ethnic group and year of delivery were significantly associated with 
prematurity only in the PSD. These findings reflect trends reported for the US 
population: crude prematurity rates in African American women in the US are higher 
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than in white women (17.8% versus 11.5%), a difference that is not fully explained 
by socio-economic or behavioural factors (Institute of Medicine, 2006). The overall 
prematurity rate is known to be increasing in the US, having risen from 10.6% in 
1990 to 12.5% in 2004, although the causes of this rise are not fully understood 
(Institute of Medicine, 2006). The fact that unadjusted prematurity rates showed no 
change over time is likely due to the decline in other risk factors (IDU and HIV-
related symptoms) among HIV-infected women, which would have counteracted the 
underlying baseline increase in prematurity associated with an increase in use of 
ART.  
A number of methodological issues have been suggested as possible explanations for 
the discrepancies observed between different studies (Table 7.2) (European 
Collaborative Study, 2004a; Tuomala et al., 2002; Tuomala et al., 2005). Some of 
these points were addressed in the analysis presented in Chapter 5 and are discussed 
below.  
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Table 7.2 Putative explanations for conflicting findings regarding ART and 
prematurity  
 
Issue Possible explanation Reference 
Study design Case ascertainment, inclusion criteria (Townsend et al., 2007) 
Analytical 
approach 
Differences in choice of reference group (Townsend et al., 2007) 
Populations Differences in baseline prematurity rate (Patel, Thorne, & Newell, 
2007) 
 Population differences, e.g. in access to 
care and in proportion from minority 
groups 
(Patel, Thorne, & Newell, 
2007; Tuomala & Yawetz, 
2006) 
Bias and 
confounding 
Lack of adjustment for other risk factors, 
including: 
- prior preterm delivery 
- duration of HAART 
- clinical disease stage or HIV 
viral load 
(Tuomala & Yawetz, 2006) 
  Differences in prescribing patterns, 
confounding by indication for treatment 
(Tuomala & Yawetz, 2006) 
 
Study design 
Differences in methodology between studies could affect the observed association 
between treatment and pregnancy outcome; in a study by Tuomala and colleagues, 
which combined data from clinical trials and cohort studies, women in one trial were 
recruited at 20-30 weeks gestation (Tuomala et al., 2002), thereby excluding those 
who failed to attend for antenatal care during that period, a factor potentially 
associated with prematurity risk as well as choice of treatment. In the collaborative 
project described in Chapter 5, no systematic exclusions were identified in any of the 
three studies. The PSD and NSHPC were comprehensive and aimed to include all 
births to HIV-infected women identified within the defined study area. The ECS was 
based in specific centres and required enrolment, but very high enrolment rates were 
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reported, with no systematic exclusions due to refusal or to late presentation or 
diagnosis (Patel, 2007).  
The PSD and ECS were based in specific hospitals and clinics, and the populations 
covered may not have been totally representative of the wider population of HIV-
infected pregnant women. In fact, the PSD was set up specifically to cover areas of 
high HIV prevalence. However, this is unlikely to have led to bias in the association 
between ART exposure and prematurity, since in most cases neither administration 
of treatment nor delivery had occurred at the time of inclusion in the study. Some 
women were already on treatment before pregnancy, but as shown for the NSHPC, 
most were on HAART (95%) (information on timing of treatment initiation was not 
available for the PSD). Overall, no specific methodological factors relating to 
inclusion criteria or case ascertainment were identified which would have led to the 
observed heterogeneity between studies.  
Population differences 
There were broad population differences between studies, as shown by variation in 
the prevalence of IDU, ethnic group and other demographic characteristics, which 
has also been highlighted elsewhere (Newell et al., 2007). Baseline prematurity rates 
also differed, ranging from 12% in the NSHPC, to 15% in the ECS, and 17% in the 
PSD. In the US, rates have traditionally been higher than in other developed 
countries, at 10-12% (Institute of Medicine, 2006), compared with 5-9% in Europe 
and other developed countries including the UK (Aveyard et al., 2002; Gardosi & 
Francis, 2000; Goldenberg et al., 2008; Tucker & McGuire, 2004). However, in the 
analysis presented in Chapter 5, the association between treatment and prematurity 
was measured using odds ratios, and multiplicative effects should therefore not be 
affected by differences in baseline prevalence (Kirkwood & Sterne, 2003). In fact, a 
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higher baseline prematurity rate would mean smaller numbers of pregnancies would 
be required to detect an effect of the same relative magnitude.  
Type of ART varied between studies, as did the drugs included within regimens. 
Although detailed information on drugs included within HAART regimens was not 
available, differences between populations were apparent, with PI-based HAART 
more commonly used in the PSD and ECS, and non-PI-based HAART more 
common in the NSHPC up to 2002. There was some variation in dual therapy 
regimens, but in all three studies dual regimens consisted predominantly (over 70%) 
of zidovudine and lamivudine. Monotherapy consisted almost entirely of zidovudine. 
Since heterogeneity was mainly apparent in the comparison of HAART with 
monotherapy, but not with dual therapy, it is unlikely that differences between 
studies were due to differences in specific regimens. No difference in prematurity 
rates between PI and non-PI HAART was observed in any of the studies. 
Furthermore, the suggested biological mechanism for the HAART-prematurity 
association relates to the overall effect of combination therapy on the cytokine 
environment (Fiore et al., 2006).  
Analytical approach 
One of the difficulties in comparing studies of ART and pregnancy outcome is the 
definition and selection of treatment groups. In some studies combination therapy 
consisted of two or more antiretroviral drugs (Mandelbrot et al., 2001), while in 
others it referred to three or more (European Collaborative Study and the Swiss 
Mother + Child HIV Cohort Study, 2000). The choice of comparison groups also 
differed, with monotherapy and dual therapy combined in some studies (European 
Collaborative Study, 2004a), but not in others (Schulte et al., 2007). In this analysis, 
the same comparison group (monotherapy) was chosen for all three studies, and 
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significant heterogeneity in the association between HAART and prematurity was 
apparent. However, there were some similarities in the pattern of prematurity by 
ART; in all three studies, rates were lowest in women on dual therapy, higher in 
those on monotherapy, and higher again in untreated women (Figure 5.7, page 186). 
However, in the ECS and NSHPC, the rate in women on HAART was higher than in 
those on monotherapy or dual therapy, while in the PSD, this rate was similar to 
those on monotherapy, but higher than in those on dual therapy. If dual therapy was 
used as a baseline, there was no significant heterogeneity in the association with 
prematurity, and unadjusted odds ratios ranged from 1.25 (PSD) to 1.80 (ECS). 
Pooling the data and adjusting for study yielded a significant 1.5-fold increase in 
prematurity associated with HAART, which remained after adjusting for ethnic 
group, region of birth, IDU, year of delivery, and clinical status. The choice of 
baseline did, therefore, affect the findings, leading to different conclusions about the 
association between HAART and prematurity. In the PSD, choosing monotherapy as 
a baseline resulted in there being no association between HAART and prematurity, 
while choosing dual therapy resulted in a significant association. In light of the 
consistency between the ECS and NSHPC with monotherapy as a reference category, 
and the consistency across the three studies with dual therapy as a baseline, HAART 
appears to be associated with a significantly increased risk of prematurity.  
Confounding and bias 
The three studies included in this project were chosen in part because of a history of 
successful collaboration and data sharing between the study groups. Although there 
were similarities in the data collected, some variables were not available in all of the 
studies, and it was not possible to control for certain risk factors consistently. In 
particular, since the PSD was a paediatric study, certain maternal variables (age, CD4 
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count and viral load) were not collected. Furthermore since none of the three studies 
were specifically set up to monitor ART and pregnancy outcome, information was 
only available on some of the known risk factors for prematurity, and there were 
differences between studies in what information was collected, and in how risk 
factors were measured (Chapter 5, Table 5.9).  
Although IDU was included in the analyses, the quality of information varied 
between studies. In the NSHPC, IDU was reported as the route of HIV acquisition, 
and did not necessarily reflect current IDU. Although there may have been some 
misclassification, it is unlikely that it would be related to ART. Misclassification 
would therefore tend to attenuate the association between ART and prematurity, 
because the decline over time in both monotherapy and IDU meant that in all three 
studies, women classified as IDU were more likely to be on monotherapy than on 
HAART (data not shown). Adjusting for IDU (along with ART, ethnic group, region 
of birth and year) led to an increase in the odds ratio for the effect of ART on 
prematurity in the ECS and NSHPC, suggesting some confounding by IDU, but this 
was not the case in the PSD. Misclassification of IDU in the PSD may have 
concealed an association between HAART and prematurity. Information on use of 
other illicit substances in pregnancy was not available, but is likely to have differed 
between studies. If, like IDU, use of other illicit drugs was associated with 
monotherapy, the inability to adjust for this in the PSD could also have masked an 
association between HAART and prematurity when monotherapy was used as a 
comparison group.  
Maternal age was not routinely available in the PSD; however, in a small subset of 
women, median maternal age was not substantially different from that in the ECS 
and NSHPC. Furthermore maternal age was not significantly associated with 
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prematurity in the ECS or NSHPC, and it is therefore unlikely that the inability to 
adjust for age in the PSD substantially altered the findings.  
The ethnic profile of the populations varied substantially between studies; there were 
differences not only in the proportion of black and white women, but also within 
these broad ethnic categories, which were not comparable across studies. In the PSD 
most black women were US-born (i.e. ‘African American’), whereas in Europe the 
majority of black women were born in sub-Saharan Africa and had arrived in Europe 
relatively recently (as shown in Chapter 3 for the NSHPC). Considering these 
differences, it is not surprising that the association between ethnic group and 
prematurity was not consistent across studies; in fact, in multivariable analysis ethnic 
group was only associated with prematurity in the PSD, with black women about 
50% more likely than white women to deliver prematurely. Ethnic differences in 
preterm delivery rates have been reported for the wider US population (Institute of 
Medicine, 2006). Observed ethnic differences in prematurity rates in the PSD could 
therefore be due to socio-economic factors or disparities in access to healthcare 
(Blustein, 2008). Nevertheless, adjusting for ethnic group in the PSD did not 
substantially alter the association between ART and prematurity, and there were no 
significant interactions between ethnicity and ART after adjusting for other factors. 
In all three studies, mothers who were born abroad had a lower risk of premature 
delivery than those born within the study region, although this was not statistically 
significant in the ECS or NSHPC. In the US, foreign-born adults fare considerably 
better than those born in the US in terms of a number of health outcomes (including 
obesity, cardiovascular disease and pregnancy outcomes, such as preterm delivery 
and low birth weight), despite limited access to healthcare and adverse social 
circumstances (Dey & Lucas, 2006; Reed et al., 2005). Furthermore, among 
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immigrant groups, length of stay in the US is associated with a deterioration in health 
measures, including prematurity and low birth weight (Callister & Birkhead, 2002; 
Dey & Lucas, 2006). Social support, diet and low rates of smoking and alcohol 
consumption may play a role (Page, 2004). 
Information on other risk factors for prematurity, such as low socio-economic status, 
smoking, sexually-transmitted infections, and prior preterm delivery (Slattery & 
Morrison, 2002) was not collected in the PSD, ECS or NSHPC, and the prevalence 
of these risk factors is likely to have differed between studies. In a secondary 
analysis of an international MTCT clinical trial involving HIV-infected pregnant 
women, US women were more likely than European women to have a history of 
sexually-transmitted infections, as well as previous pregnancies and miscarriages 
(Newell et al., 2007). Any trends over time in these risk factors would produce an 
association between those factors and treatment, since the latter also varied over 
time. In the PSD the majority of pregnancies in women on monotherapy occurred 
before 2000, when IDU and HIV-related symptoms were more common and 
monotherapy was used more widely than in recent years. In contrast, in the NSHPC 
the dramatic increase in the number of pregnancies since 2000 and continued use of 
monotherapy has meant that the majority of monotherapy exposures occurred during 
the HAART era. The comparison between HAART and monotherapy was therefore 
more historical in the PSD (and in the ECS) than in the NSHPC. A decline over time 
in unmeasured risk factors for prematurity could have led to an attenuation of the 
association between HAART and prematurity, which may have been accounted for 
to some extent, although not fully, by the inclusion of year of delivery in the models.  
On the other hand, selection bias in terms of allocation to treatment groups may have 
been a more important methodological concern in the NSHPC than in the other two 
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studies. Since none of the studies were randomised with respect to treatment, 
decisions about type of ART would have been made on the basis of availability of 
regimens, local and national treatment guidelines, and clinical indication, all of 
which would have varied between studies. Differences in the use of ART between 
the three studies were apparent: dual therapy was more widely used in the PSD than 
in the ECS or NSHPC, and monotherapy was less common in recent years in the 
PSD. It has been suggested that selective use of more potent treatments for women 
with more advanced HIV disease could explain the difference in prematurity rates in 
different treatment groups (Tuomala & Yawetz, 2006). However, since the advent of 
HAART, US treatment guidelines have been more cautious than European ones 
toward use of monotherapy for preventing MTCT, and now recommend it only be 
considered for women with viral loads <1000 copies/ml, compared with <6000-
10,000 copies/ml in current British guidelines (BHIVA/CHIVA, 2008; Coll et al., 
2002; Perinatal HIV Guidelines Working Group, 2008). This would suggest that 
when comparing HAART and monotherapy in recent years, selection bias would be 
more likely in the PSD than in the ECS or NSHPC. There was no evidence of this in 
these analyses, although an association could have been masked by concurrent 
changes in maternal characteristics. 
Adjusting for clinical status, CD4 cell count and HIV RNA viral load did not 
substantially alter the association between ART and prematurity, despite the fact that 
all three were significantly associated with prematurity. Although adjusting for these 
factors would not necessarily remove all bias introduced by indication for treatment, 
it is likely that if substantial bias were present, adjusting for factors related to it 
would reduce the magnitude of the association; in fact, controlling for these variables 
increased the association between ART and prematurity in both the ECS and the 
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NSHPC. The inability to adjust for CD4 count and/or viral load in the PSD meant 
that the possible confounding effects of indication for treatment were addressed to a 
lesser extent in this study (only through the inclusion of clinical status). It was also 
not possible to adjust for repeat pregnancies in the PSD, another factor which led to 
an increase in the odds ratios for prematurity in the ECS and NSHPC.  
An important limitation in this analysis was the inability to adjust for certain 
potential confounders, which could affect the findings in all three studies, but 
particularly in the PSD, in which maternal and pregnancy information was more 
limited. It is possible that the lack of association between HAART (versus 
monotherapy) and prematurity in the PSD could have been due to unmeasured 
confounding, since the comparison between the two groups in the PSD was more 
historical (i.e. most monotherapy exposures occurred pre-2000, and most HAART 
exposures since 2000). However, this explanation is not consistent with the fact that 
a greater association between HAART and prematurity was estimated in the ECS 
(AOR=2.9) than in the NSHPC (AOR=1.5), despite the HAART-monotherapy 
comparison being more historical in the ECS than in the NSHPC. 
Conclusions 
The PSD differed substantially from the ECS and NSHPC in the association between 
ART and premature delivery, when comparing HAART and monotherapy. Despite 
the identification of population and methodological differences, and the use of a 
standard analytical approach, no clear explanation for these conflicting findings was 
identified in this comparative analysis. However, it is possible that the inability to 
adjust for maternal viral load and CD4 cell count, or for repeat pregnancies, could 
have attenuated the association between HAART and prematurity in the PSD. There 
was no heterogeneity in terms of the HAART-prematurity association when dual 
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therapy was selected as a baseline; in this separate analysis, HAART was associated 
with a significantly increased risk of prematurity in all three studies.  
Although a randomised control trial of ART in pregnancy is not feasible, a carefully 
designed cohort study could potentially address some of the limitations of these 
studies, providing detailed information was collected on other risk factors for 
premature delivery, on clinical factors including CD4 count and viral load before and 
after initiation of treatment, and on type and timing of ART in pregnancy. However, 
to carry out full multivariable analyses in any such study would require larger 
numbers of pregnancies than those currently available.  
7.5 Risks and benefits of antiretroviral therapy in terms of 
pregnancy outcome 
Much of the focus in this thesis has been on exploring adverse outcomes associated 
with ART. Although it is important to be aware of the risks associated with 
treatment, these must be considered in relation to the benefits for any conclusions 
about the value of the treatment to be made. In Chapter 6, a risk-benefit model was 
developed to enable the observed risks of prematurity and stillbirth to be quantified 
in relation to the main benefit of treatment, a reduction in the risk of MTCT. 
Comparison was made between HAART (any time) and monotherapy in the pre-
HAART era, since use of monotherapy in more recent years has been restricted to 
women with relatively low viral load, who therefore have a lower baseline risk of 
transmission. This comparison enabled the full extent of the benefits associated with 
HAART to be quantified in the context of the reported risks. 
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The models suggested that avoiding 100 transmissions through exclusive use of 
HAART would result in an additional 68 infants born at <37 weeks, including 23 
born at <32 weeks, and 10 additional stillbirths, compared with exclusive use of 
monotherapy. Confidence intervals around the three estimates approached or crossed 
zero, and were therefore borderline or non-significant for all three outcomes. In these 
models, altering the risk of MTCT according to prematurity to allow for an increased 
risk of transmission in premature infants did not affect the results. These findings 
relate to a population level approach, where either monotherapy or HAART was 
used; although the models showed no difference between the exclusive HAART 
scenario and the selective monotherapy scenario, for individual women who do not 
require HAART for their own health, the option of minimising the risk of 
prematurity and stillbirth with no additional increase in the risk of transmission 
would clearly be optimal.  
Interpretation of the results of these risk-benefit models depends on the relative 
severity of the risks and benefits. In absolute terms, HAART would be considered 
superior to exclusive monotherapy, since more infants are prevented from becoming 
infected than are born premature or stillborn. However, further information is 
required in order to determine an appropriate risk-benefit acceptability threshold for 
these outcomes. Prematurity is associated with a significantly increased risk of 
perinatal morbidity and mortality, although this is generally confined to infants born 
very prematurely (Saigal & Doyle, 2008). On the other hand, HIV infection has 
serious lifelong consequences, including a considerable annual risk of progression to 
AIDS and death. However, it is now treatable, and prognosis for HIV-infected 
children has increased substantially over the last decade since the introduction of 
effective ART (Judd et al., 2007). Furthermore, the appropriate balance of 
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prematurity and MTCT is likely to vary by population and healthcare setting. In 
countries with poor health systems, both prematurity and HIV will be associated with 
higher rates of morbidity and mortality than in resource-rich settings, and the relative 
consequences and costs of the different outcomes will vary according to the quality 
of neonatal care facilities and availability of ART. Population-specific information 
on outcomes in premature infants and HIV-infected children would ideally be 
factored into decisions regarding the acceptable risk-benefit threshold. Additionally, 
the possibility that ART-exposed premature infants experience improved outcomes 
compared with infants born prematurely for other reasons (European Collaborative 
Study, 2004c) would also need to be considered. Finally, attitudes and preferences of 
both clinicians and patients towards the acceptability of different perinatal outcomes, 
which may be affected by the continued stigma of HIV (Anderson & Doyal, 2004; 
Bunting, 1996), may also influence decision-making with regards to ART-related 
risks and benefits. Further information on mortality, morbidity and longer-term 
outcomes, as well as their associated costs, for both HIV-infected and premature 
children would enable a more informed assessment of the acceptability of the ratio of 
risks to benefits estimated in this analysis.  
7.6 Strengths and weaknesses of NSHPC surveillance data 
The NSHPC is an active reporting system with high response rates: over 90% of 
respondents routinely return the quarterly notification card (www.nshpc.ucl.ac.uk). 
Through this study, information is sought on all HIV-infected pregnant women 
diagnosed any time up to delivery throughout the UK and Ireland, regardless of 
maternal characteristics or uptake of interventions. Comparison of the number of 
pregnancies reported to the NSHPC with national unlinked anonymous 
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seroprevalence data suggests that case ascertainment for pregnancies in HIV-infected 
women ending in a live birth is extremely high: over 95% in 2007 (Health Protection 
Agency, 2008). Since a small proportion of infected women remain undiagnosed at 
delivery, ascertainment of diagnosed women is likely to be even higher, thanks to the 
active and complementary nature of the obstetric and paediatric reporting schemes. 
About 20% of births were reported through only one of the schemes; the parallel 
approach therefore ensures a higher ascertainment rate than would be achievable 
through a single scheme. Despite the complementary nature of the schemes, it was 
not possible to estimate the likely proportion of missed cases by capture-recapture 
methods, since the two schemes are not independent. When pregnancies are notified, 
missing paediatric reports are routinely followed up, and vice versa.  
Although high coverage rates are achieved through the NSHPC, this can only be 
accomplished with the cooperation of a large number of health professionals. About 
240 obstetric respondents, in most cases one for each maternity unit, are currently 
involved in the study (see www.nshpc.ucl.ac.uk), while almost 3000 paediatricians 
report to the British Paediatric Surveillance Unit’s Orange card system (BPSU, 
2008), about 130 of whom notified cases to the NSHPC in 2005 (NSHPC 
unpublished data). Because of the number of respondents involved, and in the 
interests of maintaining high response rates, there were naturally limits on the 
amount and type of data that could be collected, and information on certain 
potentially relevant confounders was not available.  
Although considerable effort went into ensuring that missing information was kept to 
a minimum, some was inevitable. Often this was random – for example, if a 
respondent accidentally skipped a question – but in some cases, patterns to the 
missing data were apparent. Where information was missing on a particular exposure 
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or outcome, details of other characteristics were sometimes more likely to have been 
omitted, owing to a common underlying cause. For instance, late presentation for 
antenatal care or unexpected premature delivery may have resulted in limited 
maternal details being collected, as well as insufficient time for running routine 
laboratory investigations. Where cases were reported through only one branch of the 
surveillance scheme (obstetric or paediatric), information on all variables collected 
only through the other scheme were inevitably missing. Patterns in missing data were 
also caused by changes over time in guidelines or protocols, such as viral load testing 
in pregnancy. The effects of excluding cases with missing data differed for each 
analysis, and were therefore discussed in the relevant sections of this thesis.  
In most analyses, comparison was made between different treatment groups. 
Identifying an appropriate group of uninfected controls was not feasible, particularly 
given the substantial differences in demographic characteristics between HIV-
infected women and the general population.  
7.7 Conclusions and implications for clinical management 
This thesis describes the changing epidemiology of HIV in pregnancy in the UK and 
Ireland, and highlights the success of routine antenatal HIV screening policies, both 
through increased detection of HIV in pregnancy and high uptake of antiretroviral 
therapy, leading to very low mother-to-child transmission rates: only 1.2% in 2000-
2006. A range of strategies for the management of HIV in pregnancy are now 
available (BHIVA/CHIVA, 2008), and most women are recommended and receive 
HAART in pregnancy. Nevertheless, zidovudine monotherapy with planned 
caesarean section remains an alternative for women who do not require HAART for 
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their own health, and is supported by these findings, showing no transmissions 
among over 450 women opting for this approach. The more tolerant approach 
towards vaginal delivery for women who achieve full viral suppression on HAART 
was evident in these findings, with rates of planned vaginal delivery rising over time. 
These data also support this management approach, with transmission rates in 
women opting for HAART and planned vaginal delivery not significantly higher than 
with elective caesarean section. These findings must, however, be interpreted in the 
context of current guidelines, in which interventions are recommended on the basis 
of timing of maternal diagnosis, clinical presentation, response to treatment, and 
other individual factors.  
These low transmission rates in diagnosed women highlight the importance of 
ensuring that women are identified as HIV-infected in time to take up appropriate 
interventions; early testing for all pregnant women should remain a priority. 
Continuing to improve the offer and uptake of antenatal HIV testing could have a 
significant impact on further reducing MTCT, since most perinatally acquired 
infection is now among infants whose mothers remain undiagnosed at delivery 
(AIAU, NSHPC, & CHIVA, 2007).  
The potential for adverse outcomes associated with treatment is an important 
consideration for HIV-infected pregnant women, particularly those who do not 
require treatment for their own health. These findings support the premise that 
HAART in pregnancy is associated with an increased risk of premature delivery and 
possibly stillbirth. The number of births to diagnosed HIV-infected women in the UK 
and Ireland continues to rise, and an increasing number of women are on treatment at 
conception. Being on HAART in early pregnancy was not associated with an 
increased risk of congenital abnormalities, but was associated with a possible 
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increase in the risk of pre-eclampsia. Monitoring adverse pregnancy and perinatal 
outcomes should remain a priority, and further research into the mechanisms leading 
to pre-eclampsia, premature delivery and stillbirth in HIV-infected women is needed. 
Questions remain regarding the acceptable balance of risks and benefits associated 
with different treatment approaches. While HAART provides overall benefits, it 
seems appropriate to offer monotherapy to women who do not yet require HIV 
treatment for their own health, since this approach will minimise the risk of adverse 
outcomes. Earlier initiation of treatment is likely to reduce the risk of in utero 
transmission, which accounts for an increasing proportion of perinatal transmissions 
(Warszawski et al., 2008), and may cut overall transmission rates to below 1%. 
Latest guidelines now suggest starting HAART prior to fetal viability (24 weeks), or 
as early as 20 weeks if a woman has high baseline viral load and wishes to deliver 
vaginally (BHIVA/CHIVA, 2008). In risk-benefit analyses, it was not possible to 
compare scenarios involving differential timing of initiation of treatment, and indeed 
the number of transmissions in these groups would be too small to yield conclusive 
results.  
In conclusion, analysing data from ongoing prospective surveillance of HIV in 
pregnant women has enabled the impact of changes in guidelines and clinical 
practice on the uptake and effectiveness of interventions to be assessed, and has 
provided timely evidence on mother-to-child transmission rates as well as adverse 
outcomes.  
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7.8 Future work 
Mother-to-child transmission 
With MTCT rates now very low, remaining questions relating to transmission 
become increasingly difficult to answer as larger numbers of pregnancies are 
required to achieve sufficient statistical power. As many of the risk factors for 
MTCT have been identified, and can be minimised, remaining cases of perinatal 
transmission are increasingly attributable to a range of complex social and 
management issues (AIAU, NSHPC, & CHIVA, 2007). Detecting patterns relating to 
other preventable factors is challenging, and may require collaboration between 
different study groups. Information on duration of ruptured membranes is now being 
collected through the NSHPC. However, although vaginal deliveries in women with 
undetectable viral load have increased in recent years, it is not clear whether many 
women are allowed to remain undelivered several hours after membranes have 
ruptured, since current guidelines advocate “a low threshold for caesarean section in 
the face of slow or difficult labour or concern about fetal condition” 
(BHIVA/CHIVA, 2008). In any case, a large number of pregnancies will be required 
to answer this question, and as with other remaining questions around MTCT, a 
collaborative approach is more likely to produce answers than a single study.  
Adverse maternal and pregnancy effects of antiretroviral therapy  
These analyses contribute to the debate about the association between ART and 
pregnancy outcome, particularly prematurity. As mentioned previously, a carefully 
designed cohort study could potentially overcome some of the limitations inherent in 
these surveillance data and in other studies, such as issues around indication for 
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treatment and other prematurity risk factors. However, an entirely new study to 
address this question would not, at this stage, be an appropriate use of resources, 
given the current body of evidence, the balance of risks and benefits demonstrated in 
Chapter 6, and the large sample size required.  
Further research into the relationship between HIV, ART and the cytokine 
environment during pregnancy could provide useful information, not only on the 
biological plausibility of the link between HAART and preterm delivery, but also on 
the immunological mechanisms underlying other pregnancy complications, such as 
pre-eclampsia and stillbirth, which seem to be increased in ART-treated women. 
Information on risk factors for HAART-associated preterm delivery is also needed, 
to enable early identification of ‘at risk’ women, and targeted management of these 
pregnancies. 
Further investigation into the safety of zidovudine monotherapy in terms of longer-
term maternal outcomes such as future drug resistance would enable this approach to 
be recommended more confidently for women not requiring HAART, thereby 
minimising overall fetal exposure to antiretroviral drugs. Such information would 
also be relevant for African populations, where zidovudine monotherapy is used 
more widely in combination with single-dose nevirapine at delivery. Questions 
remain about the effect of postpartum treatment interruption, such as following 
zidovudine monotherapy in pregnancy, on maternal disease progression. These 
questions are currently being investigated in a cohort of HIV-infected women 
followed up after pregnancy in the Ukraine (C Thorne, personal communication, 
2009).  
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Development of risk-benefit models 
The models presented in Chapter 6 provided ratios of risks to benefits which 
suggested that despite the associated risks, exclusive HAART was overall more 
favourable than exclusive monotherapy. Optimal risk-benefit acceptability thresholds 
could be estimated quantitatively, based on cost and/or mortality data for both sets of 
outcomes, which could be obtained from the existing literature. These models could 
also be developed for use in other populations or for different scenarios or adverse 
outcomes, which were not addressed in this thesis; in a recent study, the risks of 
mitochondrial toxicity associated with a number of different ART regimens were 
compared with the benefits in a decision analysis model (Ciaranello et al., 2008). 
Best and worst case scenarios were derived, and sensitivity analyses were used to 
examine the effect of varying relevant parameters. The benefits of Monte Carlo 
methods for this type of analysis are that risk-benefit ratios are obtained, which 
facilitate comparison across groups, and that realistic confidence intervals can be 
derived. The estimates used in these models were all obtained from NSHPC data. In 
order to make the findings more generalisable, summary estimates drawing on a 
number of published studies could instead be used as inputs to the models.  
Monitoring for adverse outcomes in exposed children 
Finally, continued widespread use of potent combinations of antiretroviral drugs in 
pregnancy means that monitoring of ART in pregnancy and perinatal life is essential 
to ensure that any further adverse effects in exposed children are detected and 
quantified early on. Concerns have already been raised regarding haematological 
changes (European Collaborative Study, 2004b; Le Chenadec et al., 2003; Sperling 
et al., 1998), mitochondrial toxicity (Barret et al., 2003) and the potential for 
malignancies (Olivero et al., 2002). New drugs and drug classes are appearing 
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regularly, and the number of possible combinations of drugs is rising rapidly; each 
new drug and new regimen may be associated with risks to the fetus or mother. 
Prospective surveillance at a national level has provided invaluable information 
about the extent of these exposures, as well as their associated risks. While many 
questions around HIV and pregnancy have at least in part been answered, the 
emphasis is shifting towards addressing continued safety concerns in a sustainable 
way. Children born to HIV-infected women in the UK are now being ‘flagged’ 
through the Office for National Statistics for death and cancer registrations, allowing 
these more serious outcomes to be routinely monitored (Hankin et al., 2007). In the 
future, it may be possible to extend this data linkage protocol to include more routine 
hospital records, which would enable monitoring of other potential adverse 
outcomes, including longer-term ones (Barret et al., 2003; European Collaborative 
Study, 2005c), associated with in utero exposure to antiretroviral drugs. 
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Appendix 5 The beta distribution  
The beta distribution is a continuous probability distribution with range bounded 
between 0 and 1. It is defined in terms of two shape parameters, α and β, where α can 
be interpreted as the number of subjects within a group that experience an event, and 
β as the number who do not experience an event (Lynd & O'Brien, 2004). The mean 
of the distribution is therefore α / (α+β), and its standard deviation is  
)1()( 2 +++
×
= βαβα
βα
σ  
Beta probability density functions may be asymmetric and have different shapes to 
normal ones (e.g. they may be flatter, more peaked, or more concentrated around the 
mean than a normal distribution). Figure A.5 shows examples of the diverse beta 
probability densities that can be generated by varying the values of α and β. 
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Figure A.5  Examples of beta distributions  
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Appendix 6 Methods for calculating prematurity-specific mother-
to-child transmission rates  
Equations were derived as follows, with R corresponding to ‘risk’, and B to ‘benefit’. 
  Uninfected Infected Total 
Term a  b  ba +  
Premature c  d  dc +  
Total ca +  db +  n  
 
Given the above table, the prematurity rate is 
n
dcR +=0  which means that 
nRdc ×=+ 0 . The MTCT rate is 
n
dbB +=0  , which means that nBdb ×=+ 0 , and 
bnBd −×= )( 0 . If RR is the relative risk of transmission in the term group 
compared with the premature group, then )(
)(
)/(
)/(
dcb
bad
bab
dcdRR
+×
+×
=
+
+
= . Although 
a ,b , c and d  are not known, dc +  can be substituted with nR ×0 , ba +  with 
nR ×− )1( 0 , and d  with bnB −×0 , giving: 
0
00 )1()(
Rnb
nRbnB
RR
××
×−×−×
= , which simplifies to
0
00 )1()(
Rb
RbnB
RR
×
−×−×
= . 
Solving this equation for b gives  )1(
)1(
00
00
RRRR
RnBb
−+×
−××
= . 
The transmission rate in the term group, Bt, is ba
b
+
. Substituting b from above, and 
ba +  with nR ×− )1( 0 , gives:  
)1( 00
0
RRRR
B
Bt
−+×
=
  Equation 3 
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and  
tp BRRB ×= . Equation 4 
For each simulation of the monotherapy scenario, a mother-to-child transmission 
(MTCT) rate )ˆ( 0B  was sampled; tBˆ and pBˆ were then calculated using Equations 3 
and 4, with R0 equal to the population prematurity rate. A sampled prematurity 
rate, 0ˆR , was then obtained, and the transmission rate was adjusted by taking a 
weighted average of the term and premature transmission rates, as follows: 
))ˆ1(ˆ()ˆˆ(ˆ 000 RBRBB tp −×+×=   Equation 5 
For the highly active antiretroviral therapy (HAART) scenario, there were two 
options for adjusting for the association between transmission and prematurity 
(shown in Figure A.6), which yield slightly different results. Option 1 was chosen, as 
this method meant that the adjusted odds ratio for MTCT in the HAART group was 
applied to the overall MTCT rate in the monotherapy group, rather than to the MTCT 
rates specific to term or premature infants. This scenario is closer to the original data, 
and avoids making the assumption that the association between treatment and MTCT 
is independent of prematurity.    
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Figure A.6 Diagram showing two different ways of adjusting for the 
association between prematurity and mother-to-child transmission (MTCT)  
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HAART, highly active antiretroviral therapy; MTCT, mother-to-child transmission; 
prem, premature. 
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